CA2420277A1 - Antibodies specific for methylated lysines in histones - Google Patents
Antibodies specific for methylated lysines in histones Download PDFInfo
- Publication number
- CA2420277A1 CA2420277A1 CA002420277A CA2420277A CA2420277A1 CA 2420277 A1 CA2420277 A1 CA 2420277A1 CA 002420277 A CA002420277 A CA 002420277A CA 2420277 A CA2420277 A CA 2420277A CA 2420277 A1 CA2420277 A1 CA 2420277A1
- Authority
- CA
- Canada
- Prior art keywords
- antibody
- seq
- chromatin
- histone
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 108010033040 Histones Proteins 0.000 title claims abstract description 135
- 102000006947 Histones Human genes 0.000 title claims abstract description 76
- 235000018977 lysine Nutrition 0.000 title description 53
- 150000002669 lysines Chemical class 0.000 title 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims abstract description 104
- 108010077544 Chromatin Proteins 0.000 claims abstract description 98
- 210000003483 chromatin Anatomy 0.000 claims abstract description 98
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract description 91
- 239000004472 Lysine Substances 0.000 claims abstract description 53
- 108010034791 Heterochromatin Proteins 0.000 claims abstract description 30
- 210000004458 heterochromatin Anatomy 0.000 claims abstract description 28
- 108010022894 Euchromatin Proteins 0.000 claims abstract description 14
- 210000000632 euchromatin Anatomy 0.000 claims abstract description 14
- OLYPWXRMOFUVGH-LURJTMIESA-N N(2)-methyl-L-lysine Chemical compound CN[C@H](C(O)=O)CCCCN OLYPWXRMOFUVGH-LURJTMIESA-N 0.000 claims abstract description 7
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 64
- 238000000034 method Methods 0.000 claims description 50
- 210000000349 chromosome Anatomy 0.000 claims description 33
- 150000001413 amino acids Chemical class 0.000 claims description 27
- 238000010186 staining Methods 0.000 claims description 25
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 24
- 150000007523 nucleic acids Chemical group 0.000 claims description 20
- 210000001519 tissue Anatomy 0.000 claims description 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 16
- 239000012634 fragment Substances 0.000 claims description 16
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 16
- 201000010099 disease Diseases 0.000 claims description 15
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 13
- 230000031864 metaphase Effects 0.000 claims description 13
- 230000027455 binding Effects 0.000 claims description 10
- 238000001114 immunoprecipitation Methods 0.000 claims description 8
- 239000007787 solid Substances 0.000 claims description 8
- 229920001184 polypeptide Polymers 0.000 claims description 7
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims description 6
- 102100039869 Histone H2B type F-S Human genes 0.000 claims description 6
- 101001035372 Homo sapiens Histone H2B type F-S Proteins 0.000 claims description 6
- 241000283973 Oryctolagus cuniculus Species 0.000 claims description 6
- 230000004075 alteration Effects 0.000 claims description 6
- 230000000890 antigenic effect Effects 0.000 claims description 6
- 229940098773 bovine serum albumin Drugs 0.000 claims description 6
- 238000001514 detection method Methods 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 241000699670 Mus sp. Species 0.000 claims description 5
- 238000006467 substitution reaction Methods 0.000 claims description 5
- 239000003085 diluting agent Substances 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 230000001268 conjugating effect Effects 0.000 claims description 2
- 230000002621 immunoprecipitating effect Effects 0.000 claims description 2
- 230000003100 immobilizing effect Effects 0.000 claims 2
- 230000002194 synthesizing effect Effects 0.000 claims 1
- 238000007069 methylation reaction Methods 0.000 abstract description 97
- 230000011987 methylation Effects 0.000 abstract description 96
- 230000030279 gene silencing Effects 0.000 abstract description 11
- 238000012216 screening Methods 0.000 abstract description 7
- 238000012226 gene silencing method Methods 0.000 abstract description 2
- 108090000623 proteins and genes Proteins 0.000 description 59
- 101150118523 LYS4 gene Proteins 0.000 description 49
- 210000004027 cell Anatomy 0.000 description 48
- 230000004048 modification Effects 0.000 description 45
- 238000012986 modification Methods 0.000 description 45
- 108020004414 DNA Proteins 0.000 description 41
- 210000001766 X chromosome Anatomy 0.000 description 40
- 241000282414 Homo sapiens Species 0.000 description 38
- 230000000694 effects Effects 0.000 description 33
- 235000001014 amino acid Nutrition 0.000 description 32
- 125000003588 lysine group Chemical class [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 25
- 229940024606 amino acid Drugs 0.000 description 22
- 239000000427 antigen Substances 0.000 description 21
- 102000036639 antigens Human genes 0.000 description 21
- 108091007433 antigens Proteins 0.000 description 21
- 235000018102 proteins Nutrition 0.000 description 20
- 102000004169 proteins and genes Human genes 0.000 description 20
- 239000000523 sample Substances 0.000 description 18
- 125000003275 alpha amino acid group Chemical group 0.000 description 17
- 108091035715 XIST (gene) Proteins 0.000 description 16
- 230000008774 maternal effect Effects 0.000 description 16
- 230000008775 paternal effect Effects 0.000 description 16
- 102000017589 Chromo domains Human genes 0.000 description 15
- 108050005811 Chromo domains Proteins 0.000 description 15
- 238000002487 chromatin immunoprecipitation Methods 0.000 description 15
- 230000014509 gene expression Effects 0.000 description 15
- 230000004807 localization Effects 0.000 description 15
- 201000010769 Prader-Willi syndrome Diseases 0.000 description 13
- 230000001973 epigenetic effect Effects 0.000 description 13
- 230000030933 DNA methylation on cytosine Effects 0.000 description 12
- 238000004458 analytical method Methods 0.000 description 12
- 230000035772 mutation Effects 0.000 description 12
- 230000021736 acetylation Effects 0.000 description 11
- 238000006640 acetylation reaction Methods 0.000 description 11
- 238000010166 immunofluorescence Methods 0.000 description 11
- 238000004519 manufacturing process Methods 0.000 description 11
- 206010028980 Neoplasm Diseases 0.000 description 10
- 108091007416 X-inactive specific transcript Proteins 0.000 description 10
- 230000002759 chromosomal effect Effects 0.000 description 10
- 108020004707 nucleic acids Proteins 0.000 description 10
- 102000039446 nucleic acids Human genes 0.000 description 10
- 108700028369 Alleles Proteins 0.000 description 9
- 230000006870 function Effects 0.000 description 9
- 230000002103 transcriptional effect Effects 0.000 description 9
- JAMAWBXXKFGFGX-KZVJFYERSA-N Ala-Arg-Thr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(O)=O JAMAWBXXKFGFGX-KZVJFYERSA-N 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 8
- 108090000790 Enzymes Proteins 0.000 description 8
- 102000003964 Histone deacetylase Human genes 0.000 description 8
- 108090000353 Histone deacetylase Proteins 0.000 description 8
- 241000282412 Homo Species 0.000 description 8
- HEWWNLVEWBJBKA-WDCWCFNPSA-N Lys-Gln-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCCCN HEWWNLVEWBJBKA-WDCWCFNPSA-N 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 108091028043 Nucleic acid sequence Proteins 0.000 description 8
- 201000011510 cancer Diseases 0.000 description 8
- 229940088598 enzyme Drugs 0.000 description 8
- 230000002779 inactivation Effects 0.000 description 8
- 102000051614 SET domains Human genes 0.000 description 7
- 108700039010 SET domains Proteins 0.000 description 7
- 241000235347 Schizosaccharomyces pombe Species 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 235000018417 cysteine Nutrition 0.000 description 7
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 7
- 230000004481 post-translational protein modification Effects 0.000 description 7
- 230000000392 somatic effect Effects 0.000 description 7
- 239000000758 substrate Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- LWUWMHIOBPTZBA-DCAQKATOSA-N Ala-Arg-Lys Chemical compound NC(=N)NCCC[C@H](NC(=O)[C@@H](N)C)C(=O)N[C@@H](CCCCN)C(O)=O LWUWMHIOBPTZBA-DCAQKATOSA-N 0.000 description 6
- 208000009575 Angelman syndrome Diseases 0.000 description 6
- 241000206602 Eukaryota Species 0.000 description 6
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 6
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 6
- PQNASZJZHFPQLE-LURJTMIESA-N N(6)-methyl-L-lysine Chemical compound CNCCCC[C@H](N)C(O)=O PQNASZJZHFPQLE-LURJTMIESA-N 0.000 description 6
- PURRNJBBXDDWLX-ZDLURKLDSA-N Ser-Thr-Gly Chemical compound C[C@H]([C@@H](C(=O)NCC(=O)O)NC(=O)[C@H](CO)N)O PURRNJBBXDDWLX-ZDLURKLDSA-N 0.000 description 6
- 210000002230 centromere Anatomy 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 230000007547 defect Effects 0.000 description 6
- 230000007246 mechanism Effects 0.000 description 6
- 239000002953 phosphate buffered saline Substances 0.000 description 6
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 5
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 5
- PDUHNKAFQXQNLH-ZETCQYMHSA-N Gly-Lys-Gly Chemical compound NCCCC[C@H](NC(=O)CN)C(=O)NCC(O)=O PDUHNKAFQXQNLH-ZETCQYMHSA-N 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 5
- 102100034803 Small nuclear ribonucleoprotein-associated protein N Human genes 0.000 description 5
- 241000223892 Tetrahymena Species 0.000 description 5
- 102100037262 Ubiquitin-conjugating enzyme E2 B Human genes 0.000 description 5
- 101710193028 Ubiquitin-conjugating enzyme E2 B Proteins 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 230000000295 complement effect Effects 0.000 description 5
- 238000002509 fluorescent in situ hybridization Methods 0.000 description 5
- 238000009396 hybridization Methods 0.000 description 5
- 230000016507 interphase Effects 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 108010039827 snRNP Core Proteins Proteins 0.000 description 5
- 238000013518 transcription Methods 0.000 description 5
- 230000035897 transcription Effects 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- NPAVRDPEFVKELR-DCAQKATOSA-N Arg-Lys-Ser Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O NPAVRDPEFVKELR-DCAQKATOSA-N 0.000 description 4
- 101100491335 Caenorhabditis elegans mat-2 gene Proteins 0.000 description 4
- 230000007067 DNA methylation Effects 0.000 description 4
- PAOHIZNRJNIXQY-XQXXSGGOSA-N Gln-Thr-Ala Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O PAOHIZNRJNIXQY-XQXXSGGOSA-N 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 102100028998 Histone-lysine N-methyltransferase SUV39H1 Human genes 0.000 description 4
- 101000696705 Homo sapiens Histone-lysine N-methyltransferase SUV39H1 Proteins 0.000 description 4
- 101000772888 Homo sapiens Ubiquitin-protein ligase E3A Proteins 0.000 description 4
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 4
- 208000007466 Male Infertility Diseases 0.000 description 4
- 108010033276 Peptide Fragments Proteins 0.000 description 4
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 4
- 230000002596 correlated effect Effects 0.000 description 4
- 230000000875 corresponding effect Effects 0.000 description 4
- 108010016616 cysteinylglycine Proteins 0.000 description 4
- 230000002255 enzymatic effect Effects 0.000 description 4
- 230000004720 fertilization Effects 0.000 description 4
- 210000004090 human X chromosome Anatomy 0.000 description 4
- 210000004754 hybrid cell Anatomy 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- 230000021595 spermatogenesis Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 102100032918 Chromobox protein homolog 5 Human genes 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 101000979216 Homo sapiens Necdin Proteins 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 3
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
- 108060004795 Methyltransferase Proteins 0.000 description 3
- 102000016397 Methyltransferase Human genes 0.000 description 3
- 108010047956 Nucleosomes Proteins 0.000 description 3
- 102000007079 Peptide Fragments Human genes 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 108010007568 Protamines Proteins 0.000 description 3
- 102000007327 Protamines Human genes 0.000 description 3
- 241000235343 Saccharomycetales Species 0.000 description 3
- 241000248384 Tetrahymena thermophila Species 0.000 description 3
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 3
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 3
- 102100030434 Ubiquitin-protein ligase E3A Human genes 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 230000003466 anti-cipated effect Effects 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 3
- 238000012423 maintenance Methods 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 210000001623 nucleosome Anatomy 0.000 description 3
- 210000000287 oocyte Anatomy 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- 125000001151 peptidyl group Chemical group 0.000 description 3
- 230000026731 phosphorylation Effects 0.000 description 3
- 238000006366 phosphorylation reaction Methods 0.000 description 3
- 229940070353 protamines Drugs 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 210000001082 somatic cell Anatomy 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 230000009261 transgenic effect Effects 0.000 description 3
- 230000034512 ubiquitination Effects 0.000 description 3
- 238000010798 ubiquitination Methods 0.000 description 3
- 239000004475 Arginine Substances 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 108091029461 Constitutive heterochromatin Proteins 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 108010009540 DNA (Cytosine-5-)-Methyltransferase 1 Proteins 0.000 description 2
- 102100036279 DNA (cytosine-5)-methyltransferase 1 Human genes 0.000 description 2
- 241000255925 Diptera Species 0.000 description 2
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 2
- 108700039887 Essential Genes Proteins 0.000 description 2
- 208000007984 Female Infertility Diseases 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 102000011787 Histone Methyltransferases Human genes 0.000 description 2
- 108010036115 Histone Methyltransferases Proteins 0.000 description 2
- 102000003893 Histone acetyltransferases Human genes 0.000 description 2
- 108090000246 Histone acetyltransferases Proteins 0.000 description 2
- 101000578943 Homo sapiens MAGE-like protein 2 Proteins 0.000 description 2
- 101000905839 Homo sapiens Phospholipid-transporting ATPase VA Proteins 0.000 description 2
- 101001120872 Homo sapiens Probable E3 ubiquitin-protein ligase makorin-3 Proteins 0.000 description 2
- 206010021928 Infertility female Diseases 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- APFJUBGRZGMQFF-QWRGUYRKSA-N Leu-Gly-Lys Chemical compound CC(C)C[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCCCN APFJUBGRZGMQFF-QWRGUYRKSA-N 0.000 description 2
- 102100028333 MAGE-like protein 2 Human genes 0.000 description 2
- 102100023210 Necdin Human genes 0.000 description 2
- 102100023496 Phospholipid-transporting ATPase VA Human genes 0.000 description 2
- 102100026051 Probable E3 ubiquitin-protein ligase makorin-3 Human genes 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 108010041897 SU(VAR)3-9 Proteins 0.000 description 2
- AEGUWTFAQQWVLC-BQBZGAKWSA-N Ser-Gly-Arg Chemical compound [H]N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(O)=O AEGUWTFAQQWVLC-BQBZGAKWSA-N 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- XPNSAQMEAVSQRD-FBCQKBJTSA-N Thr-Gly-Gly Chemical compound C[C@@H](O)[C@H](N)C(=O)NCC(=O)NCC(O)=O XPNSAQMEAVSQRD-FBCQKBJTSA-N 0.000 description 2
- JKGGPMOUIAAJAA-YEPSODPASA-N Thr-Gly-Val Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](C(C)C)C(O)=O JKGGPMOUIAAJAA-YEPSODPASA-N 0.000 description 2
- 108090000848 Ubiquitin Proteins 0.000 description 2
- 102000044159 Ubiquitin Human genes 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 108700029631 X-Linked Genes Proteins 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 108010062796 arginyllysine Proteins 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 230000032823 cell division Effects 0.000 description 2
- 108091006090 chromatin-associated proteins Proteins 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 230000002153 concerted effect Effects 0.000 description 2
- 238000009833 condensation Methods 0.000 description 2
- 230000005494 condensation Effects 0.000 description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
- 230000006196 deacetylation Effects 0.000 description 2
- 238000003381 deacetylation reaction Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000002059 diagnostic imaging Methods 0.000 description 2
- 230000009274 differential gene expression Effects 0.000 description 2
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 230000013020 embryo development Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000006718 epigenetic regulation Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000006543 gametophyte development Effects 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 108010050848 glycylleucine Proteins 0.000 description 2
- 108010015792 glycyllysine Proteins 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 210000004408 hybridoma Anatomy 0.000 description 2
- 238000003119 immunoblot Methods 0.000 description 2
- 230000016784 immunoglobulin production Effects 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- -1 lysine amino acid Chemical class 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 108091005601 modified peptides Proteins 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 210000004940 nucleus Anatomy 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000017854 proteolysis Effects 0.000 description 2
- 230000007115 recruitment Effects 0.000 description 2
- 230000037425 regulation of transcription Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000007634 remodeling Methods 0.000 description 2
- 230000003252 repetitive effect Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 230000003362 replicative effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- 239000012130 whole-cell lysate Substances 0.000 description 2
- MEFKEPWMEQBLKI-QGRBLFOHSA-N (2S)-2-amino-4-[[(2S,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl-(tritritiomethyl)sulfonio]butanoate Chemical compound [3H]C([3H])([3H])[S+](CC[C@H](N)C([O-])=O)C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)ncnc12 MEFKEPWMEQBLKI-QGRBLFOHSA-N 0.000 description 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 description 1
- 229940117976 5-hydroxylysine Drugs 0.000 description 1
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical group CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 description 1
- 230000005730 ADP ribosylation Effects 0.000 description 1
- 102100022144 Achaete-scute homolog 2 Human genes 0.000 description 1
- 101710165189 Achaete-scute homolog 2 Proteins 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- HHGYNJRJIINWAK-FXQIFTODSA-N Ala-Ala-Arg Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CCCN=C(N)N HHGYNJRJIINWAK-FXQIFTODSA-N 0.000 description 1
- JBGSZRYCXBPWGX-BQBZGAKWSA-N Ala-Arg-Gly Chemical compound OC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](N)C)CCCN=C(N)N JBGSZRYCXBPWGX-BQBZGAKWSA-N 0.000 description 1
- RCAUJZASOAFTAJ-FXQIFTODSA-N Arg-Asp-Cys Chemical compound C(C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CS)C(=O)O)N)CN=C(N)N RCAUJZASOAFTAJ-FXQIFTODSA-N 0.000 description 1
- YBIAYFFIVAZXPK-AVGNSLFASA-N Arg-His-Arg Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O YBIAYFFIVAZXPK-AVGNSLFASA-N 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 102000001805 Bromodomains Human genes 0.000 description 1
- 108050009021 Bromodomains Proteins 0.000 description 1
- 101100495256 Caenorhabditis elegans mat-3 gene Proteins 0.000 description 1
- 101100262777 Caenorhabditis elegans umps-1 gene Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 101000709520 Chlamydia trachomatis serovar L2 (strain 434/Bu / ATCC VR-902B) Atypical response regulator protein ChxR Proteins 0.000 description 1
- 108010060434 Co-Repressor Proteins Proteins 0.000 description 1
- 102000008169 Co-Repressor Proteins Human genes 0.000 description 1
- 208000032170 Congenital Abnormalities Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 108091029523 CpG island Proteins 0.000 description 1
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
- 238000000018 DNA microarray Methods 0.000 description 1
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
- AHCYMLUZIRLXAA-SHYZEUOFSA-N Deoxyuridine 5'-triphosphate Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C=C1 AHCYMLUZIRLXAA-SHYZEUOFSA-N 0.000 description 1
- 206010012559 Developmental delay Diseases 0.000 description 1
- SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 1
- 206010013710 Drug interaction Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- RJIVPOXLQFJRTG-LURJTMIESA-N Gly-Arg-Gly Chemical compound OC(=O)CNC(=O)[C@@H](NC(=O)CN)CCCN=C(N)N RJIVPOXLQFJRTG-LURJTMIESA-N 0.000 description 1
- CCQOOWAONKGYKQ-BYPYZUCNSA-N Gly-Gly-Ala Chemical compound OC(=O)[C@H](C)NC(=O)CNC(=O)CN CCQOOWAONKGYKQ-BYPYZUCNSA-N 0.000 description 1
- VBOBNHSVQKKTOT-YUMQZZPRSA-N Gly-Lys-Ala Chemical compound [H]NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O VBOBNHSVQKKTOT-YUMQZZPRSA-N 0.000 description 1
- FNXSYBOHALPRHV-ONGXEEELSA-N Gly-Val-Lys Chemical compound NCC(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CCCCN FNXSYBOHALPRHV-ONGXEEELSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 108700005087 Homeobox Genes Proteins 0.000 description 1
- 101000944365 Homo sapiens Cyclin-dependent kinase inhibitor 1C Proteins 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 206010020710 Hyperphagia Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 125000000998 L-alanino group Chemical group [H]N([*])[C@](C([H])([H])[H])([H])C(=O)O[H] 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 125000000510 L-tryptophano group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C(C([H])([H])[C@@]([H])(C(O[H])=O)N([H])[*])C2=C1[H] 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
- RLZDUFRBMQNYIJ-YUMQZZPRSA-N Lys-Cys-Gly Chemical compound C(CCN)C[C@@H](C(=O)N[C@@H](CS)C(=O)NCC(=O)O)N RLZDUFRBMQNYIJ-YUMQZZPRSA-N 0.000 description 1
- ISHNZELVUVPCHY-ZETCQYMHSA-N Lys-Gly-Gly Chemical compound NCCCC[C@H](N)C(=O)NCC(=O)NCC(O)=O ISHNZELVUVPCHY-ZETCQYMHSA-N 0.000 description 1
- GQFDWEDHOQRNLC-QWRGUYRKSA-N Lys-Gly-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN GQFDWEDHOQRNLC-QWRGUYRKSA-N 0.000 description 1
- ZXFRGTAIIZHNHG-AJNGGQMLSA-N Lys-Ile-Leu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)O)NC(=O)[C@H](CCCCN)N ZXFRGTAIIZHNHG-AJNGGQMLSA-N 0.000 description 1
- MSSABBQOBUZFKZ-IHRRRGAJSA-N Lys-Pro-His Chemical compound C1C[C@H](N(C1)C(=O)[C@H](CCCCN)N)C(=O)N[C@@H](CC2=CN=CN2)C(=O)O MSSABBQOBUZFKZ-IHRRRGAJSA-N 0.000 description 1
- HKXSZKJMDBHOTG-CIUDSAMLSA-N Lys-Ser-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CCCCN HKXSZKJMDBHOTG-CIUDSAMLSA-N 0.000 description 1
- 101100163888 Mus musculus Ascl2 gene Proteins 0.000 description 1
- 208000007379 Muscle Hypotonia Diseases 0.000 description 1
- 108010021466 Mutant Proteins Proteins 0.000 description 1
- 102000008300 Mutant Proteins Human genes 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 101100426589 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) trp-3 gene Proteins 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 241000283283 Orcinus orca Species 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 108020002230 Pancreatic Ribonuclease Proteins 0.000 description 1
- 102000005891 Pancreatic ribonuclease Human genes 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 108091093037 Peptide nucleic acid Proteins 0.000 description 1
- 241000288049 Perdix perdix Species 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 108010022429 Polycomb-Group Proteins Proteins 0.000 description 1
- 102000012425 Polycomb-Group Proteins Human genes 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- STGVYUTZKGPRCI-GUBZILKMSA-N Pro-Val-Cys Chemical compound SC[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]1CCCN1 STGVYUTZKGPRCI-GUBZILKMSA-N 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108700040121 Protein Methyltransferases Proteins 0.000 description 1
- 102000055027 Protein Methyltransferases Human genes 0.000 description 1
- 101100328362 Schizosaccharomyces pombe (strain 972 / ATCC 24843) clr3 gene Proteins 0.000 description 1
- 208000036623 Severe mental retardation Diseases 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 101150069235 Snrpn gene Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 102000003629 TRPC3 Human genes 0.000 description 1
- 102000003622 TRPC4 Human genes 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 1
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 1
- 101710132695 Ubiquitin-conjugating enzyme E2 Proteins 0.000 description 1
- 102100037261 Ubiquitin-conjugating enzyme E2 A Human genes 0.000 description 1
- 101710193027 Ubiquitin-conjugating enzyme E2 A Proteins 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 241000269370 Xenopus <genus> Species 0.000 description 1
- 210000002593 Y chromosome Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 108010087924 alanylproline Proteins 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 210000000628 antibody-producing cell Anatomy 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 210000005056 cell body Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000028235 chromatin silencing at centromere Effects 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000008045 co-localization Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical group NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- YSMODUONRAFBET-UHFFFAOYSA-N delta-DL-hydroxylysine Natural products NCC(O)CCC(N)C(O)=O YSMODUONRAFBET-UHFFFAOYSA-N 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 1
- SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 230000032671 dosage compensation Effects 0.000 description 1
- 230000019975 dosage compensation by inactivation of X chromosome Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000006565 epigenetic process Effects 0.000 description 1
- YSMODUONRAFBET-UHNVWZDZSA-N erythro-5-hydroxy-L-lysine Chemical compound NC[C@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-UHNVWZDZSA-N 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 230000005283 ground state Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000006195 histone acetylation Effects 0.000 description 1
- 230000006197 histone deacetylation Effects 0.000 description 1
- 102000049771 human CDKN1C Human genes 0.000 description 1
- 102000050448 human UBE3A Human genes 0.000 description 1
- 210000003917 human chromosome Anatomy 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 239000012133 immunoprecipitate Substances 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 238000005567 liquid scintillation counting Methods 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 108010054155 lysyllysine Proteins 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- TWXDDNPPQUTEOV-FVGYRXGTSA-N methamphetamine hydrochloride Chemical compound Cl.CN[C@@H](C)CC1=CC=CC=C1 TWXDDNPPQUTEOV-FVGYRXGTSA-N 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 230000001035 methylating effect Effects 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 238000012775 microarray technology Methods 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 108091005573 modified proteins Proteins 0.000 description 1
- 102000035118 modified proteins Human genes 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 238000011587 new zealand white rabbit Methods 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 229920002113 octoxynol Polymers 0.000 description 1
- 108091008819 oncoproteins Proteins 0.000 description 1
- 102000027450 oncoproteins Human genes 0.000 description 1
- 230000034004 oogenesis Effects 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 150000004713 phosphodiesters Chemical group 0.000 description 1
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 238000002600 positron emission tomography Methods 0.000 description 1
- 230000002516 postimmunization Effects 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 230000001902 propagating effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000006916 protein interaction Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000000163 radioactive labelling Methods 0.000 description 1
- 238000011363 radioimmunotherapy Methods 0.000 description 1
- 239000012217 radiopharmaceutical Substances 0.000 description 1
- 229940121896 radiopharmaceutical Drugs 0.000 description 1
- 230000002799 radiopharmaceutical effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- MFBOGIVSZKQAPD-UHFFFAOYSA-M sodium butyrate Chemical compound [Na+].CCCC([O-])=O MFBOGIVSZKQAPD-UHFFFAOYSA-M 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- 108091006108 transcriptional coactivators Proteins 0.000 description 1
- 230000037426 transcriptional repression Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6875—Nucleoproteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
The present invention relates to the generation of methyllysine-specific histone antibodies. In particular, the H3 lysine 4 methylation specific antibody (Methyl(K4)H3) binds to histone H3 methylated at lysine 4. Methylation of lysine 4 (K4) on histone H3 has been associated with transcriptionally active regions of chromatin. A second antibody, H3 lysine 9 methylation specific antibody (Methyl(K9)H3) specifically binds to histone H 3 methylated at lysine 9. Methylation of lysine 9 (K9) on histone H3 has been associated with gene silencing. These antibodies are useful in identifying regions of heterochromatin and euchromatin and serving as diagnostic and screening tools.
Description
Antibodies Specific for Methylated Lysines in Histories This application claims priority under 35 U.S.C. ~119(e) to US
Provisional Patent Application No. 60/302,747, filed on July 3, 2001 and US
Provisional Patent Application No 60/227,767, filed on August 25, 2000, the disclosures of which are incorporated herein by reference in their entirety.
US Government Rights This invention was made with United States Government support under Grant Nos. ROl GM40922 and RO 1 GM53512, awarded by the National Institutes of Health. The United States Government has certain rights in the invention.
Field of the Invention 1 S The present invention is directed to antibodies that bind to histone epitopes created by postranslational modification of the histone protein, compositions comprising such antibodies, and the use of such compositions as diagnostic and screening tools.
Background of the Invention In eukaryotes, DNA is complexed with histone proteins to form nucleosomes, the repeating subunits of chromatin. This packaging of DNA
imposes a severe restriction to proteins seeking access to DNA for ANA-templated processes such as transcription or replication. It is becoming increasingly clear that post-translational modifications of histone amino-termini play an important role in , determining the chromatin structure of the eukaryotic cell genome as well as regulating the expression of cellular genes.
Posttranslational modifications of histone amino-termini have long been thought to play a central role in the control of chromatin structure and function.
A large number of covalent modifications of histories have been documented, including aceiylation, phosphorylation, methylation, ubiquitination, and ADP
ribosylation, that take place on the amino terminus "tail" domains of histories. Such diversity in the types of modifications and the remarkable specificity for residues undergoing these modifications suggest a complex hierarchy of order and combinatorial function that remains unclear. Of the covalent modifications known to take place on histone amino-termini, acetylation is perhaps the best studied and appreciated. Recent studies have identified previously characterized coactivators and corepressors that acetylate or deacetylate, respectively, specific lysine residues in histones in response to their recruitment to target promoters in chromatin (See Berger (1999) Curr. Opin. Genet. Dev. 1 l, 336-341). These studies provide compelling evi-dence that chromatin remodeling plays a fundamental role in the regulation of transcription from nucleosomal templates.
Chromosomes in higher eukaryotes have historically been considered to consist of regions of euchromatin and heterochromatin, which are distinguished by the degree of condensation and level of transcriptional activity of the underlying DNA
sequences. Certain regions of constitutive heterochromatin are found at or near specialized structures such as centromeres, and are comprised mostly of genetically inert repetitive sequences. In contrast, other regions that have the same primary DNA
sequences can exhibit characteristics of either type of chromatin, suggesting that epigenetic factors, such as packaging of DNA by histones and chromatin associated proteins, dictate the heterochromatin status at these loci.
Through the use of antibodies that specifically recognize histones bearing specific post-translational modifications applicants have been elucidating a "histone code." In particular, evidence is emerging that histone proteins, and their associated covalent modifications, contribute to a mechanism that can alter chromatin structure, thereby leading to inherited differences in transcriptional "on-off' states or to.the stable propagation of chromosomes by defining a specialized higher-order structure. . ' Histone methylation is one of the least-understood posttranslational modifications affecting histones. Early work suggests that H3 and H4 are the primary histones modified by methylation, and sequencing studies, using bulk histones, have shown that several lysines (e.g., 9 and 27 of H3 and 20 of H4) are often preferred sites of methylation, although species-specific differences appear to exist.
Interestingly, each modified lysine has the capacity to be mono-, di-, or trimethylated, adding yet another level of variation to this posttranslational "mark". The present invention is directed to antibodies that are specific for histone H3 and H4 that are methylated at specific lysines. More particularly, one aspect of the present invention is directed to histone H3 lysine 4 and 9. These two lysine residues are found to be methylated i~
vivo and the methylated forms axe associated with euchromatin and heterochromatin, respectively.
Definitions In describing and claiming the invention, the following terminology will be used in accordance with the definitions set forth below.
As used herein, the term "nucleic acid" encompasses RNA as well as single and double-stranded DNA and cDNA. Furthermore, the terms, "nucleic acid,"
"DNA," "RNA" and similar terms also include nucleic acid analogs, i.e. analogs having other than a phosphodiester backbone. For example, the so-called "peptide nucleic acids," which are lrnown in the art and have peptide bonds instead of phosphodiester bonds in the backbone, are considered within the scope of the present invention.
The term "peptide" encompasses a sequence of 3 or more amino acids wherein the amino acids are naturally occurring or synthetic (non-naturally occurring) amino acids. Peptide mimetics include peptides having one or more of the following modifications:
1. peptides wherein one or more of the peptidyl --C(O)NR-- linkages (bonds) have been replaced by a non-peptidyl linkage such as a --CH2-carbamate linkage (--CH20C(O)NR--), a phosphonate linkage, a -CH2-sulfonamide (-CH 2--S(O)2NR--) linkage, a urea (--NHC(O)NH--) linkage, a --CH2 -secondary amine linkage, or with an alkylated peptidyl linkage (--C(O)NR--) wherein R; is Cl-C4 alkyl;
2. peptides wherein the N-terminus is derivatized to a --NRRl group, to a -- NRC(O)R group, to a --NRC(O)OR group, to a --NRS(O)2R group, to a --NHC(O)NHR group where R and Rl are hydrogen or Cl-C4 alkyl with the proviso that R and Rl are not both hydrogen;
3. peptides wherein the C terminus is derivatized to --C(O)R2 where R 2 is selected from the group consisting of C1-C4 alkoxy, and --NR3R4 where R3 and are independently selected from the group consisting of hydrogen and C1-C4 alkyl.
Naturally occurring amino acid residues in peptides are abbreviated as recommended by the IUPAC-ILTB Biochemical Nomenclature Commission as follows: Phenylalanine is Phe or F; Leucine is Leu or L; Isoleucine is Ile or I;
Methionine is Met or M; Norleucine is Nle; Valine is Vat or V; Serine is Ser or S;
Proline is Pro or P; Threonine is Thr or T; Alanine is Ala or A; Tyrosine is Tyr or Y;
Histidine is His or H; Glutamine is Gln or Q; Asparagine is Asn or N; Lysine is Lys or K; Aspartic Acid is Asp or D; Glutamic Acid is Glu or E; Cysteine is Cys or C;
Tryptophan is Trp or W; Arginine is Arg or R; Glycine is Gly or G, and X is any amino acid. Other naturally occurring amino acids include, by way of example, hydroxyproline, 5-hydroxylysine, and the like.
As used herein, the term "conservative amino acid substitution" is defined herein as exchanges within one of the following five groups:
I. Small aliphatic, nonpolar or slightly polar residues:
Ala, Ser, Thr, Pro, Gly;
II. Polar, negatively charged residues and their amides:
Asp, Asn, Glu, Gln;
III. Polar, positively charged residues:
His, Arg, Lys;
IV. Large, aliphatic, nonpolar residues:
Met Leu, Ile, Val, Cys V. Large, aromatic residues:
Phe, Tyr, Trp As used herein, the term "purified" and like terms relate to the isolation of a molecule or compound in a form that is substantially free of contaminants normally associated with the molecule or compound in a native or natural environment.
"Operably linked" refers to a juxtaposition wherein the components are configured so as to perform their usual function. For example, control sequences or -S-promoters operably linked to a coding sequence are capable of effecting the expression of the coding sequence.
As used herein, the terms "complementary" or "complementarity" are used in reference to polynucleotides (i.e., a sequence of nucleotides) related by the base-pairing rules. For example, for the sequence "A-G-T," is complementary to the sequence"T-C-A."
As used herein, the term "hybridization" is used in reference to the pairing of complementary nucleic acids. Hybridization and the strength of hybridization (i.e., the strength of the association between the nucleic acids) is impacted by such factors as the degree of complementarity between the nucleic acids, stringency of the conditions involved, the length of the formed hybrid, and the G:C
ratio within the nucleic acids.
"Therapeutic agent," "pharmaceutical agent" or "drug" refers to any therapeutic or prophylactic agent which may be used in the treatment (including the prevention, diagnosis, alleviation, or cure) of a malady, affliction, disease or injury in a patient.
As used herein, the term "treating" includes alleviating the symptoms associated with a specific disorder or condition andlor preventing or eliminating said symptoms. For example, treating cancer includes preventing or slowing the growth and/or division of cancer cells as well as killing cancer cells.
As used herein, the term "pharmaceutically acceptable carrier"
encompasses any of the standard pharmaceutical carriers, such as a phosphate buffered saline solution, water and emulsions such as an oil/water or water/oil emulsion, and various types of wetting agents.
As used herein, the term "antigenic fragment of H3 lysine 4" or "antigenic fragment of H3 lysine 4" encompasses both natural peptide fragments of the amino terminus of Histone 3 (including the peptide fragments of SEQ ID NO:
1, SEQ ID NO: 2 and SEQ ID NO: 3) and synthetic equivalents of those fragments.
As used herein, the term "antibody" refers to a polyclonal or monoclonal antibody or a binding fragment thereof such as Fab, F(ab')2 and Fv fragments.
As used herein, the term "biologically active fragments" of the Methyl(K4)H3 or Methyl(K9)H3 antibodies encompasses natural or synthetic portions of the respective full-length antibody that are capable of specific binding to the peptide of SEQ ID NO: 4 or SEQ ID NO: 5, respectively.
As used herein, the term "parenteral" includes administration subcutaneously, intravenously or intramuscularly.
As used herein the letter K in bold face type (K), when used in the context of an amino acid sequence, will represent a lysine amino acid that has been methylated.
Summary of the Invention The present invention is directed to antibodies that bind to specific modifications of the amino terminus of histone H3 and H4 peptides. More particularly, the present invention is directed to the generation of methyllysine-specific histone antibodies. These antibodies recognize lysine residues in histones H3 and H4 that are specifically methylated and may be linked to human biology and disease. Compositions comprising these antibodies axe used as diagnostic and screening tools.
Brief Description of the Drawings Fig. 1A and 1B represent immunofluorescence patterns of human metaphase chromosomes from the normal female cell line (HH) stained with either the Methyl(K9)H3 antibody (Fig. 1A) or the Methyl(K4)H3 antibody (Fig. 1B).
Localization of the Methyl(K4)H3 and Methyl(K9)H3 antibodies was detected using Cy3-conjugated secondary antibody (red). Each of the immunofluorescence patterns obtained with the two antibodies revealed one chromosome that is preferentially stained compared to the other chromosomes (indicated by large arrow). As shown in Fig. 1B only small regions of the inactive X chromosome are enriched for Lys4 methyl H3 staining.
Fig. 2. CHIP analysis of somatic cell hybrid cell lines. Chromatin from CHO somatic hybrid cells containing the inactive (X;nactive) or active (active) human X chromosome was immunoprecipitated using the following antibodies:
lane 1 = no antibody (control lane); lane 2 = Methyl(K9)H3;
lane 3 = Methyl(K4)H3; lane 4 = Lys9/14-acetylated H3;
lane 5 = no DNA (control); lane 6 = genomic DNA
The presence of Xist and PGKl promoter DNA sequences in the immunoprecipitated DNA was assayed by PCR. The PCR products were separated on 15%
polyacrylamide gels, imaged by digital camera, and images were electronically inverted to facilitate visualization of the ethidium bromide-stained bands. As shown, from cells containing the inactive X chromosome, the Methyl(K4)H3 and Lys9/14 acetyl H3 antibodies preferentially immunoprecipitated the active Xist gene whereas the Methyl(K9)H3 antibody preferentially immunoprecipitated the inactive PGKl gene. From cells containing the active X chromosome, the exact reverse immunoprecipitation pattern was observed.
Fig. 3 Immunoblot analysis of H3 methyiation between simple vs.
complex organisms. Histories were isolated from various sources, and five ug of total core histories from each species, along with 1 ug of recombinant Xehopus H3 were resolved on a 15% SDS-PAGE, transferred to a PVDF membrane support and probed with either the Methyl(K4)H3 or Methyl(K9)H3 antibody. Lanes 1-5 represent histories isolated from recombinant Xenopus H3, budding yeast, Tetrahymena, chicken and the human cell line 293T, respectively. Identical samples were analyzed in parallel and examined by Coomassie staining to monitor histone loading.
-Detailed Description of the Invention Histone methylation is a poorly understood post-translational modification affecting histories. This modification occurs on selected lysine residues in the amino-terminus of histories. It is now becoming apparent that methylating histone enzymes are involved in both gene activation and repression. The present invention is directed to the generation of methyllysine-specific histone antibodies.
These antibodies recognize lysine residues in the histories H3 and H4 that are specifically methylated and may be linked to human biology and disease.
The present invention is directed to post-translational modifications that occur on the flexible N-terminal tails of the core histone proteins H3 and H4.
More particularly, the invention is directed to methylated lysine residues.
Applicants _g_ have discovered that methylation of the lysine residues within the first 15 amino acids of the amino terminus of H3 (SEQ ID NO: 7) and H4 (SEQ ID NO: 8) play an important role in the regulation of transcription. For example, methylation of lysine 4 (K4) on histone H3 has been associated with transcriptionally active regions of chromatin, whereas methylation of lysine 9 (K9) on histone H3 has been associated with gene silencing. Therefore, in accordance with one aspect of the present invention methylation of lysine 4 (K4) and lysine 9 (K9) on histone H3 serve as a markers of euchromatin and heterochromatin, respectively, and antibodies recognizing these modified proteins have use as important diagnostic tools.
One aspect of the present invention is directed to antigens used to produce antibodies specific to the amino terminus of H3 and H4. In one embodiment, the antigen is a purified antigenic fragment of the amino terminus of H3 or H4 methlated at a lysine and selected from the group consisting of ARTKQTARKSTGG
(SEQ ID NO: 10), ARTKQTARKSTGG (SEQ ID NO: 11), ARTKQTARKSTGV
(SEQ ID NO: 12), ARTKQTARKSTGV (SEQ ID NO: 13), SGRGKGGKGLGKG
(SEQ ID NO: 14) and SGRGKGGKGLGKG (SEQ ID NO: 15) or a synthetic equivalent thereof, wherein the bold K represents a methylated lysine residue.
In one embodiment the antigen comprises an H3 amino terminal fragment of 20 amino acids or less and comprises the sequence ARTKQTAR (SEQ ID NO: 1), QTARKSTGV
(SEQ l~ NO: 2) or QTARKSTGG (SEQ ID NO: 3), and derivatives of these amino acid sequences wherein the amino acid sequence contains one or more conservative amino acid substitutions. In one preferred embodiment the antigen is ARTKQTAR
(SEQ ID NO: 1), QTARKSTGV (SEQ ID NO: 2) or QTARKSTGG (SEQ ID NO: 3), or a derivative thereof containing additional non-native amino acids added to either end of the peptide sequence.
In an alternative embodiment, the purif ed antigen comprises a polypeptide linked to a suitable carrier, such as bovine serum albumin or Keyhole limpet hemocyanin. In one preferred embodiment the antigen consists of an H3 peptide fragment peptide comprising a sequence selected from the group ARTKQTAR (SEQ ID NO: 1), QTARKSTGV (SEQ II7 NO: 2) or QTARKSTGG
(SEQ ID NO: 3, and derivatives of this amino acid sequence wherein the amino acid sequence contains one or more conservative amino acid substitutions, and a Garner protein linked to the peptide. For example, the antigen may comprise a peptide having the sequence ARTKQTARGC (SEQ ID NO: 4), QTARKSTGVCG (SEQ ID
NO: 5), QTARKSTGGCG (SEQ ID NO: 6), AARKSAPVCG (SEQ ID NO: 16), SGGVKKPHKCG (SEQ ID NO: 17) or RHRHILRDCG (SEQ ID NO: 18) wherein the bold K represents the methylated lysine residue and the underlined GC
refers to artificial amino acids added to the natural histone sequence. Furthermore, the antigen can optionally be linked to a carrier protein. .
In addition to the antigens described above, the present invention is also directed to antibodies that specifically bind to peptide fragments of the H3 or H4 protein that have been methylated at a lysine residue. Preferably the antibody will recognize one or more methylated lysine residues present in the first 20 amino acid residues of the amino terminus of the H3 and H4 histones. More particularly, the present invention is directed to an antibody that specifically binds to the peptide ARTKQTARGC (SEQ ID NO: 4), QTARKSTGGCG (SEQ ID NO: 6), QTARKSTGVCG (SEQ ID NO: 5), AARKSAPVCG (SEQ m NO: 16), SGGVKKPHKCG (SEQ ID NO: 17) or RHRKILRDCG (SEQ ID NO: 18), wherein the bold K represents the methylated lysine residue and the underlined GC
refers to artificial amino acids added to the natural histone sequence to aid in the production of the antibody. In one embodiment the antibody is specific for a peptide comprising the amino acid selected from the group consisting of ARTKQTARGC (SEQ ID NO:
4), QTARKSTGVCG (SEQ ID NO: 5), QTARKSTGGCG (SEQ ID NO: 6); and amino acid sequences that differ from SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID or SEQ
ID NO: 6 by one or more conservative amino acid substitutions. In one preferred embodiment the antibody specifically binds to the peptide ARTKQTARGC (SEQ ID
NO: 4) or QTARKSTGVCG (SEQ ID NO: 5).
Antibodies that specifically bind an H3~ peptide that is methylated at lysine 4 (i.e. the peptide of SEQ ID NO: 4) will be referred to as Methyl(K4)H3 and antibodies that specifically bind an H3 peptide that is methylated at lysine 9 (i.e. the peptide of SEQ ID NO: 5 or SEQ ID NO: 6) will be referred to as Methyl(K9)H3.
These two antibodies do not cross react and will not bind to the non-methylated peptide sequences. The present invention also encompasses antibodies that bind to the non-methylated histone peptides. In one embodiment, the antibodies of the present invention are monoclonal antibodies.
The antibodies or antibody fragments of the present invention can be combined with a carrier or diluent to form a composition. In one embodiment, the carrier is a pharmaceutically acceptable carrier. Such carriers and diluents include sterile liquids such as water and oils, with or without the addition of a surfactant and other pharmaceutically and physiologically acceptable carrier, including adjuvants, excipients or stabilizers. Illustrative oils are those of petroleum, animal, vegetable, or synthetic origin, for example, peanut oil, soybean oil, or mineral oil. In general, water, saline, aqueous dextrose, and related sugar solution, and glycols such as, propylene glycol or polyethylene glycol, are preferred liquid carriers, particularly for injectable solutions. The compositions comprising the Methyl(K4)H3 or Methyl(K9)H3 antibody, or bioactive fragments thereof, and a carrier or diluent can be used in conjunction with the method to detect heterochromatin verses euchromatin.
One method used to generate the antibodies of the present invention involves administration of an antigen, comprising the sequence ARTKQTAR (SEQ
ID NO: 1), QTARKSTGV (SEQ ID NO: 2) or QTARKSTGG (SEQ ID NO: 3), to a laboratory animal, typically a rabbit, to trigger production of antibodies specific for the antigen. The dose and regiment of antigen administration to trigger antibody production as well as the methods for purification of the antibody are well known to those skilled in the art. Typically, such antibodies can be raised by administering the antigen of interest subcutaneously to New Zealand white rabbits which have first been bled to obtain pre-immune serum. The antigens can be injected at a total volume of 100 u1 per site at six different sites. Each injected material will contain synthetic surfactant adjuvant pluronic polyols, or pulverized acrylamide gel containing the protein or polypeptide after SDS-polyacrylamide gel electrophoresis.
The rabbits are then bled two weeks after the first injection and periodically boosted with the same antigen three times every six weeks. A
sample of serum is then collected 10 days after each boost. Polyclonal antibodies are then recovered from the serum by aff'mity chromatography using the corresponding antigen to capture the antibody. Ultimately, the rabbits are euthenized with pentobarbital 150 mg/Kg IV. This and other procedures for raising polyclonal antibodies are disclosed in E. Harlow, et. al., editors, Antibodies: A Laboratory Manual (1988), which is hereby incorporated by reference. The specificity of antibodies may be determined by enzyme-linked immunosorbent assay or immunoblotting, or similar methods known to those skilled in the art.
The present invention also encompasses monoclonal antibodies that specifically bind to the respective antigen ARTKQTAR (SEQ ID NO: 1), QTARKSTGV (SEQ ID NO: 2) or QTARKSTGG (SEQ ID NO: 3) and their non-methylated counterpart peptides. Monoclonal antibody production may be effected using techniques well-known to those skilled in the art. Basically, the process involves first obtaining immune cells (lymphocytes) from the spleen of a mammal (e.g., mouse) which has been previously immunized with the antigen of interest either i~z vivo or in vitro. The antibody-secreting lymphocytes are then fused with myeloma cells or transformed cells, which are capable of replicating indefinitely in cell culture, thereby producing an immortal, immunoglobulin-secreting cell line. The resulting fused cells, or hybridomas, are cultured, and the resulting colonies screened for the production of the desired monoclonal antibodies. Colonies producing such antibodies are cloned, and grown either in vivo or i~c vitro to produce large quantities of antibody.
One embodiment of the invention is directed to a hybridoma cell line which produces monoclonal antibodies which bind the methyl-lysine peptides of the present invention.
A description of the theoretical basis and practical methodology of fusing such cells is set forth in I~ohler and Milstein, Nature, 256:495 (1975), which is hereby incorporated by reference.
In addition to whole antibodies, fragments of antibodies can retain binding specificity for a particular antigen. Antibody fragments can be generated by several methods, including, but not limited to proteolysis or synthesis using recombinant DNA technology. An example of such an embodiment is selective proteolysis of an antibody by papain to generate Fab fragments, or by pepsin to generate a F(ab')2 fragment. These antibody fragments can be made by conventional procedures, as described in T. Goding, Monoclonal Antibodies: Principles and Practice, pp. 98~118 (N.Y. Academic Press 1983), which is hereby incorporated by reference. Other fragments of the present antibodies which retain the specific binding of the whole antibody can be generated by other means known to those skilled in the art.
In one embodiment the antibodies are labeled. It is not intended that the present invention be limited to any particular detection system or label.
The antibody may be labeled with a fluorophoxe, a radioisotope, ox a non-isotopic labeling reagent such as biotin or digoxigenin; antibodies containing biotin may be detected using "detection reagents" such as avidin conjugated to any desirable label such as a fluorochrome. In one embodiment the histone specific antibodies of the present invention are detected through the use of a secondary antibody, wherein the secondary antibody is labeled and is specific for the primary (histone specific) antibody.
Alternatively, the histone specific antibody may be directly labeled with a radioisotope or fluorochrome such as FITC ox rhodamine; in such cases secondary detection reagents may not be required for the detection of the labeled probe.
In accordance with one embodiment of the present invention a method of detecting the presence of methylated lysine residues in the H3 and H4 histones is provided. The method comprises the steps of contacting histone proteins with a labeled antibody, wherein the antibody specifically binds only to H3 that is methylated at lysine 4 or H3 methylated at lysine 9.
In accordance with one embodiment the antibodies of the present invention are labeled for use in diagnostic imaging. Examples of labels useful for diagnostic imaging in accordance with the present invention are radiolabels such as 131h 111~~ 123h 99mTc~ 32p~ 125h 3H~ 14C~ ~d 188' fluorescent labels such as fluorescein and rhodamine, nuclear magnetic resonance active labels, electron dense or radiopaque materials, positron emitting isotopes detectable by a positron emission tomography ("pET") scanner, chemilluminescers such as luciferin, and enzymatic markers such as peroxidase or phosphatase. Short-range radiation emitters, such as isotopes detectable by short-range detector probes, such as a transrectal probe, can also be employed. These isotopes and transrectal detector probes, when used in combination, are especially useful in detecting prostatic fossa recurrences and pelvic nodal disease. The antibodies of the present invention can be labeled with such reagents using techniques known in the art. For example, see Wensel and Meaxes, Radioimmunoimaging and Radioimmunotherapy, Elsevier, New York (1983), which is hereby incorporated by reference, for techniques relating to the radiolabeling of antibodies. See also, D. Colcher et al., "Use of Monoclonal Antibodies as Radiopharmaceuticals for the Localization of Human Carcinoma Xenografts in Athymic Mice," Meth. EnzvmQL, 121: 802-816 (1986), which is hereby incorporated by reference. In accordance with one preferred embodiment the antibody is labeled with a fluorophore or chromophore using standard moieties known in the art.
Applicants have discovered that methylation of histone H3 at lysines 4 and 9 (K4 and K9), correlates, respectively, with activation and inactivation of expression of genes in proximity to the modified histones. Histone H3 when methylated at K9 is a preferred binding site for the heterochromatin protein HP 1, which in turn can recruit the enzyme Suv39h responsible for K9 methylation, creating a mechanism by which the inactivation signal can be propagated. Methylation of also precludes acetylation at that site, further contributing to repression.
In contrast to the reaction at K9, methylation at histone H3 K4 is correlated with transcriptional activity. Therefore in accordance with one embodiment of the present invention, antibodies specific for the K4 methylated histone H3 can be used to detect transcriptionally active regions of chromatin and antibodies specific for K9 methylated histone H3 transcriptionally can be used to detect inactive regions of chromatin. In fact, in situ staining of chromosomes reveals that the staining patterns generated by the Methyl(K4)H3 and Methyl(K9)H3 antibodies produce mirror images of one another.
Because the Methyl(K4)H3. and Methyl(K9)H3 antibodies have the potential for use in humans as diagnostic and therapeutic agents, one embodiment of the present invention is directed to humanized versions of the Methyl(K4)H3 and Methyl(K9)H3 antibodies. Humanized versions of the antibodies are needed for therapeutic applications because antibodies from non=human species may be recognized as foreign substances by the human immune system and neutralized such that they are less useful. Humanized antibodies are immunoglobulin molecules comprising a human and non-human portion. More specifically, the antigen combining region (variable region) of a humanized antibody is derived from a non-human source (e.g. marine) and the constant region of the humanized antibody is derived from a human source. The humanized antibody should have the antigen binding specificity of the non-human antibody molecule and the effector function conferred by the human antibody molecule. Typically, creation of a humanized antibody involves the use of recombinant DNA techniques.
The-antibodies of the present invention can also be linked to an insoluble support to provide a means of isolating euchromatin or heterochromatin from cells. The support may be in particulate or solid form and could include, but is not limited to: a plate, a test tube, beads, a-ball, a filter or a membrane.
Methods for fixing antibodies to insoluble supports are known to those skilled in the art.
In one embodiment an antibody of the current invention is fixed to an insoluble support that is suitable for use in affinity chromatography.
The Methyl(K4)H3 and Methyl(K9)H3 antibodies are large-scale or domain-sensitive chromatin marks that are somehow set up by boundary elements.
In particular, chromatin that is associated with histones that include H3 methylated at Lsy4 represent an "on" domain, or at least a domain that is competent fox transcriptional activity. Alternatively, chromatin that is associated with histones that include H3 methylated at Lsy9 represent an "off" domain, that is not competent for transcriptional activity. This pattern is conserved across a diverse range of species.
Zoo blots with these antibodies suggest that most of the H3 histones from 'simple' organisms (budding yeast) and Tetrahymena, contain a methylated Lys4 (ON), whereas in striking contrast, most of the H3 histones present in 'complex' organisms have a methylated Lys9 (OFF) (see Fig. 3). This agrees well with the fording that most of the genomic DNA in yeast.and in Tetrahymena is expressed (ON) while most of the DNA in humans, mice, etc. is OFF. Thus, it may well be that the 'default' or ground state in more complex eukaryotes is OFF. Knowing how to identify ON
chromatin through use of the Lys4 methyl mark may prove invaluable in developing strategies for better targeting of transgene to more 'friendly' chromatin.
Chromatin immunoprecipitation data supports the above 'ONlOFF' marking system model. In particular, S. pombe chromatin IP data, published (Science Nakayama et al., 2001) and the work on the inactive X chromosome in humans (see Example 2) supports this model. Furthermore there are 'hot spots' of Lys4 H3 methylation on the 'inactive' X chromosome and in some cases tumor supressor genes have been mapped into this chromosomal region. Loss of heterozygosity at this gene correlates well with a significant number of advanced cases of ovarian cancers.
Therefore the present antibodies can also be used as diagnostics for detecting cancer and for determining therapy strategies. In accordance with one embodiment a method is provided for detecting chromatin alterations that are associated with a disease state.
The term "disease state" is intended to encompass any condition that is associated with an impairment of the normal state of a living animal or plant including congenital defects, pathological conditions such as cancer, and responses to environmental factors and infectious agents (bacterial, viral, etc.). The method comprises the steps of isolating chromatin from both normal and diseased tissue, contacting the two pools of chromatin with either the Methyl(K4)H3 or Methyl(K9)H3 antibody and comparing the staining pattern of the chromatin isolated from normal tissue to that of the diseased tissue. Furthermore, using chromatin immunoprecipitation, unique tumor suppressor genes could be isolation by differential screening using the antibodies of the present invention.
In accordance with one embodiment of the present invention the Methyl(K4)H3 and Methyl(K9)H3 antibodies are used to identify heterochromatin and euchromatin regions and thus detect transcriptionally active and inactive regions of chromatin. More particularly, the antibodies can be used to detect changes in chromatin structure that are associated with a given disease state. Therefore the ~0 antibodies can be used as a diagnostic to detect alterations of chromatin structure that are associated alterations in expression patterns (i.e. differences in heterochromatin vs euchromatin patterns relative to predominant native patterns). Alterations in chromatin structure for a specific region of chromatin may be diagnostic of a particular disease state. For example, conversion of a normally euchromatic region of the genome to heterochromatin may represent the suppression of a tumor suppressor gene that is indicative of cancer or a pre-cancer state. 'Similarly the conversion of a region of heterochromatin to euchromatin may be associated with the inappropriate or overexpression of a gene that has deleterious effects on the host cell/organism.
The present invention is also directed to a method of using broad-based differential screening techniques to isolate nucleic acid regions that have altered expression patterns in diseased tissues. For example, chromatin can be isolated from diseased tissues and compared to chromatin isolated from healthy tissues to determine if there are any differences in the chromatin structure (i.e. changes in heterochromatin vs. euchromatin) that are associated with the disease state. Such differences in chromatin structure may represent suppression or overexpression of genes that play a direct or indirect role in the disease. The anti-methyl(Lys 9) H3 and anti-methyl(Lys 4) H3 antibodies can be used to detect such changes in chromatin structure and help identify genes that are associated with the disease state. The identification of such genes will assist in designing more effective therapies for treating the disease.
In one embodiment the method for detecting alterations in chromatin structure associated with a particular disease comprises chromatin immunoprecipitation assays, using modification-specific histone antobodies.
This process allows for the analysis of a wide range of DNA-templated processes that are governed by the chromatin environment. More particularly, the method comprises the steps of isolating chromatin from both diseased tissue and healthy tissue, fragmenting the DNA (preferably by sonification), and immunoprecipitating chromatin using an antibody that specifically binds to the amino acid sequence of ARTKQTAR (SEQ
ID
NO: 1) or QTARKSTGV (SEQ ID NO: 2), wherein the bold I~ represents a methylated lysine residue, and comparing the chromatin (and the associated DNA
sequences) immunoprecipitated from the healthy tissue relative to the diseased tissue.
Comparison of the two pools of immunoprecipitated chromatin will allow for the ~ identification of differences between diseased and healthy tissues.
In one embodiment, comparison of the two pools of immunoprecipitated chromatin comprises the steps of isolating the nucleic acid sequences associated with the two pools of immunoprecipitated chromatin and comparing the resulting two pools of nucleic acid sequences. Comparison of the two pools of nucleic acid sequences can be conducted using any of the standard molecular techniques, including PCR, gel electrophoresis, nucleic acid sequencing and nucleic acid hybridization analysis. Those nucleic acid sequences that are present in only one of the two pools of nucleic acid sequences are then recovered. These nucleic acid sequences represent expressed/suppressed genes that are associated with either the normal or diseased tissue. In one embodiment the antibodies used to immunoprecipitate the chromatin are selected from the group consisting of Methyl(K4)H3 and Methyl(K9)H3 antibody.
The use of methyl Lys4/Lys9 histone H3 antibodies in chromatin immunoprecipitation (chromatin IP) assays is one way to enrich for genomic DNA
corresponding to the epigenetic 'ON/OFF' state of the human genome (and other genomes as well). By combining chromatin immunoprecipitated DNA with current genomic microarray technology (on chips), one has the potential to survey any portion of the human (or other) genome as to their on/off state through the 'histone code'. For example, DNA immunoprecipitated using the Methyl(K4)H3 antibody can be immobilized on a solid surface or "chip" and thus represent all the nucleic acid sequences of a given cell that is competent for transcription. Similarly, DNA
immunoprecipitated using the Methyl(K9)H3 antibody can be immobilized on a solid surface or "chip" and thus represent all the nucleic acid sequences of a given cell that is not competent for transcription. Harvesting mRNA or preparing cDNA from a target cell, labeling the target nucleic acids and then hybridizing the target DNA with the immobilized DNA will reveal abnormal expression of genes.
Knowing this information may prove invaluable in determining the on/off state of key tumor suppressor or oncogenic proteins in various human cancers.
Knowing how this epigenetic marking corresponds to genomic DNA will also guide the ability to produce transgenic animals and plants where one often finds that most transgenic DNA enters a 'bad' (Lys9) chromatin environment and is silenced.
Thus, the implications for knowing how to better 'guide' DNA into a 'good' (Lys4) chromatin environment for animal and plant transgenic work are high. In.
humans, this would impact on gene therapy issues as well. .
In one embbdiment, immunoprecipitation of chromatin will be used to map the location of active genes at a genome-wide level through the use of microarrays. For example, in one preferred embodiment the method of comparing the two pools of immunoprecipitated chromatin (i.e. the iinmunoprecipitated chromatin from diseased vs healthy tissues) comprises the use of a gene chip, DNA
microarray, or a proteomics chip using standard techniques known to those skilled in the art. For example any of the systems described in WO O1/16860,W0 01/16860, WO 01/05935, WO 00/79326, WO 00/73504, WO 00/71'746 and WO 00/53811 (the disclosures of which are expressly incorporated herein) are suitable for use in the present invention.
Preferably the chip will contain an ordered array of known compounds, such as known DNA sequences, so that interaction of the immunoprecipitated chromatin at a specific location of the chip will identify, and allow for the isolation of, DNA
sequences associated with the immunoprecipitated chromatin.
The key to this technology is the use of antibodies specific to various modification as they relate to the histone code. Applying this to human and other genomes would lay the foundation of epigenomics. While the present invention has detailed the use of Lys4/Lys9 methyl H3 antibodies as respective ON/OFF
antibodies, this concept applies more generally to any and all antibodies that are developed directed at the 'histone code'. For example, Lys9 methyl vs. SerlO phos H3 antibodies may also be a 'methyl/phos' switch that regulates differentiation vs.
proliferation. The present invention also encompasses antibodies that are directed to other methylated regions of the amino terminus of H3 and H4 histones, including H3 lysines 27 and 36 and H4 lysine 20. The peptides that will be used to generate these antibodies are listed below:
H3 lysine 27: AARKSAPVCG (SEQ ID NO: 16) H3 lysine 36: SGGVKKPHKCG (SEQ ID NO: 17) H4 lysine 20: R,HR-KTT.RDCG (SEQ ID NO: 18) wherein the bold K is the methylated lysine residue and underlined GC refers to artificial amino acids added to the H3 sequence to aid in the production of this antibody.
The antibodies of the present invention can be used in standard Molecular Biology techniques such as-Western blot analyses, immunofluorescence, and immunoprecipitation. As noted above the presence of methylated H3 at lysine 4 correlates with transcriptionally active nuclei, and therefore, this H3 antibody may be a useful in the understanding of gene regulation. In addition it is anticipated that microinjection of the Methyl(K4)H3 antibody into cells may interfere with the activation of specific genes.
In one embodiment of the present invention a kit is provided for detecting euchromatin and heterochromatin. The kit comprises an antibody that specifically binds to a lysine methlyated modified peptide selected from the group consisting of ARTKQTARGC (SEQ ID NO: 4), QTARKSTGVCG (SEQ ID NO: 5), ARTKQTAR (SEQ ID NO: 1), QTARSTGV (SEQ ID NO: 2), ARTKQTARKSTGV
(SEQ ID NO: 9), A.ARKSAPVCG (SEQ ID NO: 16), SGGVKKPHKCG (SEQ ID
NO: 17) and RHRHILRDCG (SEQ ID NO: 18). More particularly, the kit comprises an antibody that binds to the peptide ARTKQTARGC (SEQ ID NO: 4), QTARKSTGVCG (SEQ ID NO: 5) or QTARKSTGGCG (SEQ ID NO: 6), wherein the bold K represents a methylated lysine residue. In one embodiment the antibodies are attached to an insoluble support, wherein the support is either a monolithic solid or is in particular form. In one preferred embodiment the antibodies are monoclonal antibodies and in a further embodiment the antibodies are labeled. To this end, the antibodies of the present invention can be packaged in a variety of containers, e. g. , vials, tubes, microtiter well plates, bottles, and the like. Other reagents can be included in separate containers and provided with the kit; e.g., positive control samples, negative control samples, buffers, cell culture media, etc.
In an another embodiment of the invention a kit is provided for use in an assay to determine if a sample has methylase activity. The kit comprises a peptide selected from the group consisting of ARTKQTARGC (SEQ ID NO: 4), QTARKSTGVCG (SEQ ID NO: 5), ARTKQTAR (SEQ ID NO: 1), QTARSTGV
(SEQ ID NO: 2) and ARTKQTARKSTGV (SEQ ID NO: 9) and an antibody that specifically binds to a lysine methlyated modified peptide selected from the group consisting of ARTKQTARGC (SEQ ID NO: 4), QTARKSTGVCG (SEQ ID NO: 5), ARTKQTAR (SEQ ID NO: 1), QTARSTGV (SEQ ID NO: 2) and ARTKQTARKSTGV (SEQ ID NO: 9). In one embodiment the antibodies are attached to an insoluble support, wherein the support is either a monolithic solid or is in particular form. In another embodiment the kit is further provided with an antibody that specifically binds to a non-methylated peptide selected from the group consisting of ARTKQTARGC (SEQ ID NO: 4), QTARKSTGVCG (SEQ ID NO: 5), ARTKQTAR (SEQ ID NO: 1), QTARSTGV (SEQ ID NO: 2) and ARTKQTARKSTGV (SEQ 117 NO: 9). Such an antibody serves as a negative control.
In one embodiment, the method for detecting the methylase activity of a sample comprises contacting a peptide selected from the group consisting of ARTKQTARGC (SEQ ID NO: 4), QTARKSTGVCG (SEQ ID NO: 5), ARTKQTAR
(SEQ ID NO: 1), QTARSTGV (SEQ ID NO: 2) and ARTKQTARKSTGV (SEQ ID
NO: 9) for a predetermined length of time with a sample that is suspected of having methylase activity. The amount of methylation-specific antibody (i.e.
Methyl(K4)H3 or Methyl(K9)H3) that binds to the substrate is a direct correlation of the extent the substrate was methylated during the predetermined time length and thus indicates the methylase activity of the sample. This assay can also be used to screen for potential inhibitors of a methylase. For example, in one embodiment a method of screening for inhibitors of arginine methyl transfer activity comprises the steps of providing a sample, wherein the sample comprises a methylase and a substrate that is methylated by said methylase, adding a potential inhibitor of the methylase to the sample, and contacting the sample with an antibody that binds specifically to the methylated substrate, but not the non-methylated substrate. In one embodiment, the antibody is specific for the peptide ARTKQTAR (SEQ ID NO: 1) or QTARKSTGV (SEQ ID
NO: 2). Quantifying the amount of antibody bound to the peptide is a direct correlation of the level activity of the methylase in the sample. In one preferred embodiment the methylase activity to be detected is SuVar3-9 (for Lys 9) or Setl (for Lys 4).
'Knock-out' strains are available for all of the non-essential genes present in budding yeast...around 4,800. The antibodies of the present invention have such a high degree of specificity, that they only detect one or two major bands in yeast whole cell lysates, thus allowing for the development of a robotic screening method to look at all of these knock-out strains. Using Lys4 methyl H3 should lead to the entire upstream pathway of 'regulators' including the on and off enzymes (provided the gene product is non-essential).
Using the above approach in 'old-fashioned' blots, is has been found that Setl is the enzyme responsible for the Lys4 H3 methyl mark in yeast, and is also one of the Lys4 HMTases in humans. Surprisingly, using the methyl Lys4 H3 antibodies as a readout to probe yeast whole cell lysates, Lys4 methylation was discovered to be regulated by H2B ubiquitination at a conserved Lysine on the opposite side of the nucleosome. This is the first example of a 'trans-tail' effect meaning that one histone modification on one tail effect another modification on another not-so-close tail. In humans and in mice, the enzymes that add ubiquitin to proteins is human Rad6 (HR6), and HR6 comes in two isoforms, HR6A and HR6B.
Mice knockouts of HR6B -/- are male sterile in a pathway that is not known, but seems to lead to chromatin defects during spermatogenesis leading to sperm death.
Accordingly it is anticipated that HR6B is responsible for ubiquitin addition on H2B
and therefore it is possible that Lys4 H3 methyl antibodies will be a diagnostic for male infertility. Furthermore, the possibility exists that defects in Lys9 methylation could impact X-inactivation and lead to female infertility. Therefore in accordance with one embodiment of the present invention the Methyl(K4)H3 and Methyl(K9)H3 antibodies are used as a diagnostic to.screen for male and female infertility defects.
Current models suggest that Lys9 methylation is catalzyed, at least in some instances by SuVar3-9. It appears that the Lys9 methyl mark is read by chromodomains, short protein modules that act as chromatin 'velcro' patches.
Best documented is the chromodomain of the heterochromatin protein HP 1.
Interestingly, the chromodomain from HP1, binds well to Lys9 methyl H3 peptides, but binds much less well to Lys4 or unmodified peptides. It is interesting also that SuVar3-9 itself, a catalytic HMTase, also has a chromodomain, a module whose site specificity for methylated histone peptides has yet to be tested.
It seems likely that the Lys4 methyl mark in H3 will be read by a distinct chromodomain from that of HP 1. In one embodiment the uniquely-modified peptides of the present invention, including ARTKQTAR (SEQ ID NO: 1) or QTARKSTGV (SEQ ID NO: 2) are used as affinity reagents to look for polypeptides that bind Lys4 H3 peptides. Several attractive candidates include two histone acetyltransferases (HATS), Esal and.CDY, both of whom have chromodomains.
Interestingly CDY is a testis-specific HAT encoded on the male Y chromosomes, and somatic histones are well known to be hyperacetylated during a reaction that leads to replacement by protamines.
It could be that during spermatogenesis the following series of concerted reactions occur:
1. H2B ubiquitination happens, catalyzed by HR6B
2. Chromatin opening 3. Lys4 methylation catalyzed by human Setl or another Lys4 HMTase 4. Binding of the HAT CDY to the Lys4 methylation mark though its chromodomain -22_ Histone hyperacetylation occurs catalyzed by CDY
6. Somatic histones are displaced, followed by transition proteins, followed by protamines Defects in any of the above steps could lead to sperm lethality and male infertility.
Note that three of the steps require chromatin-modifying enzymes:
i) HR6B a E2 ubiquitin-conjugating enzyme ii) Setl or a resposible Lys4 HMTase iii) CDY a male-specific HAT
Antibodies to ubiquitinated H2B and H2A, Lys4 methyl H3 and sites of CDY-catalyzed acetylation would all be of potential diagnostic value in male infertility screens.
Example 1 Preparation of the Methyl(K4)H3 and the Methyl(K9)H3 antibodies To generate the Methyl(K4)H3 and the Methyl(K9)H3 antibody, a short polypeptide corresponding to the amino-acid sequence of histone H3 surrounding lysine 4 (SEQ ID NO: 4; ARTKQTARGC) or lysine 9 (SEQ ID NO: 5;
QTARKSTGVCG) was first chemically synthesized, wherein the bold K is the methylated lysine residue and underlined GC refers to artificial amino acids added to the H3 sequence to aid in the production of this antibody. This polypeptide was then conjugated to cationized bovine serum albumin (BSA), and the conjugated-peptide was injected into rabbits. One important aspect to this procedure is the fact that the standard technique of conjugating a peptide to Keyhole Limpet Hemocyanin (KLH) proved ineffective in generating high quality methyllysine 4 (H3)-specific antisera.
Thus, the use of this specialized cationized BSA is now considered a unique "method"
in generating methyllysine-specific antibodies.
Rabbit serum was harvested at regular intervals post-immunization, and the Methyl(K4)H3 and Methyl(K9)H3 antibodies were shown to be present in the Serum by standard enzyme-linked immunosorbent assays. These antibodies are suitable for use in Western blot, immunofluorescence, and immunoprecipitation assays.
Example 2 Role of Histone H3 Lysine 9 Methylation in Epigenetic Control of Heterochromatin Assembly The assembly of higher order chromatin structures has been linked to the covalent modifications of histone tails. Ih vivo evidence demonstrates that lysine 9 of histone H3 (H3 Lys 9) is preferentially methylated by. the Clr4 protein at heterochromatin-associated regions in fission yeast. Both the conserved chromo-and SET domains of Clr4 are required for H3 Lys 9 methylation i~ vivo.
The organization of the higher order chromatin structure has been linked to the posttranslational modifications of histone tails, including acetylation, phosphorylation, and methylation. It has been suggested that distinct combinations of covalent histone modifications, also referred to as the "histone code,"
provide a "mark" on the histone tails to recruit downstream chromatin-modifying proteins. This is best illustrated by recent studies indicating that the conserved bromo-domain of several transcriptional coactivators bind specifically to acetylated lysine residues on histone tails. The mechanisms responsible for the establishment and maintenance of multiple covalent modifications within the same or different histone tail are not-fully understood.
Modifications of histone tails have also been linked to heterochromatin assembly. Histones H3 and H4 are largely hypoacetylated in heterochromatic chromosomal regions in organisms as diverse as yeast, flies, and mammals. In fission yeast, hypoacetylation of histones is associated with the silent mating-type region and centromeres, chromosomal domains that share many parallels with heterochromatic regions in higher eukaryotes. Centromeric regions comprising a central core of unique sequences surrounded by inner (imr) and outer (otr) repeats are assembled into silenced chromatin structures. Similarly, a laxge ;15-kb chromosomal domain at the mating-type (mat2l3) region, including the matt and mat3 loci and an interval between them, known as the K-region, is maintained in a silent epigenetic state.
Among the traps-acting factors that affect silencing at these regions, Clr3 and Clr6 belong to family of histone deacetylases (HDACs). Swi6 and Clr4 proteins contain a chromodomain, an evolutionarily conserved motif initially identified in HP 1 and Polycomb proteins. Recently, both Clr4 and its mammalian counter-part, SUV39H1, have been shown to have intrinsic histone H3-specific methyltransferase (HMTase) activity ih vitro (S. Rea et al., Nature 406, 593 (2000)). However, it is not known whether histones are the physiological targets of these methyltransferases ih vivo.
Consistent with previous findings, recombinant Clr4 (rClr4) was found to contain HMTase activity exclusively for histone H3. To identify the specific residue of H3 methylated by rClr4, synthetic peptides derived from the NH 2 -terminus of H3 were used as substrates in an in vitro HMTase assay. In particular, five milligrams of HeLa or chicken core histones was incubated with 0.55 mCi of S-adenosyl-L-[methyl-3H]methionine (3H-AdoMet; 72 Cilmmol; 1 mM final) and 2 mg of recombinant Clr4 wild-type or mutant proteins in 25 ml of HMTase buffer [50 mM
tris ( pH 8.0), 1 mM phenylmethylsulfonyl fluoride, 0.5 mM dithiothreitol in 10%
glycerol] for 1 hour at 30°C. SDS loading buffer was added to half of each sample and boiled followed by separation on a 15% SDS-polyacrylamide gel electrophoresis (PAGE) gel. The resulting histone bands were visualized by Coomassie staining and fluorography. For the peptide analysis, 5 mg of each peptide derived from the terminus of human histone H3 containing a COOH-terminal cysteine was used.
Half of the sample was spotted on Whatman P-81 filter paper and washed four times for 10 min in 50 mM NaHC02 ( pH 9.0), followed by liquid scintillation counting. (B.
D.
Strahl, R. Ohba, R. G. Cook, C. D. Allis, P~oc. Natl. Acad. Sci. U.S.A. 96, (1999)). Clr4 preferentially methylated the H3 1-20 unmodified peptide but failed to methylate the H3 19-35 unmodified peptide, indicating that the target residue of Clr4 HMTase resides in the first 20 amino acids of H3.
To determine this target residue, a synthetic H3 1-20 peptide set was developed that contained covalent modifications on different amino acids. With these peptides as substrates, only acetyl or methyl modifications on Lys 9 effectively blocked rClr4 HMTase activity, indicating that Clr4, like its mammalian homolog SUV39H1, selectively methylates Lys 9 of H3. Furthermore, similar to SUV39H1, rClr4 HMTase activity was inhibited by phosphorylation of serine 10. These results demonstrate that enzymatic features of the Su(var)3-9 protein family are evolutionarily conserved from fission yeast to humans. A recent study demonstrated that the conserved SET domain and two flanking cysteine-rich regions were required for SUV39H1 HMTase activity in vitro. To determine whether the conserved domains, the chromo, SET, and cysteine-rich regions, were also critical for Clr4 HMTase activity, mutant Clr4 proteins were tested for HMTase activity.
Although mutations in the chromo-domain [Trp3' to- Gly (W31 G) and Trp4' to Gly (W41 G)] had little effect on Clr4 HMTase activity, mutations in the SET domain [Gly3z8 to Ser (G378S)] and both cysteine-rich regions [Arg3zo to His (R320H) and G1y486 to Asp (G486D)] greatly reduced Clr4 HMTase activity, indicating that these three regions are critical for Clr4 HMTase activity i~ vitro.
To test the hypothetical correlation between H3 Lys 9 methylation and silencing, an H3 Lys 9 methyl specific antibody was developed. In an enzyme-linked immunosorbent assay, the H3 Lys 9 -methyl antibody specifically recognized the 1-20 Lys 9 -methyl peptide in a wide range of antibody dilution. Moreover, the Lys 9 -methyl antibody did not detect recombinant histone H3 (rH3) alone compared with the HeLa core histone positive control but did detect rH3 selectively methylated by rClr4, further demonstrating the specificity of this antibody (see Nakayama et al., (2001) Science, 292, pp 110-113; the disclosure of which is incorporated herein).
Using this antibody in chromatin immunoprecipitation (ChIP) experiments (Nakayama et al, (2000) Cell, 101, 307), it was discovered that the H3 Lys 9 methyl modification is specifically localized at the silenced chromosomal regions. H3 Lys 9 methylation and Swi6 were preferentially enriched at a marker gene (King: : u~a4 1 ) inserted within the silenced mat2/3 chromosomal domain, compared with control ura4DSlE locus at the endogenous location. Similarly, H3 Lys '9 methylation was also preferentially enriched at the ui~a41 marker inserted within the highly repressed innermost repeat (imrl R: : ura41 ) and the outer repeat (otr~1 R: : ura4 1 ), but not at the weakly repressed central core (cntl:: ura4 1 )of cehl. In addition, H3 Lys 9 methylation coincided with the presence of Swi6 at these regions (Partridge et al, (2000), Genes Dev., 14, 783). These findings suggest that H3 Lys 9 methyl modification and Swi6 are preferentially localized to silent chromosomal regions and that Swi6 localization is functionally dependent on H3 Lys 9 methylation.
Compared with the relatively high levels of Swi6 and H3 Lys 9 methylation at both Kint2: : ura41 and otrl R: : ura4 1 in wild-type cells, Swi6 and H3 Lys 9 methylation were absent in a clr4D strain at both loci. This result suggests that H3 Lys 9 is the physiological target of Clr4 HMTase activity and that Clr4 appears to S be the exclusive ivy vivo H3 Lys 9 -specific HMTase at mat and cen loci. In comparison with the ire vitro result showing that only the SET domain is required for Clr4 HMTase activity, both the chromo-and SET domains are required for H3 Lys methylation and Swi6 localization ire vivo. Taken together,~these results indicate that the chromodomain is presumably required for targeting Clr4 to the mat2/3 region and centromeres, whereas the SET domain and associated cysteine-rich regions of Clr4 constitute the catalytic site. The Swi6 levels at mat and ceh in different clr4 mutant backgrounds were directly correlated with H3 Lys 9 methylation levels, further suggesting that Swi6 localization at silent chromosomal domains is functionally dependent on H3 Lys 9 methylation.
The importance of the in vivo analyses was further highlighted by observations that some mutations in Clr4 that decrease its HMTase activity ih vitro do not substantially decrease H3 Lys 9 methylation and Swi6 localization ih vivo.
In addition, mutations in the SET domain and the NH 2 -terminal cysteine-rich regions of Clr4 (G378S and R320H) greatly reduce H3 Lys 9 methylation and Swi6 localization at the mat locus; however, these mutations have moderate or negligible effects at cell. These mutations also have weak effects on centromeric silencing compared with mating-type silencing. The results are consistent with the notion that enzymatic defects displayed by recombinant monomeric proteins in vitro can be "rescued" by functioning in the context of a multisubunit complex in vivo.
Moreover, the functional organization of the mat2/3 region and centromeres may differ, and an additional factors) may help promote Clr4 activity at centromeres.
Mutations in the clr3 HDAC, which specifically deacetylates H3 Lys 14, affects silencing at mat and cen (S. I. S. Grewal, M. J. Bonaduce, A. J.
S. Klar, Genetics 150, 563 (1998)). ChIP analysis demonstrated that a clr3-735 mutant partially defective in H3 Lys 14 HDAC activity displayed a moderate decrease in H3 Lys 9 methylation and Swi6 localization at otrl: : ura4+, coincident with the apparent reduction in its HDAC activity. This result suggests that H3 Lys 14 acetylation inhibits Clr4 HMTase in vivo. To further investigate the functional interaction between Clr3 and Clr4, a double-mutant strain containing the clr3-735 and clr4R320H
mutations was created, a clr4 mutation that had the least effect on H3 Lys 9 methylation at otrl R: : ura4+. ChIP analysis of the double mutant demonstrated that H3 Lys 9 methylation and Swi6 localization were nearly abolished when compared with the single mutants. These findings indicate that Clr3 acts synergistically with Clr4 to effectively localize Swi6 to heterochromatic domains. In other words, deacetylation of H3 Lys 14 by Clr3 is required for H3 Lys 9 methylation by Clr4 and for Swi6 localization either indirectly, by altering Clr4 activity, or directly or both.
These data also support the theory that residues neighboring Lys 9, and potentially their modification states, play an important role in establishment of the appropriate H3 Lys 9 -methyl mark. Previous studies have shown that rikl + affects silencing as well as Swi6 localization at silent loci. Computational analyses revealed that Rik1 contains b-propeller domains typically found within WD-40 repeat proteins and are theorized to participate in protein:protein interactions. A mutation in rikl completely abolished H3 Lys 9 methylation and Swi6 localization at both mat and ceh compared with wild type.
WD-40 proteins are involved in many aspects of chromatin remodeling and histone metabolism, such as chromatin assembly and acetylation or deacetylation of histones. Therefore, the b-propeller domains of Rikl may form a complex with Clr4 to recruit its HMTase activity to heterochromatic regions and may play a role in coupling other transacting factors, such as Swi6 and histone deacetylases.
The possible role of Swi6 on Clr4-dependent methylation of H3 Lys 9 was also tested. Strains carrying swi6-115 (W269R) mutation that severely reduced Swi6 protein levels were used. As expected, Swi6 localization at both mat and cen was abolished as demonstrated by ChIP analysis. The'swi6-11 S mutation did not cause any detectable change in H3 Lys 9 methylation when compared with the wild-type strain. These data indicate that Swi6 is dispensable for Clr4 function and suggest that Swi6 acts down-stream of Clr4 H3 Lys 9 methylation. Collectively, the above results define a temporal sequence of events leading to establishment of the silenced chromatin state with regard to the covalent modifications of the H3 NH 2 -terminal tail. HDACs and HMTases act cooperatively to establish a "histone code" that is then _~$-recognized by Swi6. More specifically, the HDACs (Clr6 and/or Hdal) deacetylate H3 Lys 9, whereas Clr3 deacetylates H3 Lys 14 before H3 Lys 9 methylation by the Clr4/Rik1 HMTase complex. Swi6 binding to the H3 Lys 9 -methyl modification would then result in self propagating heterochromatin assembly. Because the heterochromatin-binding domain of Swi6 was mapped to its chromodomain, it is most likely that this protein motif has evolved to recognize the H3 Lys 9 -methyl modification. -It was recently shown that Swi6 remains associated with the mat2/3 region throughout the cell cycle where it acts as an important determinant of the epigenetic cellular memory, promoting inheritance of the silenced state.
Because the mouse homolog of Swi6, M31, associates with Su(var)3-9, a similar inter-action between Clr4 and Swi6 is predicted. The close association of Clr4 enzymatic HMTase activity, followed by recruitment and binding of Swi6 to Lys 9 methyl "marks" in H3 through its chromodomain, suggests a pathway of epigenetic inheritance. The extent to which the chromo-domain of Clr4 recognizes H3 Lys 9 -methyl marks is unknown, but it would provide the enzyme a means to bind chromatin as it performs subsequent methylation events. On the basis of the conservation of Clr4/SLTV39H1 and Swi6/HP1 proteins and the presence of H3 Lys methyl modification in higher eukaryotes, a similar mechanism may be responsible for higher order chromatin assembly in organisms ranging from fission yeast to humans. Considering the parallels between transcriptional repression by Polycomb group proteins in flies and mammals and silencing in fission yeast, it is likely that histone methylation coupled with histone deacetylation may help localize Polycomb in pathways that lead to the regulation of homeotic gene expression.
Example 3 Differential Sites of Histone H3 Methylation Marks the Active and Inactive Genes on the Human X Chromosome Chromosomes in higher eukaryotes have historically been considered to consist of regions of euchromatin and heterochromatin, which are distinguished by the degree of condensation and level of transcriptional activity of the underlying DNA
sequences. Certain regions of constitutive heterochromatin are found at or near specialized structures such as centromeres, and are comprised mostly of genetically inert repetitive sequences. In contrast, other regions that have the same primary DNA
sequences can exhibit characteristics of either type of chromatin, suggesting that epigenetic factors, such as packaging of DNA by histones and chromatin-associated proteins, dictate the heterochromatin status at these loci.
One of the most dramatic examples of epigenetic silencing is the X
chromosome inactivation seen in female cells of mammals. This process allows for dosage compensation of X-linked genes whereby one of the two copies of the X
chromosome in female cells is randomly inactivated during embryonic development.
Current evidence suggests that X inactivation is initiated by the up-regulation of the non-coding XIST transcript and its association in cis with the chromosome to be inactivated. Following its coating by XIST RNA, the inactive X chromosome acquires heterochromatic characteristics such as late replication timing, a condensed appearance (Barr body) in interphase cells, DNA methylation of CpG islands at house-keeping genes, and association with altered nucleosomes that are composed of hypoaceiylated histones and enriched for the H2A variant MacroH2A. While the exact roles of these properties in the onset of X inactivation remain unclear, once the inactive state has been established, these epigenetic characteristics seem to act synergistically to maintain the remarkable stability of the inactive X through many cell divisions in the adult soma.
Recently, several publications showed that histone H3 methylation is important in the assembly of heterochromatin in mouse and S pombe (Lachner et al., Nature 410, 116 (2001); Bannister et al., Nature 410, 120 (2001) and Nakayama et al Sciehce 292, 110 (2001)). The chromodoma.in of mouse HP1 (and Swi 6 in S.
pombe) can bind to H3 methylated at lysine 9, and methylatiori of H3 at this site is thought to mark and recruit factors involved in heterochromatin assembly. In addition, acetylation and methylation of H3 at lysine 9 may be competing events in uivo (Cheung et al., Cell 103, 263 (2000)). Given that H3 is hypoacetylated on the inactive X chromosome, and that H3 lysine 9 methylation is important in heterochromatin assembly, the inactive X was investigated for enrichment for Lys9-methylated H3.
Using an antibody specific for Lys9-methylated H3, female human metaphase chromosomes were examined from a normal lymphoblast cell line (HH) by indirect immunofluorescence. In particular, a normal human female lymphoblast cell line (HH) and a female lymphoblast cell line which contains five X chromosomes (6061B) were grown, harvested and collected onto microscope slides with a Cytospin 3 centrifuge. Modified histones were detected by indirect immunofluorescence, essentially as described in detail elsewhere (Costanzi and J. R. Pehrson, Nature 393, 599 (1998)). Briefly, cells were incubated for one hour at 37 °C in a humid chamber with serial dilutions of the primary Lys9 methyl H3 or acetyl H4 antisera and washed in KCM (120mM KCI, 20mM NaCI 10 mM TRIS-CL, pH 8.0, 0.5 M EDTA, 0.1%
Triton). The cells were then incubated for 30 min at room temperature with Cy3-conjugated, affinity-purified, donkey anti-rabbit IgG antibody (Jackson ImmunoResearch) diluted 1:40 in KCM. Cells were once again washed with KCM
and fixed in 4% formaldehyde for 10 min at room temperature. Following a wash in sterile water chromosomes were counterstained with 4',6-diamidino-2-phenylindole (DAPI), mounted in antifade (Vectashield) and viewed on a Zeiss Axiophot fluorescence microscope.
Indirect immunofluorescence using an antibody specific for Lys9-methylated H3 revealed that while most chromosomes have some regions of Lys9-methylated-H3, one chromosome in each metaphase spread is consistently more intensely and uniformly stained (Figure 1A, white arrow). To test whether the chromosome enriched for Lys9-methylated H3 is the inactive X chromosome, .
metaphase spreads from a cell line that contains five X chromosomes was also stained. In these cells, four out of the five X chromosomes are known to be inactivated and indeed four chromosomes of equal size show enriched staining by the Lys9-methyl H3 antibody. Together, these data suggest that while the H3 molecules on the inactive X are mostly hypoacetylated, they are highly methylated at lysine 9.
The N-terminus of histone H3 is post-translationally modified at multiple sites and lysine 4 of H3 is another documented site of methylation.
However, in contrast to lysine 9, lysine 4 methylation has been correlated with active transcription. To further compare these two sites of H3 methylation on the inactive X
chromosome, metaphase chromosomes were stained using an antibody specific for Lys4-methylated H3. Metaphase chromosomes from female cell lines HH and 6061B
were incubated with Lys4 methyl H3 antiserum and the staining pattern was analyzed by indirect immunofluorescence as described earlier. Strikingly, this antibody intensely stains all chromosomes in the metaphase spread except for a single chromosome per spread (Fig. 1B). This unique chromosome is almost totally devoid of staining except for several 'hot spots' of H3 lysine 4 methylation.
Staining of the metaphase spreads of the SX cell line shows that four of the chromosomes are understained using the Lys4 methyl H3 antibody, suggesting that the hypo-H3 Lys4-methylated-chromosomes) is the inactive X chromosome.
Closer examination.of the inactive X chromosome shows that there are several distinct regions of this chromosome that exhibit intense staining with the Lys4 methyl H3 antibody. One region appears to be located at the pseudoautosomal region of the distal end of the p arm, another is located near Xq25-26 of the q arm, and fainter staining is occasionally seen around Xp 11. With the exception of Xq25-26, the other regions of Lys4 methyl H3 staining on the inactive X correspond to the location of multiple genes known to escape inactivation (Carrel et al, Proc Natl Acad Sci LT SA 96, 14440 (1999)), and these data are therefore consistent with the idea that Lys4 methylation of H3 is associated with active gene expression.
The intense staining of the Xq25-26 region by the Lys4 methyl H3 antibody is puzzling since this region does not contain any known genes that escape X
inactivation. However, it is intriguing that loss of heterozygosity at Xq25-26.1 is associated with advanced human ovarian carcinomas (see Choi,et al, Genes Chromosomes Cancer 20, 234 (1997)). Further studies of the enrichment of Lys4-methylated H3 at this region on the inactive X chromosome, and determining whether H3 Lys4/Lys9 methylation correlate with the expression level of the putative tumor suppressor genes) at this location will provide additional information on the link between histone H3 methylation and gene expression.
The understaining of the inactive X chromosome by the Lys4 methyl H3 antibody is similar, but not identical, to the staining pattern of this chromosome with antibodies against hyperacetylated form of H4. In this study, some staining at the telomeric region of the p arm of the inactive X chromosome was seen using the antibody against hyperacetylated H4, but not at the Xpl 1 and Xq25-26 regions.
In contrast, previously published results showed that three regions on the inactive X
chromosome (Xpter-22.2, Xp11.3-11.2, and Xq22) were stained with an antibody against hyperacetylated H4, but this was seen only in sodium butyrate-treated human cells. At present, the precise relationship between the regions stained by the hyperacetylated H4 and the Lys4 methyl H3 antibodies has not been clearly defined.
Nevertheless, these data suggest that the inactive X chromosome is devoid of hyperacetylated core histones as well as Lys 4-methylated H3, but is enriched for H3 methylated at Lys9. Together, these combinations of histone modifications may be part of a series of concerted reactions that mediate transcriptional silencing of the inactive X.
To further establish the link between H3 Lys9 methylation and the inactive X chromosome, human female IMR90 interphase cells were examined by immunofluorescence in combination with Fluorescent In Situ Hybridization (FISH).
In particular, IMR. 90 (ATCC) cells were grown on coverslips for 24-48 hours then fixed in 4% formalehyde for 15 minutes at room temperature; the cells were then permeabilised in PBS containing 0.5% Triton-X for 4 min. on ice, washed in PBS
and then washed in 2xSSC prior to RNA FISH. To preserve nuclear structures, cells were kept continously hydrated. RNA FISH hybridization and washes were performed essentially as described elsewhere (Lachner et al, Nature 410, 116 (2001)).
Briefly, cells were hybridized with a XIST probe comprising a pool of four exon-derived DNA
fragments spanning a total of 4.5 kb of sequence, labeled by nick translation with Spectrum Red or Green dUTP (Vysis, Downer Grove, IL). Following hybridization overnight at 37°C, standard washes for RNA FISH (ie 3x in 50% formamide l 2xSSC
and 3x in 2xSSC) were performed. The cells were then washed in PBS / 0.5% BSA
.
prior to performing immunofluorescence. Primary antibody was incubated for 1 hour at room temperature, cells were washed four time in PBS and the secondary antibody.
(Texas red conjugated goat anti-rabbit antibody ) was then applied for 1 hour at room temperature, followed by four washes in PBS. Nuclei were counterstained with DAPI. Images were acquired using a Zeiss Axioplan 2 fluorescence microscope with an Orca 2 CCD camera (Hamamatsu) and Improvision software (IPLab).
It is well established that the XIST transcript specifically localizes to the inactive X chromosome at interphase but not at metaphase, and localization of the Xist transcript can be detected by FISH analysis. The Lys9-methyl-H3 antibody preferentially stains a region that is heterochromatin-dense as indicated by co-localization with DAPI-dense regions. This condensed region also co-localizes with the XIST RNA signal, indicating that the chromosome enriched for Lys9-methylated H3 is indeed the inactive X. Consistent with the metaphase chromosome results, staining of human interphase cells with the Lys4 methyl H3 antibody shows that the region corresponding to the inactive X (based on DAPI dense staining and localization of the Xist RNA) is devoid of Lys4 methyl H3 staining. Intriguingly, a distinct dot enriched for Lys4 methyl H3 is seen within the region of negative staining for some of the cells. Whether this localized region of Lys4 methyl. H3 staining.corrresponds to the intensely stained regions seen in the metaphase chromosome is at present not known. Side by side comparisons of the Lys9 and Lys4 methyl H3 staining in interphase and metaphase cells further showed that the respective staining pattern of these two antibodies are almost reciprocal images. These results have led to the conclusion that lysine 4 and lysine 9 methylation of H3 are 'reciprocal marks' for transcriptionally active and inactive regions respectively, and hence the inactive X
chromosome is hypomethylated at lysine 4 but is hypermethylated at lysine 9.
One resulting prediction is that the Lys4 and Lys9 methyl H3 antibodies would respectively enrich for active and inactive genes on the X
chromosome by chromatin immunoprecipitation (ChIP). On the inactive X
chromosome, the XIST gene is transcriptionally active whereas the PGKl gene is silenced. Conversely, on the active X chromosome, the XIST gene is silent whereas the PGKI gene is actively transcribed. To test the above hypothesis, two CHO
somatic hybrid cell lines were used that contain either a single active or inactive human X chromosome in ChIP assays in order to examine the histone modifications associated with genes present on the active or inactive X chromosomes.
Chromatin from these two cell lines were immunoprecipitated using antibodies against Lys9-methylated H3, Lys4-methylated H3, or Lys9/14-acetylated H3, and the immunoprecipitated DNA was PCR amplified using primers specific to the promoter regions of the human Xist and PGKl genes.
In particular, Chromatin immunoprecipitation assays were done as described in Cheung et al, Mol Cell 5, 905 (2000). In this case, formaldehyde-fixed chromatin was harvested from CHO somatic cell hybrids containing either the active or inactive human X chromosome. Approximately 3 x 106 cells-worth of sonicated chromatin were used per immunoprecipitation reaction with the antibodies indicated in the text. After extensive washing, reverse cross-linking, RNase A and proteinase K
digestions, the immunoprecipitated DNA was analyzed by PCR using primers specific for the promoter regions of the human JPIST and PGKI genes (primer sequences and PCR conditions were derived from Gilbert and P. A. Sharp, Proc Natl Acad Sci U
S A
96, 13825 (1999)), and analyzed by polyacrylamide gel electrophoresis.
Consistent with previously published reports, the acetylated H3 antibody immunoprecipitated XIST DNA only from the inactive X chromosome, and the PGKI DNA only from the active chromosome. Analogous to these results, the Lys4 methyl H3 antibody preferentially immunoprecipitated the XIST DNA from the cells actively expressing XIST (from the cells containing the inactive X
chromosome) and the PGKI DNA from the cells containing the active X chromosome. Therefore, both acetylated H3 and Lys4-methylated H3 are enriched at the actively transcribing loci on both the active and inactive X chromosomes. Immunoprecipitation using the Lys9 methyl H3 antibody showed reciprocal results to those obtained with the Lys4 methyl and acetyl H3 antibodies. In this case, XIST DNA.was immunoprecipitated only from cells containing the active X chromosome whereas the PGKI DNA was immunoprecipitated only from the inactive X chromosome.
Taken together, the chromatin immunoprecipitation data indicate that Lys4- or Lys9-methylated H3 are reciprocally associated with active and inactive genes irrespective of the chromosomal context (active versus inactive X).
Moreover, combined with~the immunofluorescence results, these data suggest that the two distinct methylation sites on H3 may mark regions of active and inactive chromatin, respectively.
The inactive X chromosomes is a well-studied paradigm for epigenetic regulation of gene expression and fox linking specialized nucleosomal architecture with transcription silencing. As mentioned earlier, the entire inactive X
chromosome seems to be largely devoid of hyperacetylated histones, and a core histone variant, MacroH2A, has been found to be enriched at the inactive X chromosome.
Interestingly, none of the above modifications alone can account for the stability associated with this form of epigenetic regulation. Histone methylation, however, has recently been described as a more 'stable' epigenetic chromatin mark whose functions in X inactivation and as a potential cellular 'memory' marker have yet to be explored.
Very recently, methylation of histone H3 at lysine 9 has been defined to be an important modification for heterochromatin assembly, and as shown here, this modification is also enriched in the facultative heterochromatin of the inactive X
chromosome. In contrast, methylation of-H3 at lysine 4 is complementarily absent in the inactive X chromosome, suggesting that methylation of H3 at these two distinct sites may be reciprocal, and that H3 molecules methylated at lysine 4 are preferentially associated with transcriptionally active genes whereas the opposite is true for H3 methylated at lysine 9. These findings provide strong evidence in support of the concept that specific modifications at specific sites on the histone amino-terminal tails can impart distinct characteristics, and perform different cellular functions.
While the precedence for H3 methylated at lysine 9 functioning to recruit chromatin-binding factors has been shown, it is still not clear how this modification may participate in the inactivation of the X chromosome.
Analogously, H3 methylated at lysine 4 may function to recruit transcription-enhancing factors or to block the association of transcription-repressive factors; however, direct evidence for either of these possibilities is still lacking. The present ChIP assays only examined promoters of X-linked genes, but it is anticipated that H3. methylated at these two , respective sites are genome-wide marks that demarcate chromosome domains.
Active and inactive regions of the eukaryotic genome not only adopt contrasting chromatin structure (euchromatin versus heterochromatin), but also have been shown to occupy distinct intranuclear domains. Therefore, methylation of H3 at lysines 4 or 9 may dictate the spatial distribution of associated chromosome regions in transcriptionally permissive versus restrictive environment.
Equally intriguing is the question of which enzyme is responsible for the methylation reaction. While previous studies have shown that the hSuVax3-9 is a H3 lysine9-specific histone methyltransferase, fibroblasts derived from SuVar3-knock out embryos retain the enrichment of lysine 9 methylated at the inactive X
chromosome.
Example 4 Parent-Specific Complementary Patterns of Histone H3 Lys9 And Lys4 Methylation at The Prader-Willi Imprinting Center Imprinted genetic loci show differential expression of maternal compared to paternal alleles in some or all tissues at some or all stages of development. The functional differences between maternal and paternal alleles of imprinted genetic loci must reflect structural differences between maternal and paternal chromosomes in the regions containing these loci. The simplest models for establishment of these structural differences hold that chromosomal domains are marked differentially during oogenesis and spermatogenesis, and that these gametic imprinting marks are maintained after fertilization in somatic cells. However, there is no a priori reason to assume that the gametic imprinting marks are identical to the imprinting marks responsible for differential gene expression after fertilization. If the gametic marks are not the same as the somatic marks, there must be a~mechanism for reading the gametic marks and using their information to impose somatic imprinting marks.
The identity of the imprinting marks in mammals has been the subject of extensive speculation and experimental analysis. An appealing candidate imprinting mark is 5-methylcytosine in CpG dinucleotides. Many imprinted loci show parent-of origin specific DNA methylation of imprinted regions, and some of these parent-specific DNA methylation marks are established during gametogenesis and maintained in somatic cells. A mechanism for replicating methylated CpG
dinucleotides exists: maintenance DNA methyltransferases (DNMTs) recognize hemimethylated DNA (DNA methylated on only one strand) and add methyl groups to cytosine residues on the complementary strand. A frequently-cited experiment in support of cytosine methylation as the imprint is the observation that DNMT1 -/-embryos, which die early in embryonic development, show biallelic expression of some imprinted loci whose normal monoallelic expression is associated with cytosine methylation of the inactive allele.
Although abundant data are consistent with cytosine methylation as the imprint, several lines of evidence exist for additional or alternative molecular imprints. First, a number of imprinted genes, including mouse Mash2, human CDKN1C, and human UBE3A, show no regions of parent-specific DNA methylation.
Second, some genes show evolutionary conservation of imprinting without showing conservation of differentially methylated regions, suggesting that the differential cytosine methylation may be a secondary consequence of a primary imprint.
Third, Mash2 imprinting is not disturbed in the DNMT1 -l- mouse embryo. Finally, the promoter region of the imprinted SNRPN-gene in the Prader-Willi syndrome (PWS) imprinting center (IC) shows differential cytosine methylation in somatic tissues of mouse and human, and the region is heavily methylated in mouse oocytes but unmethylated in mouse sperm; however, El-Maarri et al. (Nature Genet. 27, 341 (2001)) have recently shown that this region is completely unmethylated in human oocytes, as in human sperm, so that the differential cytosine methylation must arise after fertilization.
These data lead to the conclusion that, at least for some imprinted genes and some imprinted regions, the structural difference between maternal and paternal alleles inherited from the gametes that leads to differential gene expression after fertilization must be something other than cytosine methylation. In principle, this structural difference might be a heritable covalent modification of DNA
other than cytosine methylation, a DNA-associated protein that remains stably associated with either the maternal or the paternal chromosome from the gamete through somatic cell divisions, or a covalent modification of a DNA-associated protein that is inherited in a parent-specific fashion.
Histone modifications, especially acetylation, have previously been shown to mediate effects of a number of transcriptional regulatory proteins, presumably by changing chromatin structure to increase accessibility to other transcriptional factors. Unlike acetylated histones, which are quite labile, methyl groups attached to histones show a very low level of turnover, making histone methylation a good candidate modification in epigenetic processes such as imprinting. Accordingly, a histone modification that has recently been associated with the formation of stable silenced chromatin regions in Drosophila and fission yeast, (the methylation of histone H3 on Lys9) as been examined along with the methylation of histone H3 on Lys4, which has been correlated with transcriptional activity in Tetrahymena.
The Prader-Willi syndrome (PWS)/Angelman syndrome (AS) region in human chromosome 15q11-q13 contains at least 10 imprinted genes within a ~2 Mb region (Nicholls et al, Trends Genet. 14, 194 (1998)); 8 of these genes are expressed exclusively from the paternal chromosome, and loss of the active paternal alleles of these genes causes PWS, characterized by infantile hypotonia, mild developmental delay, and later-onset hyperphagia and obesity. Loss of the active maternal allele of one gene in this region, UBE3A, causes AS, characterized by severe mental retardation, lack of speech, seizures, and easily provoked laughter. This region can exist in either of two mutually exclusive epigenetic states, the paternal state and the maternal state. Establishment of the paternal state requires a DNA segment, referred to as the PWS imprinting center (PWS-IC) that includes the SNRPN promoter in cis;
establishment of the maternal state requires a DNA segment approximately 30 kb centromeric of the PWS-IC referred to as the AS-IC. The functions of the PWS-IC
and AS-IC in establishing epigenetic states of this region are not known.
Chromatin prepared from stimulated lymphocytes of controls, PWS
individuals (lacking a paternal copy of 15q11-ql3 through deletion or imprinting defect), and AS individuals (lacking a maternal copy of 15q11-q13) was immunoprecipitated with antibodies specific for either H3 methylated on Lys9 or H3 methylated on Lys4. DNA recovered from the immunoprecipitation was assayed by PCR for sequences in the PWS-IC, including the SNRPN promoter, and for other sequences in the region. The maternal copy of the PWS imprinting center (present in PWS chromatin) was immunoprecipitated by anti-methyl Lys9 H3 antibody, while there was dramatically reduced precipitation of this sequence on the paternal copy (present in AS chromatin). This result correlates welfwith the observation that .
maintenance of silenced heterochromatin in both Drosophila and fission yeast requires the function of Lys9 histone H3 methyltransferases. The region of maternal-specific H3 Lys9 methylation extends approximately 0.6 kb 5' and 0.5 kb 3'from the SNRPN promoter. Conversely, the paternal copy of the PWS-IC was immunoprecipitated by anti-methyl Lys4 H3 antibody. This sequence was not precipitated on the maternal copy. Previous reports of association of this modification with active chromatin are consistent with these findings.
Parent-specific differential association of methyl Lys9 H3 was not detected with the promoters of other imprinted genes in 15q11-q13, including ZNF127, NDN, MAGEL2, IPW, which are paternally-expressed, and UBE3A and ATP10C, which show tissue-specific maternal expression. Methyl Lys9 H3 was also not associated with the AS-IC. However; methyl Lys4 H3 was found to be specifically associated with the promoter region of the paternal allele of the paternally-active gene NDN. Parent-specific Lys4 methylation in lymphocyte chromatin was not detected for ZNF127, MAGEL2, IPW, UBE3A, or ATP10C.
Each of the modifications that has been described (cytosine methylation, histone H3 and H4 acetylation, histone H3 Lys4 methylation, and histone H3 Lys9 methylation) shows a distinct pattern of distribution and parent specificity.
The PWS-IC, which overlaps the SNRPN promoter, shows the most extensive pattern of modification, with cytosine methylation and H3 Lys9 methylation on the maternal allele, and histone H3 and H4 acetylation as well as histone H3 Lys4 methylation on the paternal allele. The paternal SNRPN promoter region is also the site of a very prominent nuclease hypersensitive site that is not present on the maternal chromosome. The promoter region of NDN, which shows differential cytosine methylation, does not show eithex differential histone acetylation or differential H3 Lys9 methylation.
It is clear that the human PWS imprinting center lacks cytosine methylation in oocytes; therefore, this modification can not be the gametic imprint for the AS/PWS region. Among the parent-specific histone modifications of the PWS
imprinting center, H3 and H4 acetylation, as well as H3 Lys4 methylation, also can not be the gametic imprint because sperm lack histones, so a paternal gametic imprint can not be a histone modification. Methyl Lys9 H3, however, is a potential candidate imprinting mark that could be imposed upon histones in the PWS imprinting center during gametogenesis. A maternal histone modification irxiprint would have.the unique feature of undergoing programmed erasure during spermatogenesis, when histones are removed from chromatin and replaced by protamines.
SEQUENCE LISTING
<110> The University of Virginia Patent Foundation Allis, C. David Strahl, Brian <120> Antibodies Specific for Methylated Lysines in Histones IS <130> 00601-02 <150> US 60/227,767 <151> 2000-08-25 <150> US 60/302,747 <151> 2001-07-03 <160> 18 <170> Patentln version 3.0 <210> 1 <211> 8 <212> PRT
4S <213> Homo Sapiens <220>
<221> MOD RES
<222> (4) . .
(4) <223> METHYLATION
<400> 1 Ala Arg Thr Lys Gln Thr Ala Arg <210> 2 <211> 9 _2_ <212> PRT
<213> Tetrahymena~thermophila <220>
<221> MOD RES
<222> (5) . . (5) <223> METHYLATION . .-<400> 2 Gln Thr Ala Arg Lys Ser Thr Gly Val <210> 3 <211> 9 <212> PRT
<213> Homo sapiens <220>
<221> MOD RES
<222> (5) . .
Provisional Patent Application No. 60/302,747, filed on July 3, 2001 and US
Provisional Patent Application No 60/227,767, filed on August 25, 2000, the disclosures of which are incorporated herein by reference in their entirety.
US Government Rights This invention was made with United States Government support under Grant Nos. ROl GM40922 and RO 1 GM53512, awarded by the National Institutes of Health. The United States Government has certain rights in the invention.
Field of the Invention 1 S The present invention is directed to antibodies that bind to histone epitopes created by postranslational modification of the histone protein, compositions comprising such antibodies, and the use of such compositions as diagnostic and screening tools.
Background of the Invention In eukaryotes, DNA is complexed with histone proteins to form nucleosomes, the repeating subunits of chromatin. This packaging of DNA
imposes a severe restriction to proteins seeking access to DNA for ANA-templated processes such as transcription or replication. It is becoming increasingly clear that post-translational modifications of histone amino-termini play an important role in , determining the chromatin structure of the eukaryotic cell genome as well as regulating the expression of cellular genes.
Posttranslational modifications of histone amino-termini have long been thought to play a central role in the control of chromatin structure and function.
A large number of covalent modifications of histories have been documented, including aceiylation, phosphorylation, methylation, ubiquitination, and ADP
ribosylation, that take place on the amino terminus "tail" domains of histories. Such diversity in the types of modifications and the remarkable specificity for residues undergoing these modifications suggest a complex hierarchy of order and combinatorial function that remains unclear. Of the covalent modifications known to take place on histone amino-termini, acetylation is perhaps the best studied and appreciated. Recent studies have identified previously characterized coactivators and corepressors that acetylate or deacetylate, respectively, specific lysine residues in histones in response to their recruitment to target promoters in chromatin (See Berger (1999) Curr. Opin. Genet. Dev. 1 l, 336-341). These studies provide compelling evi-dence that chromatin remodeling plays a fundamental role in the regulation of transcription from nucleosomal templates.
Chromosomes in higher eukaryotes have historically been considered to consist of regions of euchromatin and heterochromatin, which are distinguished by the degree of condensation and level of transcriptional activity of the underlying DNA
sequences. Certain regions of constitutive heterochromatin are found at or near specialized structures such as centromeres, and are comprised mostly of genetically inert repetitive sequences. In contrast, other regions that have the same primary DNA
sequences can exhibit characteristics of either type of chromatin, suggesting that epigenetic factors, such as packaging of DNA by histones and chromatin associated proteins, dictate the heterochromatin status at these loci.
Through the use of antibodies that specifically recognize histones bearing specific post-translational modifications applicants have been elucidating a "histone code." In particular, evidence is emerging that histone proteins, and their associated covalent modifications, contribute to a mechanism that can alter chromatin structure, thereby leading to inherited differences in transcriptional "on-off' states or to.the stable propagation of chromosomes by defining a specialized higher-order structure. . ' Histone methylation is one of the least-understood posttranslational modifications affecting histones. Early work suggests that H3 and H4 are the primary histones modified by methylation, and sequencing studies, using bulk histones, have shown that several lysines (e.g., 9 and 27 of H3 and 20 of H4) are often preferred sites of methylation, although species-specific differences appear to exist.
Interestingly, each modified lysine has the capacity to be mono-, di-, or trimethylated, adding yet another level of variation to this posttranslational "mark". The present invention is directed to antibodies that are specific for histone H3 and H4 that are methylated at specific lysines. More particularly, one aspect of the present invention is directed to histone H3 lysine 4 and 9. These two lysine residues are found to be methylated i~
vivo and the methylated forms axe associated with euchromatin and heterochromatin, respectively.
Definitions In describing and claiming the invention, the following terminology will be used in accordance with the definitions set forth below.
As used herein, the term "nucleic acid" encompasses RNA as well as single and double-stranded DNA and cDNA. Furthermore, the terms, "nucleic acid,"
"DNA," "RNA" and similar terms also include nucleic acid analogs, i.e. analogs having other than a phosphodiester backbone. For example, the so-called "peptide nucleic acids," which are lrnown in the art and have peptide bonds instead of phosphodiester bonds in the backbone, are considered within the scope of the present invention.
The term "peptide" encompasses a sequence of 3 or more amino acids wherein the amino acids are naturally occurring or synthetic (non-naturally occurring) amino acids. Peptide mimetics include peptides having one or more of the following modifications:
1. peptides wherein one or more of the peptidyl --C(O)NR-- linkages (bonds) have been replaced by a non-peptidyl linkage such as a --CH2-carbamate linkage (--CH20C(O)NR--), a phosphonate linkage, a -CH2-sulfonamide (-CH 2--S(O)2NR--) linkage, a urea (--NHC(O)NH--) linkage, a --CH2 -secondary amine linkage, or with an alkylated peptidyl linkage (--C(O)NR--) wherein R; is Cl-C4 alkyl;
2. peptides wherein the N-terminus is derivatized to a --NRRl group, to a -- NRC(O)R group, to a --NRC(O)OR group, to a --NRS(O)2R group, to a --NHC(O)NHR group where R and Rl are hydrogen or Cl-C4 alkyl with the proviso that R and Rl are not both hydrogen;
3. peptides wherein the C terminus is derivatized to --C(O)R2 where R 2 is selected from the group consisting of C1-C4 alkoxy, and --NR3R4 where R3 and are independently selected from the group consisting of hydrogen and C1-C4 alkyl.
Naturally occurring amino acid residues in peptides are abbreviated as recommended by the IUPAC-ILTB Biochemical Nomenclature Commission as follows: Phenylalanine is Phe or F; Leucine is Leu or L; Isoleucine is Ile or I;
Methionine is Met or M; Norleucine is Nle; Valine is Vat or V; Serine is Ser or S;
Proline is Pro or P; Threonine is Thr or T; Alanine is Ala or A; Tyrosine is Tyr or Y;
Histidine is His or H; Glutamine is Gln or Q; Asparagine is Asn or N; Lysine is Lys or K; Aspartic Acid is Asp or D; Glutamic Acid is Glu or E; Cysteine is Cys or C;
Tryptophan is Trp or W; Arginine is Arg or R; Glycine is Gly or G, and X is any amino acid. Other naturally occurring amino acids include, by way of example, hydroxyproline, 5-hydroxylysine, and the like.
As used herein, the term "conservative amino acid substitution" is defined herein as exchanges within one of the following five groups:
I. Small aliphatic, nonpolar or slightly polar residues:
Ala, Ser, Thr, Pro, Gly;
II. Polar, negatively charged residues and their amides:
Asp, Asn, Glu, Gln;
III. Polar, positively charged residues:
His, Arg, Lys;
IV. Large, aliphatic, nonpolar residues:
Met Leu, Ile, Val, Cys V. Large, aromatic residues:
Phe, Tyr, Trp As used herein, the term "purified" and like terms relate to the isolation of a molecule or compound in a form that is substantially free of contaminants normally associated with the molecule or compound in a native or natural environment.
"Operably linked" refers to a juxtaposition wherein the components are configured so as to perform their usual function. For example, control sequences or -S-promoters operably linked to a coding sequence are capable of effecting the expression of the coding sequence.
As used herein, the terms "complementary" or "complementarity" are used in reference to polynucleotides (i.e., a sequence of nucleotides) related by the base-pairing rules. For example, for the sequence "A-G-T," is complementary to the sequence"T-C-A."
As used herein, the term "hybridization" is used in reference to the pairing of complementary nucleic acids. Hybridization and the strength of hybridization (i.e., the strength of the association between the nucleic acids) is impacted by such factors as the degree of complementarity between the nucleic acids, stringency of the conditions involved, the length of the formed hybrid, and the G:C
ratio within the nucleic acids.
"Therapeutic agent," "pharmaceutical agent" or "drug" refers to any therapeutic or prophylactic agent which may be used in the treatment (including the prevention, diagnosis, alleviation, or cure) of a malady, affliction, disease or injury in a patient.
As used herein, the term "treating" includes alleviating the symptoms associated with a specific disorder or condition andlor preventing or eliminating said symptoms. For example, treating cancer includes preventing or slowing the growth and/or division of cancer cells as well as killing cancer cells.
As used herein, the term "pharmaceutically acceptable carrier"
encompasses any of the standard pharmaceutical carriers, such as a phosphate buffered saline solution, water and emulsions such as an oil/water or water/oil emulsion, and various types of wetting agents.
As used herein, the term "antigenic fragment of H3 lysine 4" or "antigenic fragment of H3 lysine 4" encompasses both natural peptide fragments of the amino terminus of Histone 3 (including the peptide fragments of SEQ ID NO:
1, SEQ ID NO: 2 and SEQ ID NO: 3) and synthetic equivalents of those fragments.
As used herein, the term "antibody" refers to a polyclonal or monoclonal antibody or a binding fragment thereof such as Fab, F(ab')2 and Fv fragments.
As used herein, the term "biologically active fragments" of the Methyl(K4)H3 or Methyl(K9)H3 antibodies encompasses natural or synthetic portions of the respective full-length antibody that are capable of specific binding to the peptide of SEQ ID NO: 4 or SEQ ID NO: 5, respectively.
As used herein, the term "parenteral" includes administration subcutaneously, intravenously or intramuscularly.
As used herein the letter K in bold face type (K), when used in the context of an amino acid sequence, will represent a lysine amino acid that has been methylated.
Summary of the Invention The present invention is directed to antibodies that bind to specific modifications of the amino terminus of histone H3 and H4 peptides. More particularly, the present invention is directed to the generation of methyllysine-specific histone antibodies. These antibodies recognize lysine residues in histones H3 and H4 that are specifically methylated and may be linked to human biology and disease. Compositions comprising these antibodies axe used as diagnostic and screening tools.
Brief Description of the Drawings Fig. 1A and 1B represent immunofluorescence patterns of human metaphase chromosomes from the normal female cell line (HH) stained with either the Methyl(K9)H3 antibody (Fig. 1A) or the Methyl(K4)H3 antibody (Fig. 1B).
Localization of the Methyl(K4)H3 and Methyl(K9)H3 antibodies was detected using Cy3-conjugated secondary antibody (red). Each of the immunofluorescence patterns obtained with the two antibodies revealed one chromosome that is preferentially stained compared to the other chromosomes (indicated by large arrow). As shown in Fig. 1B only small regions of the inactive X chromosome are enriched for Lys4 methyl H3 staining.
Fig. 2. CHIP analysis of somatic cell hybrid cell lines. Chromatin from CHO somatic hybrid cells containing the inactive (X;nactive) or active (active) human X chromosome was immunoprecipitated using the following antibodies:
lane 1 = no antibody (control lane); lane 2 = Methyl(K9)H3;
lane 3 = Methyl(K4)H3; lane 4 = Lys9/14-acetylated H3;
lane 5 = no DNA (control); lane 6 = genomic DNA
The presence of Xist and PGKl promoter DNA sequences in the immunoprecipitated DNA was assayed by PCR. The PCR products were separated on 15%
polyacrylamide gels, imaged by digital camera, and images were electronically inverted to facilitate visualization of the ethidium bromide-stained bands. As shown, from cells containing the inactive X chromosome, the Methyl(K4)H3 and Lys9/14 acetyl H3 antibodies preferentially immunoprecipitated the active Xist gene whereas the Methyl(K9)H3 antibody preferentially immunoprecipitated the inactive PGKl gene. From cells containing the active X chromosome, the exact reverse immunoprecipitation pattern was observed.
Fig. 3 Immunoblot analysis of H3 methyiation between simple vs.
complex organisms. Histories were isolated from various sources, and five ug of total core histories from each species, along with 1 ug of recombinant Xehopus H3 were resolved on a 15% SDS-PAGE, transferred to a PVDF membrane support and probed with either the Methyl(K4)H3 or Methyl(K9)H3 antibody. Lanes 1-5 represent histories isolated from recombinant Xenopus H3, budding yeast, Tetrahymena, chicken and the human cell line 293T, respectively. Identical samples were analyzed in parallel and examined by Coomassie staining to monitor histone loading.
-Detailed Description of the Invention Histone methylation is a poorly understood post-translational modification affecting histories. This modification occurs on selected lysine residues in the amino-terminus of histories. It is now becoming apparent that methylating histone enzymes are involved in both gene activation and repression. The present invention is directed to the generation of methyllysine-specific histone antibodies.
These antibodies recognize lysine residues in the histories H3 and H4 that are specifically methylated and may be linked to human biology and disease.
The present invention is directed to post-translational modifications that occur on the flexible N-terminal tails of the core histone proteins H3 and H4.
More particularly, the invention is directed to methylated lysine residues.
Applicants _g_ have discovered that methylation of the lysine residues within the first 15 amino acids of the amino terminus of H3 (SEQ ID NO: 7) and H4 (SEQ ID NO: 8) play an important role in the regulation of transcription. For example, methylation of lysine 4 (K4) on histone H3 has been associated with transcriptionally active regions of chromatin, whereas methylation of lysine 9 (K9) on histone H3 has been associated with gene silencing. Therefore, in accordance with one aspect of the present invention methylation of lysine 4 (K4) and lysine 9 (K9) on histone H3 serve as a markers of euchromatin and heterochromatin, respectively, and antibodies recognizing these modified proteins have use as important diagnostic tools.
One aspect of the present invention is directed to antigens used to produce antibodies specific to the amino terminus of H3 and H4. In one embodiment, the antigen is a purified antigenic fragment of the amino terminus of H3 or H4 methlated at a lysine and selected from the group consisting of ARTKQTARKSTGG
(SEQ ID NO: 10), ARTKQTARKSTGG (SEQ ID NO: 11), ARTKQTARKSTGV
(SEQ ID NO: 12), ARTKQTARKSTGV (SEQ ID NO: 13), SGRGKGGKGLGKG
(SEQ ID NO: 14) and SGRGKGGKGLGKG (SEQ ID NO: 15) or a synthetic equivalent thereof, wherein the bold K represents a methylated lysine residue.
In one embodiment the antigen comprises an H3 amino terminal fragment of 20 amino acids or less and comprises the sequence ARTKQTAR (SEQ ID NO: 1), QTARKSTGV
(SEQ l~ NO: 2) or QTARKSTGG (SEQ ID NO: 3), and derivatives of these amino acid sequences wherein the amino acid sequence contains one or more conservative amino acid substitutions. In one preferred embodiment the antigen is ARTKQTAR
(SEQ ID NO: 1), QTARKSTGV (SEQ ID NO: 2) or QTARKSTGG (SEQ ID NO: 3), or a derivative thereof containing additional non-native amino acids added to either end of the peptide sequence.
In an alternative embodiment, the purif ed antigen comprises a polypeptide linked to a suitable carrier, such as bovine serum albumin or Keyhole limpet hemocyanin. In one preferred embodiment the antigen consists of an H3 peptide fragment peptide comprising a sequence selected from the group ARTKQTAR (SEQ ID NO: 1), QTARKSTGV (SEQ II7 NO: 2) or QTARKSTGG
(SEQ ID NO: 3, and derivatives of this amino acid sequence wherein the amino acid sequence contains one or more conservative amino acid substitutions, and a Garner protein linked to the peptide. For example, the antigen may comprise a peptide having the sequence ARTKQTARGC (SEQ ID NO: 4), QTARKSTGVCG (SEQ ID
NO: 5), QTARKSTGGCG (SEQ ID NO: 6), AARKSAPVCG (SEQ ID NO: 16), SGGVKKPHKCG (SEQ ID NO: 17) or RHRHILRDCG (SEQ ID NO: 18) wherein the bold K represents the methylated lysine residue and the underlined GC
refers to artificial amino acids added to the natural histone sequence. Furthermore, the antigen can optionally be linked to a carrier protein. .
In addition to the antigens described above, the present invention is also directed to antibodies that specifically bind to peptide fragments of the H3 or H4 protein that have been methylated at a lysine residue. Preferably the antibody will recognize one or more methylated lysine residues present in the first 20 amino acid residues of the amino terminus of the H3 and H4 histones. More particularly, the present invention is directed to an antibody that specifically binds to the peptide ARTKQTARGC (SEQ ID NO: 4), QTARKSTGGCG (SEQ ID NO: 6), QTARKSTGVCG (SEQ ID NO: 5), AARKSAPVCG (SEQ m NO: 16), SGGVKKPHKCG (SEQ ID NO: 17) or RHRKILRDCG (SEQ ID NO: 18), wherein the bold K represents the methylated lysine residue and the underlined GC
refers to artificial amino acids added to the natural histone sequence to aid in the production of the antibody. In one embodiment the antibody is specific for a peptide comprising the amino acid selected from the group consisting of ARTKQTARGC (SEQ ID NO:
4), QTARKSTGVCG (SEQ ID NO: 5), QTARKSTGGCG (SEQ ID NO: 6); and amino acid sequences that differ from SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID or SEQ
ID NO: 6 by one or more conservative amino acid substitutions. In one preferred embodiment the antibody specifically binds to the peptide ARTKQTARGC (SEQ ID
NO: 4) or QTARKSTGVCG (SEQ ID NO: 5).
Antibodies that specifically bind an H3~ peptide that is methylated at lysine 4 (i.e. the peptide of SEQ ID NO: 4) will be referred to as Methyl(K4)H3 and antibodies that specifically bind an H3 peptide that is methylated at lysine 9 (i.e. the peptide of SEQ ID NO: 5 or SEQ ID NO: 6) will be referred to as Methyl(K9)H3.
These two antibodies do not cross react and will not bind to the non-methylated peptide sequences. The present invention also encompasses antibodies that bind to the non-methylated histone peptides. In one embodiment, the antibodies of the present invention are monoclonal antibodies.
The antibodies or antibody fragments of the present invention can be combined with a carrier or diluent to form a composition. In one embodiment, the carrier is a pharmaceutically acceptable carrier. Such carriers and diluents include sterile liquids such as water and oils, with or without the addition of a surfactant and other pharmaceutically and physiologically acceptable carrier, including adjuvants, excipients or stabilizers. Illustrative oils are those of petroleum, animal, vegetable, or synthetic origin, for example, peanut oil, soybean oil, or mineral oil. In general, water, saline, aqueous dextrose, and related sugar solution, and glycols such as, propylene glycol or polyethylene glycol, are preferred liquid carriers, particularly for injectable solutions. The compositions comprising the Methyl(K4)H3 or Methyl(K9)H3 antibody, or bioactive fragments thereof, and a carrier or diluent can be used in conjunction with the method to detect heterochromatin verses euchromatin.
One method used to generate the antibodies of the present invention involves administration of an antigen, comprising the sequence ARTKQTAR (SEQ
ID NO: 1), QTARKSTGV (SEQ ID NO: 2) or QTARKSTGG (SEQ ID NO: 3), to a laboratory animal, typically a rabbit, to trigger production of antibodies specific for the antigen. The dose and regiment of antigen administration to trigger antibody production as well as the methods for purification of the antibody are well known to those skilled in the art. Typically, such antibodies can be raised by administering the antigen of interest subcutaneously to New Zealand white rabbits which have first been bled to obtain pre-immune serum. The antigens can be injected at a total volume of 100 u1 per site at six different sites. Each injected material will contain synthetic surfactant adjuvant pluronic polyols, or pulverized acrylamide gel containing the protein or polypeptide after SDS-polyacrylamide gel electrophoresis.
The rabbits are then bled two weeks after the first injection and periodically boosted with the same antigen three times every six weeks. A
sample of serum is then collected 10 days after each boost. Polyclonal antibodies are then recovered from the serum by aff'mity chromatography using the corresponding antigen to capture the antibody. Ultimately, the rabbits are euthenized with pentobarbital 150 mg/Kg IV. This and other procedures for raising polyclonal antibodies are disclosed in E. Harlow, et. al., editors, Antibodies: A Laboratory Manual (1988), which is hereby incorporated by reference. The specificity of antibodies may be determined by enzyme-linked immunosorbent assay or immunoblotting, or similar methods known to those skilled in the art.
The present invention also encompasses monoclonal antibodies that specifically bind to the respective antigen ARTKQTAR (SEQ ID NO: 1), QTARKSTGV (SEQ ID NO: 2) or QTARKSTGG (SEQ ID NO: 3) and their non-methylated counterpart peptides. Monoclonal antibody production may be effected using techniques well-known to those skilled in the art. Basically, the process involves first obtaining immune cells (lymphocytes) from the spleen of a mammal (e.g., mouse) which has been previously immunized with the antigen of interest either i~z vivo or in vitro. The antibody-secreting lymphocytes are then fused with myeloma cells or transformed cells, which are capable of replicating indefinitely in cell culture, thereby producing an immortal, immunoglobulin-secreting cell line. The resulting fused cells, or hybridomas, are cultured, and the resulting colonies screened for the production of the desired monoclonal antibodies. Colonies producing such antibodies are cloned, and grown either in vivo or i~c vitro to produce large quantities of antibody.
One embodiment of the invention is directed to a hybridoma cell line which produces monoclonal antibodies which bind the methyl-lysine peptides of the present invention.
A description of the theoretical basis and practical methodology of fusing such cells is set forth in I~ohler and Milstein, Nature, 256:495 (1975), which is hereby incorporated by reference.
In addition to whole antibodies, fragments of antibodies can retain binding specificity for a particular antigen. Antibody fragments can be generated by several methods, including, but not limited to proteolysis or synthesis using recombinant DNA technology. An example of such an embodiment is selective proteolysis of an antibody by papain to generate Fab fragments, or by pepsin to generate a F(ab')2 fragment. These antibody fragments can be made by conventional procedures, as described in T. Goding, Monoclonal Antibodies: Principles and Practice, pp. 98~118 (N.Y. Academic Press 1983), which is hereby incorporated by reference. Other fragments of the present antibodies which retain the specific binding of the whole antibody can be generated by other means known to those skilled in the art.
In one embodiment the antibodies are labeled. It is not intended that the present invention be limited to any particular detection system or label.
The antibody may be labeled with a fluorophoxe, a radioisotope, ox a non-isotopic labeling reagent such as biotin or digoxigenin; antibodies containing biotin may be detected using "detection reagents" such as avidin conjugated to any desirable label such as a fluorochrome. In one embodiment the histone specific antibodies of the present invention are detected through the use of a secondary antibody, wherein the secondary antibody is labeled and is specific for the primary (histone specific) antibody.
Alternatively, the histone specific antibody may be directly labeled with a radioisotope or fluorochrome such as FITC ox rhodamine; in such cases secondary detection reagents may not be required for the detection of the labeled probe.
In accordance with one embodiment of the present invention a method of detecting the presence of methylated lysine residues in the H3 and H4 histones is provided. The method comprises the steps of contacting histone proteins with a labeled antibody, wherein the antibody specifically binds only to H3 that is methylated at lysine 4 or H3 methylated at lysine 9.
In accordance with one embodiment the antibodies of the present invention are labeled for use in diagnostic imaging. Examples of labels useful for diagnostic imaging in accordance with the present invention are radiolabels such as 131h 111~~ 123h 99mTc~ 32p~ 125h 3H~ 14C~ ~d 188' fluorescent labels such as fluorescein and rhodamine, nuclear magnetic resonance active labels, electron dense or radiopaque materials, positron emitting isotopes detectable by a positron emission tomography ("pET") scanner, chemilluminescers such as luciferin, and enzymatic markers such as peroxidase or phosphatase. Short-range radiation emitters, such as isotopes detectable by short-range detector probes, such as a transrectal probe, can also be employed. These isotopes and transrectal detector probes, when used in combination, are especially useful in detecting prostatic fossa recurrences and pelvic nodal disease. The antibodies of the present invention can be labeled with such reagents using techniques known in the art. For example, see Wensel and Meaxes, Radioimmunoimaging and Radioimmunotherapy, Elsevier, New York (1983), which is hereby incorporated by reference, for techniques relating to the radiolabeling of antibodies. See also, D. Colcher et al., "Use of Monoclonal Antibodies as Radiopharmaceuticals for the Localization of Human Carcinoma Xenografts in Athymic Mice," Meth. EnzvmQL, 121: 802-816 (1986), which is hereby incorporated by reference. In accordance with one preferred embodiment the antibody is labeled with a fluorophore or chromophore using standard moieties known in the art.
Applicants have discovered that methylation of histone H3 at lysines 4 and 9 (K4 and K9), correlates, respectively, with activation and inactivation of expression of genes in proximity to the modified histones. Histone H3 when methylated at K9 is a preferred binding site for the heterochromatin protein HP 1, which in turn can recruit the enzyme Suv39h responsible for K9 methylation, creating a mechanism by which the inactivation signal can be propagated. Methylation of also precludes acetylation at that site, further contributing to repression.
In contrast to the reaction at K9, methylation at histone H3 K4 is correlated with transcriptional activity. Therefore in accordance with one embodiment of the present invention, antibodies specific for the K4 methylated histone H3 can be used to detect transcriptionally active regions of chromatin and antibodies specific for K9 methylated histone H3 transcriptionally can be used to detect inactive regions of chromatin. In fact, in situ staining of chromosomes reveals that the staining patterns generated by the Methyl(K4)H3 and Methyl(K9)H3 antibodies produce mirror images of one another.
Because the Methyl(K4)H3. and Methyl(K9)H3 antibodies have the potential for use in humans as diagnostic and therapeutic agents, one embodiment of the present invention is directed to humanized versions of the Methyl(K4)H3 and Methyl(K9)H3 antibodies. Humanized versions of the antibodies are needed for therapeutic applications because antibodies from non=human species may be recognized as foreign substances by the human immune system and neutralized such that they are less useful. Humanized antibodies are immunoglobulin molecules comprising a human and non-human portion. More specifically, the antigen combining region (variable region) of a humanized antibody is derived from a non-human source (e.g. marine) and the constant region of the humanized antibody is derived from a human source. The humanized antibody should have the antigen binding specificity of the non-human antibody molecule and the effector function conferred by the human antibody molecule. Typically, creation of a humanized antibody involves the use of recombinant DNA techniques.
The-antibodies of the present invention can also be linked to an insoluble support to provide a means of isolating euchromatin or heterochromatin from cells. The support may be in particulate or solid form and could include, but is not limited to: a plate, a test tube, beads, a-ball, a filter or a membrane.
Methods for fixing antibodies to insoluble supports are known to those skilled in the art.
In one embodiment an antibody of the current invention is fixed to an insoluble support that is suitable for use in affinity chromatography.
The Methyl(K4)H3 and Methyl(K9)H3 antibodies are large-scale or domain-sensitive chromatin marks that are somehow set up by boundary elements.
In particular, chromatin that is associated with histones that include H3 methylated at Lsy4 represent an "on" domain, or at least a domain that is competent fox transcriptional activity. Alternatively, chromatin that is associated with histones that include H3 methylated at Lsy9 represent an "off" domain, that is not competent for transcriptional activity. This pattern is conserved across a diverse range of species.
Zoo blots with these antibodies suggest that most of the H3 histones from 'simple' organisms (budding yeast) and Tetrahymena, contain a methylated Lys4 (ON), whereas in striking contrast, most of the H3 histones present in 'complex' organisms have a methylated Lys9 (OFF) (see Fig. 3). This agrees well with the fording that most of the genomic DNA in yeast.and in Tetrahymena is expressed (ON) while most of the DNA in humans, mice, etc. is OFF. Thus, it may well be that the 'default' or ground state in more complex eukaryotes is OFF. Knowing how to identify ON
chromatin through use of the Lys4 methyl mark may prove invaluable in developing strategies for better targeting of transgene to more 'friendly' chromatin.
Chromatin immunoprecipitation data supports the above 'ONlOFF' marking system model. In particular, S. pombe chromatin IP data, published (Science Nakayama et al., 2001) and the work on the inactive X chromosome in humans (see Example 2) supports this model. Furthermore there are 'hot spots' of Lys4 H3 methylation on the 'inactive' X chromosome and in some cases tumor supressor genes have been mapped into this chromosomal region. Loss of heterozygosity at this gene correlates well with a significant number of advanced cases of ovarian cancers.
Therefore the present antibodies can also be used as diagnostics for detecting cancer and for determining therapy strategies. In accordance with one embodiment a method is provided for detecting chromatin alterations that are associated with a disease state.
The term "disease state" is intended to encompass any condition that is associated with an impairment of the normal state of a living animal or plant including congenital defects, pathological conditions such as cancer, and responses to environmental factors and infectious agents (bacterial, viral, etc.). The method comprises the steps of isolating chromatin from both normal and diseased tissue, contacting the two pools of chromatin with either the Methyl(K4)H3 or Methyl(K9)H3 antibody and comparing the staining pattern of the chromatin isolated from normal tissue to that of the diseased tissue. Furthermore, using chromatin immunoprecipitation, unique tumor suppressor genes could be isolation by differential screening using the antibodies of the present invention.
In accordance with one embodiment of the present invention the Methyl(K4)H3 and Methyl(K9)H3 antibodies are used to identify heterochromatin and euchromatin regions and thus detect transcriptionally active and inactive regions of chromatin. More particularly, the antibodies can be used to detect changes in chromatin structure that are associated with a given disease state. Therefore the ~0 antibodies can be used as a diagnostic to detect alterations of chromatin structure that are associated alterations in expression patterns (i.e. differences in heterochromatin vs euchromatin patterns relative to predominant native patterns). Alterations in chromatin structure for a specific region of chromatin may be diagnostic of a particular disease state. For example, conversion of a normally euchromatic region of the genome to heterochromatin may represent the suppression of a tumor suppressor gene that is indicative of cancer or a pre-cancer state. 'Similarly the conversion of a region of heterochromatin to euchromatin may be associated with the inappropriate or overexpression of a gene that has deleterious effects on the host cell/organism.
The present invention is also directed to a method of using broad-based differential screening techniques to isolate nucleic acid regions that have altered expression patterns in diseased tissues. For example, chromatin can be isolated from diseased tissues and compared to chromatin isolated from healthy tissues to determine if there are any differences in the chromatin structure (i.e. changes in heterochromatin vs. euchromatin) that are associated with the disease state. Such differences in chromatin structure may represent suppression or overexpression of genes that play a direct or indirect role in the disease. The anti-methyl(Lys 9) H3 and anti-methyl(Lys 4) H3 antibodies can be used to detect such changes in chromatin structure and help identify genes that are associated with the disease state. The identification of such genes will assist in designing more effective therapies for treating the disease.
In one embodiment the method for detecting alterations in chromatin structure associated with a particular disease comprises chromatin immunoprecipitation assays, using modification-specific histone antobodies.
This process allows for the analysis of a wide range of DNA-templated processes that are governed by the chromatin environment. More particularly, the method comprises the steps of isolating chromatin from both diseased tissue and healthy tissue, fragmenting the DNA (preferably by sonification), and immunoprecipitating chromatin using an antibody that specifically binds to the amino acid sequence of ARTKQTAR (SEQ
ID
NO: 1) or QTARKSTGV (SEQ ID NO: 2), wherein the bold I~ represents a methylated lysine residue, and comparing the chromatin (and the associated DNA
sequences) immunoprecipitated from the healthy tissue relative to the diseased tissue.
Comparison of the two pools of immunoprecipitated chromatin will allow for the ~ identification of differences between diseased and healthy tissues.
In one embodiment, comparison of the two pools of immunoprecipitated chromatin comprises the steps of isolating the nucleic acid sequences associated with the two pools of immunoprecipitated chromatin and comparing the resulting two pools of nucleic acid sequences. Comparison of the two pools of nucleic acid sequences can be conducted using any of the standard molecular techniques, including PCR, gel electrophoresis, nucleic acid sequencing and nucleic acid hybridization analysis. Those nucleic acid sequences that are present in only one of the two pools of nucleic acid sequences are then recovered. These nucleic acid sequences represent expressed/suppressed genes that are associated with either the normal or diseased tissue. In one embodiment the antibodies used to immunoprecipitate the chromatin are selected from the group consisting of Methyl(K4)H3 and Methyl(K9)H3 antibody.
The use of methyl Lys4/Lys9 histone H3 antibodies in chromatin immunoprecipitation (chromatin IP) assays is one way to enrich for genomic DNA
corresponding to the epigenetic 'ON/OFF' state of the human genome (and other genomes as well). By combining chromatin immunoprecipitated DNA with current genomic microarray technology (on chips), one has the potential to survey any portion of the human (or other) genome as to their on/off state through the 'histone code'. For example, DNA immunoprecipitated using the Methyl(K4)H3 antibody can be immobilized on a solid surface or "chip" and thus represent all the nucleic acid sequences of a given cell that is competent for transcription. Similarly, DNA
immunoprecipitated using the Methyl(K9)H3 antibody can be immobilized on a solid surface or "chip" and thus represent all the nucleic acid sequences of a given cell that is not competent for transcription. Harvesting mRNA or preparing cDNA from a target cell, labeling the target nucleic acids and then hybridizing the target DNA with the immobilized DNA will reveal abnormal expression of genes.
Knowing this information may prove invaluable in determining the on/off state of key tumor suppressor or oncogenic proteins in various human cancers.
Knowing how this epigenetic marking corresponds to genomic DNA will also guide the ability to produce transgenic animals and plants where one often finds that most transgenic DNA enters a 'bad' (Lys9) chromatin environment and is silenced.
Thus, the implications for knowing how to better 'guide' DNA into a 'good' (Lys4) chromatin environment for animal and plant transgenic work are high. In.
humans, this would impact on gene therapy issues as well. .
In one embbdiment, immunoprecipitation of chromatin will be used to map the location of active genes at a genome-wide level through the use of microarrays. For example, in one preferred embodiment the method of comparing the two pools of immunoprecipitated chromatin (i.e. the iinmunoprecipitated chromatin from diseased vs healthy tissues) comprises the use of a gene chip, DNA
microarray, or a proteomics chip using standard techniques known to those skilled in the art. For example any of the systems described in WO O1/16860,W0 01/16860, WO 01/05935, WO 00/79326, WO 00/73504, WO 00/71'746 and WO 00/53811 (the disclosures of which are expressly incorporated herein) are suitable for use in the present invention.
Preferably the chip will contain an ordered array of known compounds, such as known DNA sequences, so that interaction of the immunoprecipitated chromatin at a specific location of the chip will identify, and allow for the isolation of, DNA
sequences associated with the immunoprecipitated chromatin.
The key to this technology is the use of antibodies specific to various modification as they relate to the histone code. Applying this to human and other genomes would lay the foundation of epigenomics. While the present invention has detailed the use of Lys4/Lys9 methyl H3 antibodies as respective ON/OFF
antibodies, this concept applies more generally to any and all antibodies that are developed directed at the 'histone code'. For example, Lys9 methyl vs. SerlO phos H3 antibodies may also be a 'methyl/phos' switch that regulates differentiation vs.
proliferation. The present invention also encompasses antibodies that are directed to other methylated regions of the amino terminus of H3 and H4 histones, including H3 lysines 27 and 36 and H4 lysine 20. The peptides that will be used to generate these antibodies are listed below:
H3 lysine 27: AARKSAPVCG (SEQ ID NO: 16) H3 lysine 36: SGGVKKPHKCG (SEQ ID NO: 17) H4 lysine 20: R,HR-KTT.RDCG (SEQ ID NO: 18) wherein the bold K is the methylated lysine residue and underlined GC refers to artificial amino acids added to the H3 sequence to aid in the production of this antibody.
The antibodies of the present invention can be used in standard Molecular Biology techniques such as-Western blot analyses, immunofluorescence, and immunoprecipitation. As noted above the presence of methylated H3 at lysine 4 correlates with transcriptionally active nuclei, and therefore, this H3 antibody may be a useful in the understanding of gene regulation. In addition it is anticipated that microinjection of the Methyl(K4)H3 antibody into cells may interfere with the activation of specific genes.
In one embodiment of the present invention a kit is provided for detecting euchromatin and heterochromatin. The kit comprises an antibody that specifically binds to a lysine methlyated modified peptide selected from the group consisting of ARTKQTARGC (SEQ ID NO: 4), QTARKSTGVCG (SEQ ID NO: 5), ARTKQTAR (SEQ ID NO: 1), QTARSTGV (SEQ ID NO: 2), ARTKQTARKSTGV
(SEQ ID NO: 9), A.ARKSAPVCG (SEQ ID NO: 16), SGGVKKPHKCG (SEQ ID
NO: 17) and RHRHILRDCG (SEQ ID NO: 18). More particularly, the kit comprises an antibody that binds to the peptide ARTKQTARGC (SEQ ID NO: 4), QTARKSTGVCG (SEQ ID NO: 5) or QTARKSTGGCG (SEQ ID NO: 6), wherein the bold K represents a methylated lysine residue. In one embodiment the antibodies are attached to an insoluble support, wherein the support is either a monolithic solid or is in particular form. In one preferred embodiment the antibodies are monoclonal antibodies and in a further embodiment the antibodies are labeled. To this end, the antibodies of the present invention can be packaged in a variety of containers, e. g. , vials, tubes, microtiter well plates, bottles, and the like. Other reagents can be included in separate containers and provided with the kit; e.g., positive control samples, negative control samples, buffers, cell culture media, etc.
In an another embodiment of the invention a kit is provided for use in an assay to determine if a sample has methylase activity. The kit comprises a peptide selected from the group consisting of ARTKQTARGC (SEQ ID NO: 4), QTARKSTGVCG (SEQ ID NO: 5), ARTKQTAR (SEQ ID NO: 1), QTARSTGV
(SEQ ID NO: 2) and ARTKQTARKSTGV (SEQ ID NO: 9) and an antibody that specifically binds to a lysine methlyated modified peptide selected from the group consisting of ARTKQTARGC (SEQ ID NO: 4), QTARKSTGVCG (SEQ ID NO: 5), ARTKQTAR (SEQ ID NO: 1), QTARSTGV (SEQ ID NO: 2) and ARTKQTARKSTGV (SEQ ID NO: 9). In one embodiment the antibodies are attached to an insoluble support, wherein the support is either a monolithic solid or is in particular form. In another embodiment the kit is further provided with an antibody that specifically binds to a non-methylated peptide selected from the group consisting of ARTKQTARGC (SEQ ID NO: 4), QTARKSTGVCG (SEQ ID NO: 5), ARTKQTAR (SEQ ID NO: 1), QTARSTGV (SEQ ID NO: 2) and ARTKQTARKSTGV (SEQ 117 NO: 9). Such an antibody serves as a negative control.
In one embodiment, the method for detecting the methylase activity of a sample comprises contacting a peptide selected from the group consisting of ARTKQTARGC (SEQ ID NO: 4), QTARKSTGVCG (SEQ ID NO: 5), ARTKQTAR
(SEQ ID NO: 1), QTARSTGV (SEQ ID NO: 2) and ARTKQTARKSTGV (SEQ ID
NO: 9) for a predetermined length of time with a sample that is suspected of having methylase activity. The amount of methylation-specific antibody (i.e.
Methyl(K4)H3 or Methyl(K9)H3) that binds to the substrate is a direct correlation of the extent the substrate was methylated during the predetermined time length and thus indicates the methylase activity of the sample. This assay can also be used to screen for potential inhibitors of a methylase. For example, in one embodiment a method of screening for inhibitors of arginine methyl transfer activity comprises the steps of providing a sample, wherein the sample comprises a methylase and a substrate that is methylated by said methylase, adding a potential inhibitor of the methylase to the sample, and contacting the sample with an antibody that binds specifically to the methylated substrate, but not the non-methylated substrate. In one embodiment, the antibody is specific for the peptide ARTKQTAR (SEQ ID NO: 1) or QTARKSTGV (SEQ ID
NO: 2). Quantifying the amount of antibody bound to the peptide is a direct correlation of the level activity of the methylase in the sample. In one preferred embodiment the methylase activity to be detected is SuVar3-9 (for Lys 9) or Setl (for Lys 4).
'Knock-out' strains are available for all of the non-essential genes present in budding yeast...around 4,800. The antibodies of the present invention have such a high degree of specificity, that they only detect one or two major bands in yeast whole cell lysates, thus allowing for the development of a robotic screening method to look at all of these knock-out strains. Using Lys4 methyl H3 should lead to the entire upstream pathway of 'regulators' including the on and off enzymes (provided the gene product is non-essential).
Using the above approach in 'old-fashioned' blots, is has been found that Setl is the enzyme responsible for the Lys4 H3 methyl mark in yeast, and is also one of the Lys4 HMTases in humans. Surprisingly, using the methyl Lys4 H3 antibodies as a readout to probe yeast whole cell lysates, Lys4 methylation was discovered to be regulated by H2B ubiquitination at a conserved Lysine on the opposite side of the nucleosome. This is the first example of a 'trans-tail' effect meaning that one histone modification on one tail effect another modification on another not-so-close tail. In humans and in mice, the enzymes that add ubiquitin to proteins is human Rad6 (HR6), and HR6 comes in two isoforms, HR6A and HR6B.
Mice knockouts of HR6B -/- are male sterile in a pathway that is not known, but seems to lead to chromatin defects during spermatogenesis leading to sperm death.
Accordingly it is anticipated that HR6B is responsible for ubiquitin addition on H2B
and therefore it is possible that Lys4 H3 methyl antibodies will be a diagnostic for male infertility. Furthermore, the possibility exists that defects in Lys9 methylation could impact X-inactivation and lead to female infertility. Therefore in accordance with one embodiment of the present invention the Methyl(K4)H3 and Methyl(K9)H3 antibodies are used as a diagnostic to.screen for male and female infertility defects.
Current models suggest that Lys9 methylation is catalzyed, at least in some instances by SuVar3-9. It appears that the Lys9 methyl mark is read by chromodomains, short protein modules that act as chromatin 'velcro' patches.
Best documented is the chromodomain of the heterochromatin protein HP 1.
Interestingly, the chromodomain from HP1, binds well to Lys9 methyl H3 peptides, but binds much less well to Lys4 or unmodified peptides. It is interesting also that SuVar3-9 itself, a catalytic HMTase, also has a chromodomain, a module whose site specificity for methylated histone peptides has yet to be tested.
It seems likely that the Lys4 methyl mark in H3 will be read by a distinct chromodomain from that of HP 1. In one embodiment the uniquely-modified peptides of the present invention, including ARTKQTAR (SEQ ID NO: 1) or QTARKSTGV (SEQ ID NO: 2) are used as affinity reagents to look for polypeptides that bind Lys4 H3 peptides. Several attractive candidates include two histone acetyltransferases (HATS), Esal and.CDY, both of whom have chromodomains.
Interestingly CDY is a testis-specific HAT encoded on the male Y chromosomes, and somatic histones are well known to be hyperacetylated during a reaction that leads to replacement by protamines.
It could be that during spermatogenesis the following series of concerted reactions occur:
1. H2B ubiquitination happens, catalyzed by HR6B
2. Chromatin opening 3. Lys4 methylation catalyzed by human Setl or another Lys4 HMTase 4. Binding of the HAT CDY to the Lys4 methylation mark though its chromodomain -22_ Histone hyperacetylation occurs catalyzed by CDY
6. Somatic histones are displaced, followed by transition proteins, followed by protamines Defects in any of the above steps could lead to sperm lethality and male infertility.
Note that three of the steps require chromatin-modifying enzymes:
i) HR6B a E2 ubiquitin-conjugating enzyme ii) Setl or a resposible Lys4 HMTase iii) CDY a male-specific HAT
Antibodies to ubiquitinated H2B and H2A, Lys4 methyl H3 and sites of CDY-catalyzed acetylation would all be of potential diagnostic value in male infertility screens.
Example 1 Preparation of the Methyl(K4)H3 and the Methyl(K9)H3 antibodies To generate the Methyl(K4)H3 and the Methyl(K9)H3 antibody, a short polypeptide corresponding to the amino-acid sequence of histone H3 surrounding lysine 4 (SEQ ID NO: 4; ARTKQTARGC) or lysine 9 (SEQ ID NO: 5;
QTARKSTGVCG) was first chemically synthesized, wherein the bold K is the methylated lysine residue and underlined GC refers to artificial amino acids added to the H3 sequence to aid in the production of this antibody. This polypeptide was then conjugated to cationized bovine serum albumin (BSA), and the conjugated-peptide was injected into rabbits. One important aspect to this procedure is the fact that the standard technique of conjugating a peptide to Keyhole Limpet Hemocyanin (KLH) proved ineffective in generating high quality methyllysine 4 (H3)-specific antisera.
Thus, the use of this specialized cationized BSA is now considered a unique "method"
in generating methyllysine-specific antibodies.
Rabbit serum was harvested at regular intervals post-immunization, and the Methyl(K4)H3 and Methyl(K9)H3 antibodies were shown to be present in the Serum by standard enzyme-linked immunosorbent assays. These antibodies are suitable for use in Western blot, immunofluorescence, and immunoprecipitation assays.
Example 2 Role of Histone H3 Lysine 9 Methylation in Epigenetic Control of Heterochromatin Assembly The assembly of higher order chromatin structures has been linked to the covalent modifications of histone tails. Ih vivo evidence demonstrates that lysine 9 of histone H3 (H3 Lys 9) is preferentially methylated by. the Clr4 protein at heterochromatin-associated regions in fission yeast. Both the conserved chromo-and SET domains of Clr4 are required for H3 Lys 9 methylation i~ vivo.
The organization of the higher order chromatin structure has been linked to the posttranslational modifications of histone tails, including acetylation, phosphorylation, and methylation. It has been suggested that distinct combinations of covalent histone modifications, also referred to as the "histone code,"
provide a "mark" on the histone tails to recruit downstream chromatin-modifying proteins. This is best illustrated by recent studies indicating that the conserved bromo-domain of several transcriptional coactivators bind specifically to acetylated lysine residues on histone tails. The mechanisms responsible for the establishment and maintenance of multiple covalent modifications within the same or different histone tail are not-fully understood.
Modifications of histone tails have also been linked to heterochromatin assembly. Histones H3 and H4 are largely hypoacetylated in heterochromatic chromosomal regions in organisms as diverse as yeast, flies, and mammals. In fission yeast, hypoacetylation of histones is associated with the silent mating-type region and centromeres, chromosomal domains that share many parallels with heterochromatic regions in higher eukaryotes. Centromeric regions comprising a central core of unique sequences surrounded by inner (imr) and outer (otr) repeats are assembled into silenced chromatin structures. Similarly, a laxge ;15-kb chromosomal domain at the mating-type (mat2l3) region, including the matt and mat3 loci and an interval between them, known as the K-region, is maintained in a silent epigenetic state.
Among the traps-acting factors that affect silencing at these regions, Clr3 and Clr6 belong to family of histone deacetylases (HDACs). Swi6 and Clr4 proteins contain a chromodomain, an evolutionarily conserved motif initially identified in HP 1 and Polycomb proteins. Recently, both Clr4 and its mammalian counter-part, SUV39H1, have been shown to have intrinsic histone H3-specific methyltransferase (HMTase) activity ih vitro (S. Rea et al., Nature 406, 593 (2000)). However, it is not known whether histones are the physiological targets of these methyltransferases ih vivo.
Consistent with previous findings, recombinant Clr4 (rClr4) was found to contain HMTase activity exclusively for histone H3. To identify the specific residue of H3 methylated by rClr4, synthetic peptides derived from the NH 2 -terminus of H3 were used as substrates in an in vitro HMTase assay. In particular, five milligrams of HeLa or chicken core histones was incubated with 0.55 mCi of S-adenosyl-L-[methyl-3H]methionine (3H-AdoMet; 72 Cilmmol; 1 mM final) and 2 mg of recombinant Clr4 wild-type or mutant proteins in 25 ml of HMTase buffer [50 mM
tris ( pH 8.0), 1 mM phenylmethylsulfonyl fluoride, 0.5 mM dithiothreitol in 10%
glycerol] for 1 hour at 30°C. SDS loading buffer was added to half of each sample and boiled followed by separation on a 15% SDS-polyacrylamide gel electrophoresis (PAGE) gel. The resulting histone bands were visualized by Coomassie staining and fluorography. For the peptide analysis, 5 mg of each peptide derived from the terminus of human histone H3 containing a COOH-terminal cysteine was used.
Half of the sample was spotted on Whatman P-81 filter paper and washed four times for 10 min in 50 mM NaHC02 ( pH 9.0), followed by liquid scintillation counting. (B.
D.
Strahl, R. Ohba, R. G. Cook, C. D. Allis, P~oc. Natl. Acad. Sci. U.S.A. 96, (1999)). Clr4 preferentially methylated the H3 1-20 unmodified peptide but failed to methylate the H3 19-35 unmodified peptide, indicating that the target residue of Clr4 HMTase resides in the first 20 amino acids of H3.
To determine this target residue, a synthetic H3 1-20 peptide set was developed that contained covalent modifications on different amino acids. With these peptides as substrates, only acetyl or methyl modifications on Lys 9 effectively blocked rClr4 HMTase activity, indicating that Clr4, like its mammalian homolog SUV39H1, selectively methylates Lys 9 of H3. Furthermore, similar to SUV39H1, rClr4 HMTase activity was inhibited by phosphorylation of serine 10. These results demonstrate that enzymatic features of the Su(var)3-9 protein family are evolutionarily conserved from fission yeast to humans. A recent study demonstrated that the conserved SET domain and two flanking cysteine-rich regions were required for SUV39H1 HMTase activity in vitro. To determine whether the conserved domains, the chromo, SET, and cysteine-rich regions, were also critical for Clr4 HMTase activity, mutant Clr4 proteins were tested for HMTase activity.
Although mutations in the chromo-domain [Trp3' to- Gly (W31 G) and Trp4' to Gly (W41 G)] had little effect on Clr4 HMTase activity, mutations in the SET domain [Gly3z8 to Ser (G378S)] and both cysteine-rich regions [Arg3zo to His (R320H) and G1y486 to Asp (G486D)] greatly reduced Clr4 HMTase activity, indicating that these three regions are critical for Clr4 HMTase activity i~ vitro.
To test the hypothetical correlation between H3 Lys 9 methylation and silencing, an H3 Lys 9 methyl specific antibody was developed. In an enzyme-linked immunosorbent assay, the H3 Lys 9 -methyl antibody specifically recognized the 1-20 Lys 9 -methyl peptide in a wide range of antibody dilution. Moreover, the Lys 9 -methyl antibody did not detect recombinant histone H3 (rH3) alone compared with the HeLa core histone positive control but did detect rH3 selectively methylated by rClr4, further demonstrating the specificity of this antibody (see Nakayama et al., (2001) Science, 292, pp 110-113; the disclosure of which is incorporated herein).
Using this antibody in chromatin immunoprecipitation (ChIP) experiments (Nakayama et al, (2000) Cell, 101, 307), it was discovered that the H3 Lys 9 methyl modification is specifically localized at the silenced chromosomal regions. H3 Lys 9 methylation and Swi6 were preferentially enriched at a marker gene (King: : u~a4 1 ) inserted within the silenced mat2/3 chromosomal domain, compared with control ura4DSlE locus at the endogenous location. Similarly, H3 Lys '9 methylation was also preferentially enriched at the ui~a41 marker inserted within the highly repressed innermost repeat (imrl R: : ura41 ) and the outer repeat (otr~1 R: : ura4 1 ), but not at the weakly repressed central core (cntl:: ura4 1 )of cehl. In addition, H3 Lys 9 methylation coincided with the presence of Swi6 at these regions (Partridge et al, (2000), Genes Dev., 14, 783). These findings suggest that H3 Lys 9 methyl modification and Swi6 are preferentially localized to silent chromosomal regions and that Swi6 localization is functionally dependent on H3 Lys 9 methylation.
Compared with the relatively high levels of Swi6 and H3 Lys 9 methylation at both Kint2: : ura41 and otrl R: : ura4 1 in wild-type cells, Swi6 and H3 Lys 9 methylation were absent in a clr4D strain at both loci. This result suggests that H3 Lys 9 is the physiological target of Clr4 HMTase activity and that Clr4 appears to S be the exclusive ivy vivo H3 Lys 9 -specific HMTase at mat and cen loci. In comparison with the ire vitro result showing that only the SET domain is required for Clr4 HMTase activity, both the chromo-and SET domains are required for H3 Lys methylation and Swi6 localization ire vivo. Taken together,~these results indicate that the chromodomain is presumably required for targeting Clr4 to the mat2/3 region and centromeres, whereas the SET domain and associated cysteine-rich regions of Clr4 constitute the catalytic site. The Swi6 levels at mat and ceh in different clr4 mutant backgrounds were directly correlated with H3 Lys 9 methylation levels, further suggesting that Swi6 localization at silent chromosomal domains is functionally dependent on H3 Lys 9 methylation.
The importance of the in vivo analyses was further highlighted by observations that some mutations in Clr4 that decrease its HMTase activity ih vitro do not substantially decrease H3 Lys 9 methylation and Swi6 localization ih vivo.
In addition, mutations in the SET domain and the NH 2 -terminal cysteine-rich regions of Clr4 (G378S and R320H) greatly reduce H3 Lys 9 methylation and Swi6 localization at the mat locus; however, these mutations have moderate or negligible effects at cell. These mutations also have weak effects on centromeric silencing compared with mating-type silencing. The results are consistent with the notion that enzymatic defects displayed by recombinant monomeric proteins in vitro can be "rescued" by functioning in the context of a multisubunit complex in vivo.
Moreover, the functional organization of the mat2/3 region and centromeres may differ, and an additional factors) may help promote Clr4 activity at centromeres.
Mutations in the clr3 HDAC, which specifically deacetylates H3 Lys 14, affects silencing at mat and cen (S. I. S. Grewal, M. J. Bonaduce, A. J.
S. Klar, Genetics 150, 563 (1998)). ChIP analysis demonstrated that a clr3-735 mutant partially defective in H3 Lys 14 HDAC activity displayed a moderate decrease in H3 Lys 9 methylation and Swi6 localization at otrl: : ura4+, coincident with the apparent reduction in its HDAC activity. This result suggests that H3 Lys 14 acetylation inhibits Clr4 HMTase in vivo. To further investigate the functional interaction between Clr3 and Clr4, a double-mutant strain containing the clr3-735 and clr4R320H
mutations was created, a clr4 mutation that had the least effect on H3 Lys 9 methylation at otrl R: : ura4+. ChIP analysis of the double mutant demonstrated that H3 Lys 9 methylation and Swi6 localization were nearly abolished when compared with the single mutants. These findings indicate that Clr3 acts synergistically with Clr4 to effectively localize Swi6 to heterochromatic domains. In other words, deacetylation of H3 Lys 14 by Clr3 is required for H3 Lys 9 methylation by Clr4 and for Swi6 localization either indirectly, by altering Clr4 activity, or directly or both.
These data also support the theory that residues neighboring Lys 9, and potentially their modification states, play an important role in establishment of the appropriate H3 Lys 9 -methyl mark. Previous studies have shown that rikl + affects silencing as well as Swi6 localization at silent loci. Computational analyses revealed that Rik1 contains b-propeller domains typically found within WD-40 repeat proteins and are theorized to participate in protein:protein interactions. A mutation in rikl completely abolished H3 Lys 9 methylation and Swi6 localization at both mat and ceh compared with wild type.
WD-40 proteins are involved in many aspects of chromatin remodeling and histone metabolism, such as chromatin assembly and acetylation or deacetylation of histones. Therefore, the b-propeller domains of Rikl may form a complex with Clr4 to recruit its HMTase activity to heterochromatic regions and may play a role in coupling other transacting factors, such as Swi6 and histone deacetylases.
The possible role of Swi6 on Clr4-dependent methylation of H3 Lys 9 was also tested. Strains carrying swi6-115 (W269R) mutation that severely reduced Swi6 protein levels were used. As expected, Swi6 localization at both mat and cen was abolished as demonstrated by ChIP analysis. The'swi6-11 S mutation did not cause any detectable change in H3 Lys 9 methylation when compared with the wild-type strain. These data indicate that Swi6 is dispensable for Clr4 function and suggest that Swi6 acts down-stream of Clr4 H3 Lys 9 methylation. Collectively, the above results define a temporal sequence of events leading to establishment of the silenced chromatin state with regard to the covalent modifications of the H3 NH 2 -terminal tail. HDACs and HMTases act cooperatively to establish a "histone code" that is then _~$-recognized by Swi6. More specifically, the HDACs (Clr6 and/or Hdal) deacetylate H3 Lys 9, whereas Clr3 deacetylates H3 Lys 14 before H3 Lys 9 methylation by the Clr4/Rik1 HMTase complex. Swi6 binding to the H3 Lys 9 -methyl modification would then result in self propagating heterochromatin assembly. Because the heterochromatin-binding domain of Swi6 was mapped to its chromodomain, it is most likely that this protein motif has evolved to recognize the H3 Lys 9 -methyl modification. -It was recently shown that Swi6 remains associated with the mat2/3 region throughout the cell cycle where it acts as an important determinant of the epigenetic cellular memory, promoting inheritance of the silenced state.
Because the mouse homolog of Swi6, M31, associates with Su(var)3-9, a similar inter-action between Clr4 and Swi6 is predicted. The close association of Clr4 enzymatic HMTase activity, followed by recruitment and binding of Swi6 to Lys 9 methyl "marks" in H3 through its chromodomain, suggests a pathway of epigenetic inheritance. The extent to which the chromo-domain of Clr4 recognizes H3 Lys 9 -methyl marks is unknown, but it would provide the enzyme a means to bind chromatin as it performs subsequent methylation events. On the basis of the conservation of Clr4/SLTV39H1 and Swi6/HP1 proteins and the presence of H3 Lys methyl modification in higher eukaryotes, a similar mechanism may be responsible for higher order chromatin assembly in organisms ranging from fission yeast to humans. Considering the parallels between transcriptional repression by Polycomb group proteins in flies and mammals and silencing in fission yeast, it is likely that histone methylation coupled with histone deacetylation may help localize Polycomb in pathways that lead to the regulation of homeotic gene expression.
Example 3 Differential Sites of Histone H3 Methylation Marks the Active and Inactive Genes on the Human X Chromosome Chromosomes in higher eukaryotes have historically been considered to consist of regions of euchromatin and heterochromatin, which are distinguished by the degree of condensation and level of transcriptional activity of the underlying DNA
sequences. Certain regions of constitutive heterochromatin are found at or near specialized structures such as centromeres, and are comprised mostly of genetically inert repetitive sequences. In contrast, other regions that have the same primary DNA
sequences can exhibit characteristics of either type of chromatin, suggesting that epigenetic factors, such as packaging of DNA by histones and chromatin-associated proteins, dictate the heterochromatin status at these loci.
One of the most dramatic examples of epigenetic silencing is the X
chromosome inactivation seen in female cells of mammals. This process allows for dosage compensation of X-linked genes whereby one of the two copies of the X
chromosome in female cells is randomly inactivated during embryonic development.
Current evidence suggests that X inactivation is initiated by the up-regulation of the non-coding XIST transcript and its association in cis with the chromosome to be inactivated. Following its coating by XIST RNA, the inactive X chromosome acquires heterochromatic characteristics such as late replication timing, a condensed appearance (Barr body) in interphase cells, DNA methylation of CpG islands at house-keeping genes, and association with altered nucleosomes that are composed of hypoaceiylated histones and enriched for the H2A variant MacroH2A. While the exact roles of these properties in the onset of X inactivation remain unclear, once the inactive state has been established, these epigenetic characteristics seem to act synergistically to maintain the remarkable stability of the inactive X through many cell divisions in the adult soma.
Recently, several publications showed that histone H3 methylation is important in the assembly of heterochromatin in mouse and S pombe (Lachner et al., Nature 410, 116 (2001); Bannister et al., Nature 410, 120 (2001) and Nakayama et al Sciehce 292, 110 (2001)). The chromodoma.in of mouse HP1 (and Swi 6 in S.
pombe) can bind to H3 methylated at lysine 9, and methylatiori of H3 at this site is thought to mark and recruit factors involved in heterochromatin assembly. In addition, acetylation and methylation of H3 at lysine 9 may be competing events in uivo (Cheung et al., Cell 103, 263 (2000)). Given that H3 is hypoacetylated on the inactive X chromosome, and that H3 lysine 9 methylation is important in heterochromatin assembly, the inactive X was investigated for enrichment for Lys9-methylated H3.
Using an antibody specific for Lys9-methylated H3, female human metaphase chromosomes were examined from a normal lymphoblast cell line (HH) by indirect immunofluorescence. In particular, a normal human female lymphoblast cell line (HH) and a female lymphoblast cell line which contains five X chromosomes (6061B) were grown, harvested and collected onto microscope slides with a Cytospin 3 centrifuge. Modified histones were detected by indirect immunofluorescence, essentially as described in detail elsewhere (Costanzi and J. R. Pehrson, Nature 393, 599 (1998)). Briefly, cells were incubated for one hour at 37 °C in a humid chamber with serial dilutions of the primary Lys9 methyl H3 or acetyl H4 antisera and washed in KCM (120mM KCI, 20mM NaCI 10 mM TRIS-CL, pH 8.0, 0.5 M EDTA, 0.1%
Triton). The cells were then incubated for 30 min at room temperature with Cy3-conjugated, affinity-purified, donkey anti-rabbit IgG antibody (Jackson ImmunoResearch) diluted 1:40 in KCM. Cells were once again washed with KCM
and fixed in 4% formaldehyde for 10 min at room temperature. Following a wash in sterile water chromosomes were counterstained with 4',6-diamidino-2-phenylindole (DAPI), mounted in antifade (Vectashield) and viewed on a Zeiss Axiophot fluorescence microscope.
Indirect immunofluorescence using an antibody specific for Lys9-methylated H3 revealed that while most chromosomes have some regions of Lys9-methylated-H3, one chromosome in each metaphase spread is consistently more intensely and uniformly stained (Figure 1A, white arrow). To test whether the chromosome enriched for Lys9-methylated H3 is the inactive X chromosome, .
metaphase spreads from a cell line that contains five X chromosomes was also stained. In these cells, four out of the five X chromosomes are known to be inactivated and indeed four chromosomes of equal size show enriched staining by the Lys9-methyl H3 antibody. Together, these data suggest that while the H3 molecules on the inactive X are mostly hypoacetylated, they are highly methylated at lysine 9.
The N-terminus of histone H3 is post-translationally modified at multiple sites and lysine 4 of H3 is another documented site of methylation.
However, in contrast to lysine 9, lysine 4 methylation has been correlated with active transcription. To further compare these two sites of H3 methylation on the inactive X
chromosome, metaphase chromosomes were stained using an antibody specific for Lys4-methylated H3. Metaphase chromosomes from female cell lines HH and 6061B
were incubated with Lys4 methyl H3 antiserum and the staining pattern was analyzed by indirect immunofluorescence as described earlier. Strikingly, this antibody intensely stains all chromosomes in the metaphase spread except for a single chromosome per spread (Fig. 1B). This unique chromosome is almost totally devoid of staining except for several 'hot spots' of H3 lysine 4 methylation.
Staining of the metaphase spreads of the SX cell line shows that four of the chromosomes are understained using the Lys4 methyl H3 antibody, suggesting that the hypo-H3 Lys4-methylated-chromosomes) is the inactive X chromosome.
Closer examination.of the inactive X chromosome shows that there are several distinct regions of this chromosome that exhibit intense staining with the Lys4 methyl H3 antibody. One region appears to be located at the pseudoautosomal region of the distal end of the p arm, another is located near Xq25-26 of the q arm, and fainter staining is occasionally seen around Xp 11. With the exception of Xq25-26, the other regions of Lys4 methyl H3 staining on the inactive X correspond to the location of multiple genes known to escape inactivation (Carrel et al, Proc Natl Acad Sci LT SA 96, 14440 (1999)), and these data are therefore consistent with the idea that Lys4 methylation of H3 is associated with active gene expression.
The intense staining of the Xq25-26 region by the Lys4 methyl H3 antibody is puzzling since this region does not contain any known genes that escape X
inactivation. However, it is intriguing that loss of heterozygosity at Xq25-26.1 is associated with advanced human ovarian carcinomas (see Choi,et al, Genes Chromosomes Cancer 20, 234 (1997)). Further studies of the enrichment of Lys4-methylated H3 at this region on the inactive X chromosome, and determining whether H3 Lys4/Lys9 methylation correlate with the expression level of the putative tumor suppressor genes) at this location will provide additional information on the link between histone H3 methylation and gene expression.
The understaining of the inactive X chromosome by the Lys4 methyl H3 antibody is similar, but not identical, to the staining pattern of this chromosome with antibodies against hyperacetylated form of H4. In this study, some staining at the telomeric region of the p arm of the inactive X chromosome was seen using the antibody against hyperacetylated H4, but not at the Xpl 1 and Xq25-26 regions.
In contrast, previously published results showed that three regions on the inactive X
chromosome (Xpter-22.2, Xp11.3-11.2, and Xq22) were stained with an antibody against hyperacetylated H4, but this was seen only in sodium butyrate-treated human cells. At present, the precise relationship between the regions stained by the hyperacetylated H4 and the Lys4 methyl H3 antibodies has not been clearly defined.
Nevertheless, these data suggest that the inactive X chromosome is devoid of hyperacetylated core histones as well as Lys 4-methylated H3, but is enriched for H3 methylated at Lys9. Together, these combinations of histone modifications may be part of a series of concerted reactions that mediate transcriptional silencing of the inactive X.
To further establish the link between H3 Lys9 methylation and the inactive X chromosome, human female IMR90 interphase cells were examined by immunofluorescence in combination with Fluorescent In Situ Hybridization (FISH).
In particular, IMR. 90 (ATCC) cells were grown on coverslips for 24-48 hours then fixed in 4% formalehyde for 15 minutes at room temperature; the cells were then permeabilised in PBS containing 0.5% Triton-X for 4 min. on ice, washed in PBS
and then washed in 2xSSC prior to RNA FISH. To preserve nuclear structures, cells were kept continously hydrated. RNA FISH hybridization and washes were performed essentially as described elsewhere (Lachner et al, Nature 410, 116 (2001)).
Briefly, cells were hybridized with a XIST probe comprising a pool of four exon-derived DNA
fragments spanning a total of 4.5 kb of sequence, labeled by nick translation with Spectrum Red or Green dUTP (Vysis, Downer Grove, IL). Following hybridization overnight at 37°C, standard washes for RNA FISH (ie 3x in 50% formamide l 2xSSC
and 3x in 2xSSC) were performed. The cells were then washed in PBS / 0.5% BSA
.
prior to performing immunofluorescence. Primary antibody was incubated for 1 hour at room temperature, cells were washed four time in PBS and the secondary antibody.
(Texas red conjugated goat anti-rabbit antibody ) was then applied for 1 hour at room temperature, followed by four washes in PBS. Nuclei were counterstained with DAPI. Images were acquired using a Zeiss Axioplan 2 fluorescence microscope with an Orca 2 CCD camera (Hamamatsu) and Improvision software (IPLab).
It is well established that the XIST transcript specifically localizes to the inactive X chromosome at interphase but not at metaphase, and localization of the Xist transcript can be detected by FISH analysis. The Lys9-methyl-H3 antibody preferentially stains a region that is heterochromatin-dense as indicated by co-localization with DAPI-dense regions. This condensed region also co-localizes with the XIST RNA signal, indicating that the chromosome enriched for Lys9-methylated H3 is indeed the inactive X. Consistent with the metaphase chromosome results, staining of human interphase cells with the Lys4 methyl H3 antibody shows that the region corresponding to the inactive X (based on DAPI dense staining and localization of the Xist RNA) is devoid of Lys4 methyl H3 staining. Intriguingly, a distinct dot enriched for Lys4 methyl H3 is seen within the region of negative staining for some of the cells. Whether this localized region of Lys4 methyl. H3 staining.corrresponds to the intensely stained regions seen in the metaphase chromosome is at present not known. Side by side comparisons of the Lys9 and Lys4 methyl H3 staining in interphase and metaphase cells further showed that the respective staining pattern of these two antibodies are almost reciprocal images. These results have led to the conclusion that lysine 4 and lysine 9 methylation of H3 are 'reciprocal marks' for transcriptionally active and inactive regions respectively, and hence the inactive X
chromosome is hypomethylated at lysine 4 but is hypermethylated at lysine 9.
One resulting prediction is that the Lys4 and Lys9 methyl H3 antibodies would respectively enrich for active and inactive genes on the X
chromosome by chromatin immunoprecipitation (ChIP). On the inactive X
chromosome, the XIST gene is transcriptionally active whereas the PGKl gene is silenced. Conversely, on the active X chromosome, the XIST gene is silent whereas the PGKI gene is actively transcribed. To test the above hypothesis, two CHO
somatic hybrid cell lines were used that contain either a single active or inactive human X chromosome in ChIP assays in order to examine the histone modifications associated with genes present on the active or inactive X chromosomes.
Chromatin from these two cell lines were immunoprecipitated using antibodies against Lys9-methylated H3, Lys4-methylated H3, or Lys9/14-acetylated H3, and the immunoprecipitated DNA was PCR amplified using primers specific to the promoter regions of the human Xist and PGKl genes.
In particular, Chromatin immunoprecipitation assays were done as described in Cheung et al, Mol Cell 5, 905 (2000). In this case, formaldehyde-fixed chromatin was harvested from CHO somatic cell hybrids containing either the active or inactive human X chromosome. Approximately 3 x 106 cells-worth of sonicated chromatin were used per immunoprecipitation reaction with the antibodies indicated in the text. After extensive washing, reverse cross-linking, RNase A and proteinase K
digestions, the immunoprecipitated DNA was analyzed by PCR using primers specific for the promoter regions of the human JPIST and PGKI genes (primer sequences and PCR conditions were derived from Gilbert and P. A. Sharp, Proc Natl Acad Sci U
S A
96, 13825 (1999)), and analyzed by polyacrylamide gel electrophoresis.
Consistent with previously published reports, the acetylated H3 antibody immunoprecipitated XIST DNA only from the inactive X chromosome, and the PGKI DNA only from the active chromosome. Analogous to these results, the Lys4 methyl H3 antibody preferentially immunoprecipitated the XIST DNA from the cells actively expressing XIST (from the cells containing the inactive X
chromosome) and the PGKI DNA from the cells containing the active X chromosome. Therefore, both acetylated H3 and Lys4-methylated H3 are enriched at the actively transcribing loci on both the active and inactive X chromosomes. Immunoprecipitation using the Lys9 methyl H3 antibody showed reciprocal results to those obtained with the Lys4 methyl and acetyl H3 antibodies. In this case, XIST DNA.was immunoprecipitated only from cells containing the active X chromosome whereas the PGKI DNA was immunoprecipitated only from the inactive X chromosome.
Taken together, the chromatin immunoprecipitation data indicate that Lys4- or Lys9-methylated H3 are reciprocally associated with active and inactive genes irrespective of the chromosomal context (active versus inactive X).
Moreover, combined with~the immunofluorescence results, these data suggest that the two distinct methylation sites on H3 may mark regions of active and inactive chromatin, respectively.
The inactive X chromosomes is a well-studied paradigm for epigenetic regulation of gene expression and fox linking specialized nucleosomal architecture with transcription silencing. As mentioned earlier, the entire inactive X
chromosome seems to be largely devoid of hyperacetylated histones, and a core histone variant, MacroH2A, has been found to be enriched at the inactive X chromosome.
Interestingly, none of the above modifications alone can account for the stability associated with this form of epigenetic regulation. Histone methylation, however, has recently been described as a more 'stable' epigenetic chromatin mark whose functions in X inactivation and as a potential cellular 'memory' marker have yet to be explored.
Very recently, methylation of histone H3 at lysine 9 has been defined to be an important modification for heterochromatin assembly, and as shown here, this modification is also enriched in the facultative heterochromatin of the inactive X
chromosome. In contrast, methylation of-H3 at lysine 4 is complementarily absent in the inactive X chromosome, suggesting that methylation of H3 at these two distinct sites may be reciprocal, and that H3 molecules methylated at lysine 4 are preferentially associated with transcriptionally active genes whereas the opposite is true for H3 methylated at lysine 9. These findings provide strong evidence in support of the concept that specific modifications at specific sites on the histone amino-terminal tails can impart distinct characteristics, and perform different cellular functions.
While the precedence for H3 methylated at lysine 9 functioning to recruit chromatin-binding factors has been shown, it is still not clear how this modification may participate in the inactivation of the X chromosome.
Analogously, H3 methylated at lysine 4 may function to recruit transcription-enhancing factors or to block the association of transcription-repressive factors; however, direct evidence for either of these possibilities is still lacking. The present ChIP assays only examined promoters of X-linked genes, but it is anticipated that H3. methylated at these two , respective sites are genome-wide marks that demarcate chromosome domains.
Active and inactive regions of the eukaryotic genome not only adopt contrasting chromatin structure (euchromatin versus heterochromatin), but also have been shown to occupy distinct intranuclear domains. Therefore, methylation of H3 at lysines 4 or 9 may dictate the spatial distribution of associated chromosome regions in transcriptionally permissive versus restrictive environment.
Equally intriguing is the question of which enzyme is responsible for the methylation reaction. While previous studies have shown that the hSuVax3-9 is a H3 lysine9-specific histone methyltransferase, fibroblasts derived from SuVar3-knock out embryos retain the enrichment of lysine 9 methylated at the inactive X
chromosome.
Example 4 Parent-Specific Complementary Patterns of Histone H3 Lys9 And Lys4 Methylation at The Prader-Willi Imprinting Center Imprinted genetic loci show differential expression of maternal compared to paternal alleles in some or all tissues at some or all stages of development. The functional differences between maternal and paternal alleles of imprinted genetic loci must reflect structural differences between maternal and paternal chromosomes in the regions containing these loci. The simplest models for establishment of these structural differences hold that chromosomal domains are marked differentially during oogenesis and spermatogenesis, and that these gametic imprinting marks are maintained after fertilization in somatic cells. However, there is no a priori reason to assume that the gametic imprinting marks are identical to the imprinting marks responsible for differential gene expression after fertilization. If the gametic marks are not the same as the somatic marks, there must be a~mechanism for reading the gametic marks and using their information to impose somatic imprinting marks.
The identity of the imprinting marks in mammals has been the subject of extensive speculation and experimental analysis. An appealing candidate imprinting mark is 5-methylcytosine in CpG dinucleotides. Many imprinted loci show parent-of origin specific DNA methylation of imprinted regions, and some of these parent-specific DNA methylation marks are established during gametogenesis and maintained in somatic cells. A mechanism for replicating methylated CpG
dinucleotides exists: maintenance DNA methyltransferases (DNMTs) recognize hemimethylated DNA (DNA methylated on only one strand) and add methyl groups to cytosine residues on the complementary strand. A frequently-cited experiment in support of cytosine methylation as the imprint is the observation that DNMT1 -/-embryos, which die early in embryonic development, show biallelic expression of some imprinted loci whose normal monoallelic expression is associated with cytosine methylation of the inactive allele.
Although abundant data are consistent with cytosine methylation as the imprint, several lines of evidence exist for additional or alternative molecular imprints. First, a number of imprinted genes, including mouse Mash2, human CDKN1C, and human UBE3A, show no regions of parent-specific DNA methylation.
Second, some genes show evolutionary conservation of imprinting without showing conservation of differentially methylated regions, suggesting that the differential cytosine methylation may be a secondary consequence of a primary imprint.
Third, Mash2 imprinting is not disturbed in the DNMT1 -l- mouse embryo. Finally, the promoter region of the imprinted SNRPN-gene in the Prader-Willi syndrome (PWS) imprinting center (IC) shows differential cytosine methylation in somatic tissues of mouse and human, and the region is heavily methylated in mouse oocytes but unmethylated in mouse sperm; however, El-Maarri et al. (Nature Genet. 27, 341 (2001)) have recently shown that this region is completely unmethylated in human oocytes, as in human sperm, so that the differential cytosine methylation must arise after fertilization.
These data lead to the conclusion that, at least for some imprinted genes and some imprinted regions, the structural difference between maternal and paternal alleles inherited from the gametes that leads to differential gene expression after fertilization must be something other than cytosine methylation. In principle, this structural difference might be a heritable covalent modification of DNA
other than cytosine methylation, a DNA-associated protein that remains stably associated with either the maternal or the paternal chromosome from the gamete through somatic cell divisions, or a covalent modification of a DNA-associated protein that is inherited in a parent-specific fashion.
Histone modifications, especially acetylation, have previously been shown to mediate effects of a number of transcriptional regulatory proteins, presumably by changing chromatin structure to increase accessibility to other transcriptional factors. Unlike acetylated histones, which are quite labile, methyl groups attached to histones show a very low level of turnover, making histone methylation a good candidate modification in epigenetic processes such as imprinting. Accordingly, a histone modification that has recently been associated with the formation of stable silenced chromatin regions in Drosophila and fission yeast, (the methylation of histone H3 on Lys9) as been examined along with the methylation of histone H3 on Lys4, which has been correlated with transcriptional activity in Tetrahymena.
The Prader-Willi syndrome (PWS)/Angelman syndrome (AS) region in human chromosome 15q11-q13 contains at least 10 imprinted genes within a ~2 Mb region (Nicholls et al, Trends Genet. 14, 194 (1998)); 8 of these genes are expressed exclusively from the paternal chromosome, and loss of the active paternal alleles of these genes causes PWS, characterized by infantile hypotonia, mild developmental delay, and later-onset hyperphagia and obesity. Loss of the active maternal allele of one gene in this region, UBE3A, causes AS, characterized by severe mental retardation, lack of speech, seizures, and easily provoked laughter. This region can exist in either of two mutually exclusive epigenetic states, the paternal state and the maternal state. Establishment of the paternal state requires a DNA segment, referred to as the PWS imprinting center (PWS-IC) that includes the SNRPN promoter in cis;
establishment of the maternal state requires a DNA segment approximately 30 kb centromeric of the PWS-IC referred to as the AS-IC. The functions of the PWS-IC
and AS-IC in establishing epigenetic states of this region are not known.
Chromatin prepared from stimulated lymphocytes of controls, PWS
individuals (lacking a paternal copy of 15q11-ql3 through deletion or imprinting defect), and AS individuals (lacking a maternal copy of 15q11-q13) was immunoprecipitated with antibodies specific for either H3 methylated on Lys9 or H3 methylated on Lys4. DNA recovered from the immunoprecipitation was assayed by PCR for sequences in the PWS-IC, including the SNRPN promoter, and for other sequences in the region. The maternal copy of the PWS imprinting center (present in PWS chromatin) was immunoprecipitated by anti-methyl Lys9 H3 antibody, while there was dramatically reduced precipitation of this sequence on the paternal copy (present in AS chromatin). This result correlates welfwith the observation that .
maintenance of silenced heterochromatin in both Drosophila and fission yeast requires the function of Lys9 histone H3 methyltransferases. The region of maternal-specific H3 Lys9 methylation extends approximately 0.6 kb 5' and 0.5 kb 3'from the SNRPN promoter. Conversely, the paternal copy of the PWS-IC was immunoprecipitated by anti-methyl Lys4 H3 antibody. This sequence was not precipitated on the maternal copy. Previous reports of association of this modification with active chromatin are consistent with these findings.
Parent-specific differential association of methyl Lys9 H3 was not detected with the promoters of other imprinted genes in 15q11-q13, including ZNF127, NDN, MAGEL2, IPW, which are paternally-expressed, and UBE3A and ATP10C, which show tissue-specific maternal expression. Methyl Lys9 H3 was also not associated with the AS-IC. However; methyl Lys4 H3 was found to be specifically associated with the promoter region of the paternal allele of the paternally-active gene NDN. Parent-specific Lys4 methylation in lymphocyte chromatin was not detected for ZNF127, MAGEL2, IPW, UBE3A, or ATP10C.
Each of the modifications that has been described (cytosine methylation, histone H3 and H4 acetylation, histone H3 Lys4 methylation, and histone H3 Lys9 methylation) shows a distinct pattern of distribution and parent specificity.
The PWS-IC, which overlaps the SNRPN promoter, shows the most extensive pattern of modification, with cytosine methylation and H3 Lys9 methylation on the maternal allele, and histone H3 and H4 acetylation as well as histone H3 Lys4 methylation on the paternal allele. The paternal SNRPN promoter region is also the site of a very prominent nuclease hypersensitive site that is not present on the maternal chromosome. The promoter region of NDN, which shows differential cytosine methylation, does not show eithex differential histone acetylation or differential H3 Lys9 methylation.
It is clear that the human PWS imprinting center lacks cytosine methylation in oocytes; therefore, this modification can not be the gametic imprint for the AS/PWS region. Among the parent-specific histone modifications of the PWS
imprinting center, H3 and H4 acetylation, as well as H3 Lys4 methylation, also can not be the gametic imprint because sperm lack histones, so a paternal gametic imprint can not be a histone modification. Methyl Lys9 H3, however, is a potential candidate imprinting mark that could be imposed upon histones in the PWS imprinting center during gametogenesis. A maternal histone modification irxiprint would have.the unique feature of undergoing programmed erasure during spermatogenesis, when histones are removed from chromatin and replaced by protamines.
SEQUENCE LISTING
<110> The University of Virginia Patent Foundation Allis, C. David Strahl, Brian <120> Antibodies Specific for Methylated Lysines in Histones IS <130> 00601-02 <150> US 60/227,767 <151> 2000-08-25 <150> US 60/302,747 <151> 2001-07-03 <160> 18 <170> Patentln version 3.0 <210> 1 <211> 8 <212> PRT
4S <213> Homo Sapiens <220>
<221> MOD RES
<222> (4) . .
(4) <223> METHYLATION
<400> 1 Ala Arg Thr Lys Gln Thr Ala Arg <210> 2 <211> 9 _2_ <212> PRT
<213> Tetrahymena~thermophila <220>
<221> MOD RES
<222> (5) . . (5) <223> METHYLATION . .-<400> 2 Gln Thr Ala Arg Lys Ser Thr Gly Val <210> 3 <211> 9 <212> PRT
<213> Homo sapiens <220>
<221> MOD RES
<222> (5) . .
(5) <223> METHYLATION
<400> 3 Gln Thr Ala Arg Lys Ser Thr Gly Gly <210> 4 <211> 10 <212> PRT
<213> Artificial <220>
<223> synthetic peptide used to raise antibodies against the H3 amino terminus having MeLys at the fourth amino acid position <220>
<221> MOD RES
<222> (4) . . (4) 0 <223> METHYLATION
<220>
<221> VARIANT
<222> (9) . . (10) <223> artificial amino acids added to the natural histone sequence to aid in the production of the antibody <400>
Ala Arg Thr Lys Gln Thr Ala Arg Gly Cys <210> 5 <211> 11 <212> PRT
<213> Artificial <220>
<223> synthetic peptide used to raise antibodies against the H3 amino terminus having MeLys at the fifth amino acid position <220>
<221> MOD RES
<222> (5) . . (5) <223> METHYLATION
<220>
<221> VARIANT
<222> (10)..(11) <223> artificial amino acids added to the natural histone sequence to aid in the production of the antibody <400> 5 Gln Thr Ala Arg Lys Ser Thr Gly val Cys Gly <210> 6 <211> 11 0 <212> PRT
<213> Artificial <220>
<223> synthetic peptide used to raise antibodies agains the H3 amino terminus having MeLys at the fifth amino acid position <220>
<221> MOD RES
<222> (5) . . (5) <223> METHYLATION
<220>
. .
<221> VARIANT
<222> (10) . . (11) , . ' ':
<223> artificial amino acids added to the natural histone sequence to aid in the production of the antibody $0 <400> 6 Gln Thr Ala Arg Lys Ser Thr Gly Gly Cys Gly r 1 5 10 -S-<210> 7 <211> 15 S <212> PRT
<213> Homo Sapiens <400> 7 Ala Arg Thr Lys Gln Thr Ala Arg Lys Ser Thr Gly Gly Lys Ala <210> 8 <211> 15 <212> PRT
ZS <213> Homo sapiens <400> 8 Ser Gly Arg Gly Lys Gly Gly Lys Gly Leu Gly Lys Gly Gly Ala <210> 9 <211> 13 <212> PRT
<213> Tetrahymena thermophila <400> 9 Ala Arg Thr Lys Gln Thr Ala Arg Lys Ser Thr Gly Val S0 1 . 5 10 SS
<400> 3 Gln Thr Ala Arg Lys Ser Thr Gly Gly <210> 4 <211> 10 <212> PRT
<213> Artificial <220>
<223> synthetic peptide used to raise antibodies against the H3 amino terminus having MeLys at the fourth amino acid position <220>
<221> MOD RES
<222> (4) . . (4) 0 <223> METHYLATION
<220>
<221> VARIANT
<222> (9) . . (10) <223> artificial amino acids added to the natural histone sequence to aid in the production of the antibody <400>
Ala Arg Thr Lys Gln Thr Ala Arg Gly Cys <210> 5 <211> 11 <212> PRT
<213> Artificial <220>
<223> synthetic peptide used to raise antibodies against the H3 amino terminus having MeLys at the fifth amino acid position <220>
<221> MOD RES
<222> (5) . . (5) <223> METHYLATION
<220>
<221> VARIANT
<222> (10)..(11) <223> artificial amino acids added to the natural histone sequence to aid in the production of the antibody <400> 5 Gln Thr Ala Arg Lys Ser Thr Gly val Cys Gly <210> 6 <211> 11 0 <212> PRT
<213> Artificial <220>
<223> synthetic peptide used to raise antibodies agains the H3 amino terminus having MeLys at the fifth amino acid position <220>
<221> MOD RES
<222> (5) . . (5) <223> METHYLATION
<220>
. .
<221> VARIANT
<222> (10) . . (11) , . ' ':
<223> artificial amino acids added to the natural histone sequence to aid in the production of the antibody $0 <400> 6 Gln Thr Ala Arg Lys Ser Thr Gly Gly Cys Gly r 1 5 10 -S-<210> 7 <211> 15 S <212> PRT
<213> Homo Sapiens <400> 7 Ala Arg Thr Lys Gln Thr Ala Arg Lys Ser Thr Gly Gly Lys Ala <210> 8 <211> 15 <212> PRT
ZS <213> Homo sapiens <400> 8 Ser Gly Arg Gly Lys Gly Gly Lys Gly Leu Gly Lys Gly Gly Ala <210> 9 <211> 13 <212> PRT
<213> Tetrahymena thermophila <400> 9 Ala Arg Thr Lys Gln Thr Ala Arg Lys Ser Thr Gly Val S0 1 . 5 10 SS
<210> 10 <211> 13 S <212> PRT
<213> Homo Sapiens <220>
<221> MOD RES
<222> (4) . . (4) IS <223> METHYLATION
<400> 10 Ala Arg Thr Lys Gln Thr Ala Arg Lys Ser Thr Gly Gly <210> 11 <211> 13 <212> PRT
<213> Homo Sapiens 3S <2zo>
<221> MOD RES
<222> (9) . .
(9) <223> METHYLATION
4S <400> 11 Ala Arg Thr Lys Gln Thr Ala Arg Lys Ser Thr Gly Gly <210> 12 <211> 13 <212> PRT
<213> Tetrahymena thermophila <220>
<221> MOD RES
<222> (4) . . (4) IS <223> METHYLATION
<400> 12 Ala Arg Thr Lys Gln Thr Ala Arg Lys Ser Thr Gly Val <210> 13 <211> 13 <212> PRT
<213> Tetrahymena thermophila <z2o>
<221> MOD RES
<222> (9)..(9) <223> METHYLATION
<400> 13 Ala Arg Thr Lys Gln Thr Ala Arg Lys Ser Thr Gly Val _$_ <210> 14 <211> 13 <212> PRT
<213> Homo Sapiens <220>
<221> MOD RES
<222> (5) . .
(5) <223> METHYLATION
<400> 14 5er Gly Arg Gly Lys Gly Gly Lys Gly Leu Gly Lys Gly <210> 15 <211> 13 <212> PRT
<213> Homo Sapiens <220>
<221> MOD RES
<222> (8)..(8) <223> METHYLATION
<400> 15 Ser Gly Arg Gly Lys Gly Gly Lys Gly Leu Gly Lys Gly <210> 16 <211> 10 <212> PRT
<213> Artificial <220>
<223> synthetic peptide used to raise antibodies against the H3 amino terminus having MeLys at the fourth amino acid position <220>
<221> MOD RES
<222> (4) . . (4) <223> METHYLATION
<220>
<221> VARIANT
<222> (9) . . (10) <223> artificial amino acids added to the natural histone sequence to aid in the production of the antibody <400> 16 Ala Ala Arg Lys Ser Ala Pro Val Cys Gly <z1o> 17 <211> 11 <2l2> PRT
<213> Artificial <220>
<223> synthetic peptide used to raise antibodies against the H3 SS amino terminus having MeLys at the fifth amino acid position <220>
<221> MOD RES
<222> (S) . . (5) <223> METHYLATION
<220>
<221> VARIANT
<222> (10)..(11) <223> artificial amino acids added to the natural histone sequence to aid in the production of the antibody <400> 17 Ser G1y Gly Val Lys Lys Pro His Lys Cys Gly <210> 18 <211> 10 <212> PRT
<213> Artificial <220>
<223> synthetic peptide used to raise antibodies against the H3 amino terminus having MeLys at the fourth amino acid position <220>
<221> MOD
RES
<222> _ (4) .(4) <223> METHYLATION
<220>
<221> VARIANT
<222> (9) . . (10) <223> artificial amino acids added to the natural histone sequence to aid in the production of the antibody <400> 18 Arg His Arg Lys Ile Leu Arg Asp Cys Gly
<213> Homo Sapiens <220>
<221> MOD RES
<222> (4) . . (4) IS <223> METHYLATION
<400> 10 Ala Arg Thr Lys Gln Thr Ala Arg Lys Ser Thr Gly Gly <210> 11 <211> 13 <212> PRT
<213> Homo Sapiens 3S <2zo>
<221> MOD RES
<222> (9) . .
(9) <223> METHYLATION
4S <400> 11 Ala Arg Thr Lys Gln Thr Ala Arg Lys Ser Thr Gly Gly <210> 12 <211> 13 <212> PRT
<213> Tetrahymena thermophila <220>
<221> MOD RES
<222> (4) . . (4) IS <223> METHYLATION
<400> 12 Ala Arg Thr Lys Gln Thr Ala Arg Lys Ser Thr Gly Val <210> 13 <211> 13 <212> PRT
<213> Tetrahymena thermophila <z2o>
<221> MOD RES
<222> (9)..(9) <223> METHYLATION
<400> 13 Ala Arg Thr Lys Gln Thr Ala Arg Lys Ser Thr Gly Val _$_ <210> 14 <211> 13 <212> PRT
<213> Homo Sapiens <220>
<221> MOD RES
<222> (5) . .
(5) <223> METHYLATION
<400> 14 5er Gly Arg Gly Lys Gly Gly Lys Gly Leu Gly Lys Gly <210> 15 <211> 13 <212> PRT
<213> Homo Sapiens <220>
<221> MOD RES
<222> (8)..(8) <223> METHYLATION
<400> 15 Ser Gly Arg Gly Lys Gly Gly Lys Gly Leu Gly Lys Gly <210> 16 <211> 10 <212> PRT
<213> Artificial <220>
<223> synthetic peptide used to raise antibodies against the H3 amino terminus having MeLys at the fourth amino acid position <220>
<221> MOD RES
<222> (4) . . (4) <223> METHYLATION
<220>
<221> VARIANT
<222> (9) . . (10) <223> artificial amino acids added to the natural histone sequence to aid in the production of the antibody <400> 16 Ala Ala Arg Lys Ser Ala Pro Val Cys Gly <z1o> 17 <211> 11 <2l2> PRT
<213> Artificial <220>
<223> synthetic peptide used to raise antibodies against the H3 SS amino terminus having MeLys at the fifth amino acid position <220>
<221> MOD RES
<222> (S) . . (5) <223> METHYLATION
<220>
<221> VARIANT
<222> (10)..(11) <223> artificial amino acids added to the natural histone sequence to aid in the production of the antibody <400> 17 Ser G1y Gly Val Lys Lys Pro His Lys Cys Gly <210> 18 <211> 10 <212> PRT
<213> Artificial <220>
<223> synthetic peptide used to raise antibodies against the H3 amino terminus having MeLys at the fourth amino acid position <220>
<221> MOD
RES
<222> _ (4) .(4) <223> METHYLATION
<220>
<221> VARIANT
<222> (9) . . (10) <223> artificial amino acids added to the natural histone sequence to aid in the production of the antibody <400> 18 Arg His Arg Lys Ile Leu Arg Asp Cys Gly
Claims (25)
1. A purified peptide comprising an antigenic fragment of the first 15 amino acids of the amino terminus of H3, said antigenic fragment comprising an amino acid sequence selected from the group consisting of:
ARTKQTAR (SEQ ID NO: 1), QTARKSTGV (SEQ ID NO: 2), QTARKSTGG (SEQ ID NO: 3), ARTKQTARGC (SEQ ID NO: 4), QTARKSTGVCG (SEQ ID NO: 5), and QTARKSTGGCG (SEQ ID NO: 6); and amino acid sequences that differ from SEQ ID NO: 1-6 by one or more conservative amino acid substitutions.
ARTKQTAR (SEQ ID NO: 1), QTARKSTGV (SEQ ID NO: 2), QTARKSTGG (SEQ ID NO: 3), ARTKQTARGC (SEQ ID NO: 4), QTARKSTGVCG (SEQ ID NO: 5), and QTARKSTGGCG (SEQ ID NO: 6); and amino acid sequences that differ from SEQ ID NO: 1-6 by one or more conservative amino acid substitutions.
2. The purified peptide of claim 1 wherein the peptide consists of ARTKQTARGC (SEQ ID NO: 4), QTARKSTGVCG (SEQ ID NO: 5) or QTARKSTGGCG (SEQ ID NO: 6).
3. An antibody that binds specifically to a peptide selected from the group consisting of ARTKQTARGC (SEQ ID NO: 4), QTARKSTGVCG (SEQ ID NO: 5) QTARKSTGGCG (SEQ ID NO: 6), AARKSAPVCG (SEQ ID NO: 16), SGGVKKPHKCG (SEQ ID NO: 17) and RHRKILRDCG (SEQ ID NO: 18).
4 The antibody of claim 3 wherein the peptide is selected from the group consisting of ARTKQTARGC (SEQ ID NO: 4), QTARKSTGVCG (SEQ ID NO: 5) and QTARKSTGGCG (SEQ ID NO: 6).
5. The antibody of claim 3, wherein the antibody specifically binds to the sequence ARTKQTARGC (SEQ ID NO: 4).
6. The antibody of claim 3, wherein the antibody specifically binds to the sequence QTARKSTGVCG (SEQ ID NO: 5).
7. The antibody of claim 3, wherein the antibody specifically binds to the sequence QTARKSTGGCG (SEQ ID NO: 6).
8. The antibody of claim 3, wherein the antibody is a monoclonal antibody.
9. The antibody of claim 3, wherein the antibody is labeled.
10. A fragment of the antibody of claim 4 that retains binding specificity for the antigenic fragment of claim 2.
11. A composition comprising the antibody of claim 4 and a diluent or pharmaceutically acceptable carrier.
12. A method of detecting transcriptionally active chromatin, said method comprising the steps of contacting said chromatin with an antibody, wherein the antibody specifically binds only to methylated lysine 4 residues in H3 histones;
removing unbound and non-specific bond antibody from the sample; and detecting the antibody bound to the sample.
removing unbound and non-specific bond antibody from the sample; and detecting the antibody bound to the sample.
13. The method of claim 12, wherein the detection step comprises contacting said antibody with a labeled secondary antibody wherein said secondary antibody is an anti-immunoglobulin antibody.
14. A method of detecting transcriptionally inactive chromatin, said method comprising the steps of contacting said chromatin with an antibody, wherein the antibody specifically binds only to methylated lysine 9 residues in H3 histones;
removing unbound and non-specific bond antibody from the sample; and detecting the antibody bound to the sample.
removing unbound and non-specific bond antibody from the sample; and detecting the antibody bound to the sample.
15. The method of claim 14, wherein the detection step comprises contacting said antibody with a labeled secondary antibody wherein said secondary antibody is an anti-immunoglobulin antibody.
16. A kit for detecting euchromatin and heterochromatin, said kit comprising an antibody that specifically binds to a peptide selected from the group consisting of ARTKQTARGC (SEQ ID NO: 4), QTARKSTGVCG (SEQ ID NO: 5), QTARKSTGGCG (SEQ ID NO: 6), AARKSAPVCG (SEQ ID NO: 16), SGGVKKPHKCG (SEQ ID NO: 17) and RHRKILRDCG (SEQ ID NO: 18).
17. The kit of claim 16 wherein the antibody specifically binds to a peptide selected from the group consisting of ARTKQTARGC (SEQ ID NO: 4), QTARKSTGVCG (SEQ ID NO: 5) and QTARKSTGGCG (SEQ ID NO: 6).
18. The kit of claim 16 comprising a first antibody that specifically binds to ARTKQTARGC (SEQ ID NO: 4), and a second antibody that specifically binds to QTARKSTGVCG (SEQ ID NO: 5) or QTARKSTGGCG (SEQ ID NO: 6),
19. A method of generating methyllysine 4 (histone)-specific antisera, said method comprising the steps of chemically synthesizing a short polypeptide comprising the histone amino-acid sequence flanking the target methylated lysine;
conjugating the polypeptide to cationized bovine serum albumin; and injecting the conjugated-peptide into rabbits or mice.
conjugating the polypeptide to cationized bovine serum albumin; and injecting the conjugated-peptide into rabbits or mice.
20. A method of detecting the presence of methylated H3 histones, said method comprises the steps of contacting histone proteins with an antibody, wherein the antibody specifically binds to H3 that is methylated at lysine 4 or lysine 9.
21. A method of detecting chromatin alterations that are associated with a disease state, said method comprising the steps of isolating chromatin from both normal and diseased tissue to create a first and second pool of chromatin;
contacting the first and second pools of chromatin with an antibody selected from the group consisting of Methyl(K4)H3 and Methyl(K9)H3; and comparing the staining pattern of the antibody bound chromatin isolated from normal tissue to the staining pattern of the antibody bound chromatin isolated from the diseased tissue.
contacting the first and second pools of chromatin with an antibody selected from the group consisting of Methyl(K4)H3 and Methyl(K9)H3; and comparing the staining pattern of the antibody bound chromatin isolated from normal tissue to the staining pattern of the antibody bound chromatin isolated from the diseased tissue.
22. The method of claim 21 wherein the chromatin comprises metaphase chromosomes.
23. A method of identifying nucleic acid sequences that are associated with a disease state, said method comprising the steps of isolating chromatin from both normal and diseased tissue to create a first and second pool of chromatin;
immunoprecipitating the fragmented chromatin with an antibody selected from the group consisting of Methyl(K4)H3 and Methyl(K9)H3;
isolating DNA from the immunoprecipitated fragmented chromatin; and comparing the DNA isolated from the first pool of chromatin to the DNA
isolated from the second pool of chromatin.
immunoprecipitating the fragmented chromatin with an antibody selected from the group consisting of Methyl(K4)H3 and Methyl(K9)H3;
isolating DNA from the immunoprecipitated fragmented chromatin; and comparing the DNA isolated from the first pool of chromatin to the DNA
isolated from the second pool of chromatin.
24. The method of claim 23 further comprising the step of fragmenting the isolated chromatin before the immunoprecipitation step.
25. The method of claim 24 wherein the step of comparing the DNA
comprises immobilizing the DNA isolated from the first pool of chromatin onto a first solid surface;
immobilizing the DNA recovered from the second pool of chromatin onto.a second solid surface;
probing the first and second solid surfaces with identical labeled nucleic acid sequences; and identifying those sequences that bind only to the immobilized DNA isolated form the first pool of chromatin.
comprises immobilizing the DNA isolated from the first pool of chromatin onto a first solid surface;
immobilizing the DNA recovered from the second pool of chromatin onto.a second solid surface;
probing the first and second solid surfaces with identical labeled nucleic acid sequences; and identifying those sequences that bind only to the immobilized DNA isolated form the first pool of chromatin.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US22776700P | 2000-08-25 | 2000-08-25 | |
US60/227,767 | 2000-08-25 | ||
US30274701P | 2001-07-03 | 2001-07-03 | |
US60/302,747 | 2001-07-03 | ||
PCT/US2001/026283 WO2002018418A1 (en) | 2000-08-25 | 2001-08-23 | Antibodies specific for methylated lysines in histones |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2420277A1 true CA2420277A1 (en) | 2002-03-07 |
Family
ID=26921747
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002420277A Abandoned CA2420277A1 (en) | 2000-08-25 | 2001-08-23 | Antibodies specific for methylated lysines in histones |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1313756A4 (en) |
JP (1) | JP2004520270A (en) |
AU (1) | AU2001285214A1 (en) |
CA (1) | CA2420277A1 (en) |
WO (1) | WO2002018418A1 (en) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0111218D0 (en) | 2001-05-08 | 2001-06-27 | Cancer Res Ventures Ltd | Assays methods and means |
JP2005517431A (en) * | 2002-02-20 | 2005-06-16 | ユニバーシティ オブ バージニア パテント ファウンデーション | Noninvasive diagnostic test using histone modified markers |
US7153691B2 (en) * | 2002-11-13 | 2006-12-26 | G6 Science Corp. | Method of identifying and assessing DNA euchromatin in biological cells for detecting disease, monitoring wellness, assessing bio-activity, and screening pharmacological agents |
US20060073517A1 (en) * | 2003-03-10 | 2006-04-06 | Allis C D | Post-translational modifications of proteins as regulatory switches |
WO2005054296A1 (en) * | 2003-12-02 | 2005-06-16 | Advanced Life Science Institute, Inc. | Antibodies recognizing methyllysine, process for producing the same and utilization thereof |
JP2008522616A (en) * | 2004-12-09 | 2008-07-03 | ザ ブライハム アンド ウイメンズ ホスピタル, インコーポレイテッド | Compositions and methods based on kinase haspin |
US20160069903A1 (en) * | 2014-09-10 | 2016-03-10 | Fundació Institute De Ciències Foròniques | Method for detecting cells |
US10441644B2 (en) | 2015-05-05 | 2019-10-15 | The Regents Of The University Of California | H3.3 CTL peptides and uses thereof |
KR101590450B1 (en) | 2015-05-22 | 2016-02-02 | 중앙대학교 산학협력단 | Method for detecting histone modifications of the Filaggrin gene promoter and composition for diagnosing inflammatory skin diseases using thereof |
WO2017184873A2 (en) * | 2016-04-20 | 2017-10-26 | Aelan Cell Technologies, Inc. | Compositions and methods related to the methylation of histone h1.0 protein |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5989829A (en) * | 1991-08-09 | 1999-11-23 | Washington University | Autoantibodies and their targets in the diagnosis of peripheral neuropathies |
WO2003004050A1 (en) * | 2001-07-03 | 2003-01-16 | University Of Virginia Patent Foundation | Methylation of histone h4 at arginine 3 |
-
2001
- 2001-08-23 JP JP2002523932A patent/JP2004520270A/en not_active Withdrawn
- 2001-08-23 EP EP01964349A patent/EP1313756A4/en not_active Withdrawn
- 2001-08-23 WO PCT/US2001/026283 patent/WO2002018418A1/en not_active Application Discontinuation
- 2001-08-23 AU AU2001285214A patent/AU2001285214A1/en not_active Abandoned
- 2001-08-23 CA CA002420277A patent/CA2420277A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AU2001285214A1 (en) | 2002-03-13 |
EP1313756A4 (en) | 2004-12-22 |
EP1313756A1 (en) | 2003-05-28 |
JP2004520270A (en) | 2004-07-08 |
WO2002018418A1 (en) | 2002-03-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2420277A1 (en) | Antibodies specific for methylated lysines in histones | |
US20040186274A1 (en) | Methylation of histone h4 at arginine 3 | |
WO2007004692A1 (en) | Prophylactic/therapeutic agent and diagnostic agent for non-small cell lung cancer | |
US7291492B2 (en) | Histone deacetylase 9 | |
US20040053848A1 (en) | Antibodies specific for methylated lysines in histones | |
US20040197838A1 (en) | Phosphorylated histone h2b as apoptosis marker | |
US6307035B1 (en) | BRCA1 associated polynucleotide (BAP-1) and uses therefor | |
WO2004048565A9 (en) | Apoptosis-associated protein and use thereof | |
US7053053B2 (en) | Humanin-like peptide and use thereof | |
WO2000071581A1 (en) | Novel polypeptide | |
WO2001048203A1 (en) | Novel protein and dna thereof | |
US20060078953A1 (en) | Epad, an oocyte specific protein | |
WO2004028558A1 (en) | Preventives/remedies for neurodegenerative disease | |
WO2002033071A1 (en) | Survivin-like polypeptides and dnas thereof | |
JP4300008B2 (en) | Novel protein and its DNA | |
AU2002322372A1 (en) | Methylation of histone H4 at arginine 3 | |
JP2004217634A (en) | Preventing/treating agent for cancer | |
JP2001299363A (en) | New polypeptide and dna encoding the same | |
EP1162460A1 (en) | Mammalian Suv39h2 proteins and isolated DNA molecules encoding them | |
JP2004089182A (en) | Preventive/therapeutic agent for cancer | |
JP2001299364A (en) | New polypeptide and dna encoding the same | |
JP2004201674A (en) | New protein and prophylactic/remedy for cancer | |
JP2004339109A (en) | MONOCLONAL ANTIBODY AGAINST METHYLATED (di-CH3) LYSINE 9 OF HISTONE H3 | |
JP2004135666A (en) | Prophylactic/remedy for neurodegenerative disease | |
JP2004059502A (en) | Prophylactic/therapeutic agent for hormone independent cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Discontinued |